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The cellular integrity of the blood is maintained by the cellular 
output of the haematopoietic stem cell population which produces the 
specialized precursors and differentiated cells which constitute the blood. 
The investigation of haematopoietic stem cell behaviour and regulation 
has been hampered by both the difficulty in their identification and the 
development of relevant assay systems. The purpose of this investigation 
was to study the behaviour and regulation of the haematopoietic stem 
cell population in normal and leukaemic haematopoiesis using an in vitro 
assay of a primitive haematopoietic precursor.
The use of a combination of haematopoietic colony-stimulating 
factors [interleukin 3 (IL3)/multl-CSF and macrophage colony-stimulating 
factor (M-CSF/CSF-1)] in semi-solid agar culture of murine
haematopoietic tissue, stimulated the proliferation of a haematopoietic 
colony-forming cell, defined as the "HPP-CFC|L3+csf-i" population, 
which was characterized by a high proliferative potential, a multipotency 
and behavioural and regulatory properties consistent with its being a 
primitive haematopoietic precursor and possibly a component of the 
haematopoietic stem cell population.
The proportion of the ./n vitro HPP-CFC|[_3+csf-i population in 
S-phase in normal murine marrow, was determined to be relatively low at 
approximately 10%, increasing to approximately 40% in sublethaliy 
X-irradiated, regenerating murine marrow and the respective presence of 
the haematopoietic stem cell proliferation inhibitor and stimulator was 
demonstrable by the induction of appropriate kinetic changes in the 
in vitro HPP-CFC||_3+csf-i population.
in leukaemic haematopoiesis, leukaemic proliferation often occurs 
at the expense of apparently suppressed normal haematopoiesis. in vitro 
HPP-CFC|L3+csf-i assay of the haematopoietic stem cell proliferation 
regulators in a number of murine, myeloid leukaemic cell lines, failed to
vn
demonstrate either increased levels of the haematopoietic stem cell 
proliferation inhibitor, or evidence of a direct-acting, leukaemia- 
associated proliferation inhibitor, however, evidence of a leukaemia- 
associated impairment of inhibitor and stimuiator production was 
observed and this may be a possible mechanism by which the leukaemic 
population develops a proliferative advantage over normal 
haematopoietic tissue. The identification of a possible mechanism of 
leukaemic progression and suppression of normal haematopoiesis may 
subsequently allow the development of potentially more effective disease 
treatment and management regimes. -
The endogenous haemoregulatory tetrapeptide: Acetyl-N-Ser- 
Asp-Lys-Pro [AcSDKP, Mr=487 amu] is reported to prevent the Go-Gi 
transition of haematopoietic stem cells into S-phase. The mechanism of 
action of AcSDKP and a number of related peptides, was investigated in 
relation to the stem cell proliferation stimulator and inhibitor. AcSDKP 
demonstrated no direct haemoregulatory role against the in vitro 
HPP-CFCh_3+csf-i population, which is consistent with reports that 
AcSDKP is not active against cells already in late Ci, or S-phase, rather 
it appeared to act indirectly by impairing the capacity of the 
haematopoietic stem cell proliferation stimulatorXo increase the 
proportion of the in vitro HPP-CFC||_3+csf-i population in S-phase. An 
apparent impairment of stimulator action may explain the reported 
AcSDKP-associated ’block' of haematopoietic stem cell recruitment. A 
putative endogenous AcSDKP precursor and synthetic and degradative 
enzyme systems have been reported and the possible
physiopathological role of AcSDKP in a number of myeloproliferative 
disorders has been implicated. The potential application of AcSDKP as a 
'haemoprotective' agent administered prior to the use of S-phase- 
speciflc chemotherapy may be of clinical significance.
viii
The in vitro HPP-CFC|L3+csf-i assay of a primitive haematopoietic 
precursor cell population, which may be a component of the 
haematopoietic stem cell population, should play a significant role in the 
investigation of haematopoietic stem cell behaviour and regulation in 
both normal and aberrant haematopoiesis. With the characterization of 
the mechanism(s) of action of the haematopoietic stem cell proliferation 
inhibitor and stimulator and the haemoregulatory tetrapeptide AcSDKP, 
the manipulation of the haematopoietic system to clinical advantage can 
be envisaged, while the identification of the aberrant regulatory 
mechanism(s) in haematopoietic dysfunction may allow, the development 
of more effective disease treatment and management regimes.
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Chapter 1:
Introduction.
1.1 Introduction.
All the cells of the body are descended from a small population of 
specialized precursors known as "stem ce//5". Stem cells are capable 
of multiplying rapidly, under the control of subtle regulatory cues, to 
give rise to a large number of terminally differentiated, non­
proliferating progeny. This cellular amplification occurs through a 
population of ’transit’ progenitor ceiis which, with maturation, 
develop a reduced probability for proliferation and an increased 
probability for differentiation. In this way ceil multiplication is kept in 
check, matching cell production to the requirements of the body - 
sufficient new cells are produced to replace those dead or dying, so 
maintaining tissue integrity, or to produce new tissue as required. 
While providing a continuously varying output to meet the cellular 
requirements of the body, stem cells must, of necessity, be capable 
of maintaining their own numbers, through a stem cell-specific ’self­
renewal’ mechanism. The processes which regulate stem ceil 
proliferation and cellular differentiation are of considerable interest 
and an understanding of such processes will undoubtedly make it 
possible to investigate tissues where cell production is proceeding in 
an inappropriate manner in, for example, cancerous growth.
''Haematopoiesis*' is the process by which the body generates 
new blood cells. The cellular integrity of the blood is maintained by 
the haematopoietic stem ceii popuiation, which produces the 
specialized precursor and differentiated cells which constitute the 
blood [Figure /]. investigation of haematopoietic stem cell regulation 
and behaviour is of considerable interest, however, difficulty in both 
their identification and the development of relevant assay systems 
has hampered such investigations.
Figure 1: Organization of the haematopoietic system.
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1,2 Evidence for a haematopoietic stem cell.
Mice subjected to 8.2 Gray (Gy) whole body X-irradiation die after 
approximately 14 days due to haematopoietic failure. if the spleens of 
such mice were exteriorized and shielded prior to irradiation this
haematopoietic death couid be prevented [Jacobson ef a/,1949]. Left 
in situior 1-48 hours before removal a shielded spleen would still 
improve haematopoietic recovery [Jacobson ef a/,1951].
Transplanted unirradiated, syngeneic spleen cells also enhanced the 
survival of lethally irradiated mice and similar results were obtained 
for syngeneic bone marrow, Initially a haematopoietic humoral factor 
was considered responsible, however, a cell within the donor tissue 
was determined to be the agent responsible for the haematopoietic 
recovery [Ford ef a/,1956]
To maintain adequate haematopoietic output, mice utilize all bone 
cavities In active haematopolesis. If haematopoieticaliy stressed, 
mice resort to extramedullary haematopoiesis, that is haematopolesis 
outside the bone cavities, and the murine spleen becomes a focus of 
haematopolesis. if lethally X-irradiated mice are given sufficient 
haematopoietic cells in a transplant, they survive and an enlarged 
haematopoieticaliy active spleen is usually evident. However, if fewer 
haematopoietic cells are given in a transplant, a point is reached 
where insufficient cells for haematopoietic recovery are present and 
the mice die due to haematopoietic failure. Examination of the 
spleens from such mice at autopsy, revealed discrete 'patches', or 
'islands', of light-coloured tissue within the otherwise degenerating 
spleen. These 'islands', or 'nodules', were found to contain 
recognisable haematopoietic cells and precursors and were foci of 
haematopoietic regeneration. The number of spleen 'nodules' was 
found to be proportional to the number of haematopoietic cells given
3in the transplant [Till & McCulloch,1961]. Unique chromosome 
markers identified the spleen nodules as derived from donor tissue 
and the use of combinations of chromosomal markers demonstrated 
that individual nodules were derived from a single cell and so were 
cfonafln nature [Becker ef a/,1963; Wu ef a/,1967; Chen & 
Schooley,1968]. To give rise to visible, macroscopic nodules, the 
single colony-forming cell responsible was demonstrating a high 
proliferative potential and histological analysis of individual colonies 
demonstrated that while some colonies consisted of cells of a single 
lineage, others consisted of ceils of two, or three different lineages, 
evidence that the single colony-forming ceil also had a multipotential 
nature [Lewis & Trobaugh,1964; Fowler ef a/,1967; Lewis ef a/,1968]. 
Excised single spleen colonies, if re-transplanted to lethally X- 
irradiated mice were demonstrated to produce more than one nodule 
in the recipient spleen, also giving evidence of a self-renewal 
capacity within the spleen colony-forming cell population 
[Siminovitch ef a/,1963]. To summarize, a haematopoietic colony­
forming cell population of high proliferative potential, with a 
multipotential nature and self-renewal capacity was demonstrable in 
murine haematopoietic tissue. The significance of this spleen coiony- 
forming unit (CFU-S) was realised since such characteristics would 
be expected of a putative haematopoietic stem cell population 
[Figure 2]. The CFU-S assay was thus adopted as a method with 
which to quantitatively and qualitatively investigate the behaviour and 
regulation of the haematopoietic stem cell population.
1.3 The murine spleen colony-forming unit (CFU-S) assay.
[Till & McCulioch,1961] Recipient mice are subjected to 8.2 Gy 
whole body X-irradiation, a dose which ablates host haematopolesis
High proliferative potential
STEM CELLS Multipotency
Self-renewal capacity
Figure 2: Characteristics of the haematopoietic stem cell population.
4and will prove lethal after approximately 14 days. A single cell 
suspension of donor syngeneic bone marrow, spleen or 
haematopoietic foetal liver, is produced, its ceilularity adjusted and is
injected intravenously into one of the two lateral tail veins of 
prewarmed recipient mice.
Recipient mice will die after approximately 14 days due to 
haematopoietic failure since the inoculum contains a sub-survival 
haematopoietic dose. Spleen colonies are assayed by killing the mice 
after 8-12 days. The time of assay is again critical since, while the 
number of colonies on a spleen may be the same at day 8 or day 12, 
some spleen colonies are transient [Magli ef a/,1982]. Some colonies 
arise to be counted at day 8, disperse and are absent at day 12. 
Similarly, other colonies do not arise until after day 8 to be counted at 
day 12. Other spleen colonies appear fixed and are present at both 
day 8 and day 12. This has important implications in relation to an 
age-related hierarchy within the CFU-S population and will be 
discussed. At assay colonies are counted on both sides of the 
spleen, and a near maximal 15 colonies per spleen is apparent with 
larger numbers increasing counting errors due to colony overlap.
Only a fraction of the haematopoietic colony-forming ceils in an 
inoculum will seed into the spleens of lethally X-irradiated mice to 
subsequently give rise to macroscopic colonies (CFU-S). This 
fraction of colony-forming cells is determined by a secondary 
transplantation technique [Siminovitch ef a/,1963]. Lethally X- 
irradiated mice receive an inoculum containing a known dilution of 
colony-forming cells and from the number of colonies which 
subsequently form on the spleen a "seeding factor", -or "f-number" can 
be calculated [Siminovitch ef a/,1963]. The determination of a 
seeding factor allows an assessment of the absolute numbers of 
colony-forming cells in an inoculum.
5Siminovitch et al [1963] calculated a seeding factor of 17%, while 
Playfair and Cole [1965] calculated a seeding factor of 8% (that is,
17% and 8% respectively, of potential colony-forming cells injected, 
seed into the spleen to give rise to CFU-S). A difference in 
experimental protocol relating to the post-irradlatlon collapse of the 
spleen was responsible for the observed discrepancy. Siminovitch et 
a! [1963] allowed 2-3 hours to elapse between inoculation of the 
lethally X-lrradiated mice and removal of the seeded spleen for 
retransplantation, while Playfair and Cole [1965] allowed a 24 hour 
period to elapse. Lord [1971] found that a 2-3 hour period was 
sufficient for maximal colony-forming ceil accumulation in the spleen, 
however spleens removed at this time had yet to undergo post­
irradiation collapse. With this collapse, which is complete after 24 
hours, spleen ceilularity reduces and a proportion of the colony­
forming cells initially seeding into the spleen are expelled 
[Lord,1971]. Assay of the colony-forming cell content of a collapsed 
spleen [Playfair & Cole,1965] is thus a more representative model 
with which to investigate seeding.
The complications associated with the post-irradiation collapse of 
the spleen and the determination of a seeding factor, are reduced if 
mice are inoculated 24-48 hours after X-irradiation. After 2-3 hours, 
colony-forming cells maximally seed into the already collapsed 
spleen and it is removed for secondary transplantation. In such a 
case, a seeding factor of approximately 8% is observed.
1,4 Haematopoietic stem cell self-renewaL
The murine haematopoietic transplantation (CFU-S) assay 
demonstrates a ceil population which fuifilis many of the criteria for a 
putative haematopoietic stem cell population. The capacity of CFU-S
6to self-renew under different conditions has revealed evidence of an 
age-related hierarchical organization within the CFU-S population.
The self-renewal capacity of CFU-S does not differ significantly 
between very young and very old mice [Lajtha & Schofield,197T] 
implying a stem ceil ’immortality’. However, serial transplantation of 
bone marrow from healthy to lethally irradiated mice and 
subsequently into other lethally irradiated mice, demonstrates a rapid 
and progressive decline in the regenerative capacity of the bone 
marrow transplant [Siminovitch ef a/,1964]. Even if long periods 
separated successive transplants and CFU-S numbers were 
standardized, the decline in the regenerative capacity remained 
[Lajtha & Schofield,1971; Pozzi ef a/,1973]. Investigation of serially 
transplanted CFU-S self-renewal showed a reduction with each 
transplant. Sublethal chronic [Wu & Lajtha,1975] or repeated acute 
[Hendry & Lajtha,1972] X-irradiation showed a similar reduction in 
CFU-S seif-renewal.
To explain the contradictory evidence of stem cell ’immortality’ 
and ’mortality’ the ’niche hypothesis was developed 
[Schofield,1978]. A specialized microenvironmental niche was 
envisaged within the haematopoietic system. If a stem ceil inhabits a 
niche, it exhibits it’s immortality - it has a high self-renewal capacity. 
Outside the niche, It becomes subject to ’maturation’ cues - it 
develops a reduced self-renewal capacity and an increased 
probability for differentiation. This hypothesis may also explain the 
asymmetry of fate of stem cell progeny. At division, one daughter cell 
remains in the niche microenvironment, the other is expelled and 
becomes subject to differentiation cues [Figure 3].
It is proposed that X-irradlation damages the haematopoietic 
system by subjecting the niche-inhabiting stem cells to lethal 
damage. Transplanted haematopoietic tissue and specifically the
Daughter cell 
progeny:
Niche-inhabiting 
stem cell.
Stem cell 1) Retained within niche microenvironment
Hivicinn and displaying ’’immortal" character.
2) Expelled from niche microenvironment 
and subject to differentiation cues.
Figure 3: The "niche" hypothesis. A possible explanation of the assymetrv of fate of stem cell progeny.
7stem cells therin, can seed into the now 'empty' niches and adopt an 
immortal character. However, the majority of donor stem cells 
seeding Into the niches are likely to be the more numerous, more 
mature haematopoietic stem cells of lower self-renewal capacity - 
essentially of a lower 'quality' than the original niche-inhabiting stem 
cell. While at the first transplantation sufficient haematopoietic output 
is sustained to allow haematopoietic recovery, with successive 
transplantation, the niche-filling stem cells are of a progressively 
poorer 'quality', with a still lower self-renewal capacity. By the third 
successive transplant insufficient self-renewal and proliferative 
potential exists to supply differentiated haematopoietic precursors 
and haematopoietic failure ensues.
Similarly, both sublethal chronic and repeated acute X- 
irradlations directly insult the niche-inhabiting stem cell population. 
'High quality' stem cells are subsequently replaced by successively 
'lower quality' stem cells giving the observed and sustained reduction 
in both CFU-S numbers and CFU-S self-renewal.
This evidence suggests an age-related hierarchical organization 
within the haematopoietic stem cell system. A component of the stem 
cell population is a primitive precursor with a high self-renewal 
capacity and proliferative potential. It possesses a high probability of 
self-renewal and a low probability of differentiation - essentially a 
'high quality' stem cell. With maturation, a haematopoietic precursor 
with a lower self-renewal and proliferative potential develops. It 
possesses a lower probability of self-renewal and a higher probability 
of differentiation - essentially a 'lower quality' stem cell [Figure 4].
Use of chemical agents reinforces this age-related heterogeneity 
of the haematopoietic stem cell population. Isopropylmethane 
sulphate (IMS) [Schofield & Lajtha,1973] reduces CFU-S numbers 
dramatically, however, haematopoietic recovery is rapid and
▲Probability
Figure 4: Putative age-related hierarchical organization within the haematopoietic stem cell population.
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8complete. IMS appears to act against CFU-S of a specific age within 
the CFU-S maturation scheme. ’High quality’, primitive and more 
mature 'low quality’ stem ceils are spared. Myleran [Morley & 
Blake,1974] also reduces CFU-S numbers, however, haematopoietic 
recovery is never complete, implying damage at the level of the more 
primitive ’high quality' stem cell population. Haematopoietic 
transpiantation, repiacing the damaged, primitive, 'high quality' stem 
cells, corrects the haematopoietic failure [Morley ef a/,1975].
While the niche hypothesis is essentially a theoretical model, 
considerable evidence for the existence of a specific stem cell 
microenironment, or ’niche', exists [Dexter ef a/,1973; Dexter & 
Lajtha,1974; Allen & Dexter,1976]. Use of genetic haematopoietic 
disorders In mice has reinforced this evidence. Briefly, the W/W" 
defect is an apparent stem cell maturation defect. ’Low quality' stem 
cells with a low probability of self-renewal and a high probability of 
differentiation are produced. In SI/Sd mice a microenvironmental 
defect exists possibly at the level of the haematopoietic stem cell 
niche. Neither defective systems will sustain haematopoiesis in 
culture, however, a combination of W/\W stromal tissue and Sl/SId 
haematopoietic tissue will sustain haematopoiesis in culture - 
implying a healthy stem cell population and a healthy stromal 
microenvironment are required [Dexter & Moore,1977].
Haematopoietic stem cells are not uniformly or randomly 
distributed throughout the marrow. Axial cores of actively 
haematopoietic murine femoral marrow demonstrate a considerable 
degree of microarchitectural organization exists. This may reinforce 
the evidence of a specialized microenvironmental stem cell niche. 
Samples of endosteal marrow have a 2-3 fold higher CFU-S content 
than samples of axial marrow [Lord ef a/,1975]. Conversely, samples 
of endosteal marrow have markedly fewer of the more mature
9haematopoietic progenitors than samples of axial marrow [Frassoni 
ef a/,1982]. This may imply a migration of haematopoietic progenitors
with maturation from the endosteal to the axial marrow. The 
significance of this microarchitecture may become more apparent 
during the discussion of the relative distribution of the stem cell 
proliferation regulator-producing cells.
Endosteal marrow is a particularly rich source of CFU-S 
[Gong ef a/,1978] and the use of a bone-seeking radionuclide: 
radium (226Ra)[Svoboda,1975], a source of alpha radiation, 
demonstrates a marked reduction in CFU-S numbers with cells near 
the endosteal surface of the bone subject to intense radiation. 
Observations of haematopoietic recovery after X-irradiation also 
demonstrate the significance of this region with haematopoietic 
repopulation occuring from this endosteal tissue [Maloney & 
Pratt,1969; Lambersten & Weiss,1984] and while the majority of CFU- 
S can be removed in femoral marrow, even if the marrow cavity is 
vigorously washed a further CFU-S population can be released if the 
bone itself is ground and washed, implying a very Intimate contact 
between a component of the CFU-S population and bone. This 
endosteal region may well contain certain components of the specific 
microenvironmental stem cell niche.
1,5 Evidence of a spleen colony-forming unit (CFU-S)
age-related hierachy,
Magli ef al [1982] described the transient nature of some spleen 
colonies in the murine CFU-S assay. While colony numbers may not 
differ between spleens assayed at day 7-8 and day 10-12, some 
colonies appear and are counted at day 7-8, to disperse by day 10-12, 
while others do not appear until after day 7-8 to be counted at day 10-
10
12. Other colonies appear fixed and are present both at day 7-8 and 
day 10-12. Analysis of day 8 CFU-S and day 12 CFU-S demonstrates a 
difference in character. Day 8 CFU-S have a relatively low' ' self­
renewal capacity which would be consistent with their being a 
component of the more mature haematopoietic stem cell population, 
while day 12 CFU-S have a relatively high self-renewal capacity, 
consistent with their being a more primitive component of the 
haematopoietic stem ceil population [Magli ef a/,1982]. This evidence 
of an age-related CFU-S and so stem cell heterogeny, is reinforced 
by a number of drug studies.
5-fluorouracil (5FU) [Hodgson & Bradley,1979; Hodgson ef 
a/,1982], cyclophosphamide (CY)[Moiineux ef a/,1986], hydroxyurea 
(HU)[Rosendaal ef a/,1979] and bromodeoxyurldlne (BrdU) [Hodgson 
& Bradiey,1984], preferentially kill more mature haematopoietic 
precursors. CFU-S assay of treated marrow showed a reduction in 
day 8 CFU-S numbers with little, or no change in day 12 CFU-S. This 
again implies the day 8 CFU-S is a more mature haematopoietic 
precursor than the day 12 CFU-S. This CFU-S age-related hierarchy 
becomes of greater significance when considering their respective 
sensitivities to the haematopoietic stem cell proliferation regulators.
1,6 Evidence of a ’pre-CFU-S* haematopoietic precursor.
The murine CFU-S assay [Till & McCuiloch,1961], has been taken 
as the primary assay of a primitive haematopoietic precursor, 
however, there is evidence that it may not be an assay of the 
fundamental haematopoietic stem cell, with evidence of a more 
primitive ’pre-CFU-S’ population. It is suggested that the pre-CFU-S 
population is responsible for both haematopoietic recovery after X- 
irradiation, it having a radioprotective ability (RPA) and for the
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production of CFU-S. As discussed previously, the drugs 5FU, CY, HU 
and BrdU selectively kill the more mature haematopoietic precursors. 
If used in transplant, it becomes clear that the number of CFU-S in 
the treated tissue is not necessarily an accurate predictor of the 
capacity of that transplant to rescue the haematopoieticaliy deficient 
recipients, rather recovery seems to be due to a ’pre-CFU-S’ 
population.
Primitive haematopoietic precursors can be purified from 
haematopoietic tissue using a number of different techniques. 
Pioemacher and Brons [1988a; 1988b] used fluorescence activated 
cell sorting (FACS) of wheat germ agglutinin (WGA) - fluoroscein 
isothiocyanate (FITC) binding cells to purify day 12 CFU-S and ’pre- 
CFU-S’ 50-200 fold. 50-80 of these enriched cells per animal (in 
contrast to in excess of 10d complete bone marrow cells) were 
capable of rescuing 50% of a group of lethally irradiated mice. The 
ability of the haematopoietic transplant to rescue it’s recipients 
seemed closely related to it’s day 12 CFU-S and ’pre-CFU-S’ content 
rather than its more mature day 8 CFU-S content.
Bertoncello efal [1985], Mulder and Visser [1987] and 
Pioemacher and Brons [1988c; 1988d] used counter flow centrifugal 
elutriation (CCE) and the fluorescent supravital mitochondrial 
membrane stain, rhodamine-123 (Rh-123). CCE and FACS of Rh-123 
treated marrow produces a Rh-123 dim fraction containing day 12 
CFU-S with a high RPA/’pre-CFU-S’ content and a Rh-123 bright 
fraction with a high day 12 CFU-S content but few RPA/’pre-CFU-S’. 
This suggests a possible maturation scheme of a Rh-123 dim, 
RPA/’pre-CFU-S’ population to a Rh-123 dim, day 12 CFU-S 
population to a Rh-123 bright, day 12 CFU-S population and 
subsequently to a Rh-123 bright, day 8 CFU-S population.
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Bertoncello ef a/ [1989b] used antibody labeiled magnetic 
microspheres to concentrate and resolve primitive haematopoietic 
precursors while Spangrude ef a/[1988], used fluorescence-labelled 
antibodies against ceil surface antigens and FACS. Spangrude ef al 
[1988] isooated a f faction oo containnng 55% oo the tootal day 11
CFU-S and the RPA/’pre-CFU-S’ population from complete marrow. 
(The fraction containing the remaining day 12 CFU-S had little or no 
RPA/’pre-CFU-S’ content. This again implies a maturation of 
RPA/’pre-CFU-S’, through a similar staining ’transition’ day 12 CFU-S 
fraction to a differently staining day 12 CFU-S population). 30-40 of 
these cells per animal were capable of rescuing 50% of a group of 
lethally X-irradiated mice.
Jones ef a/[1990] have applied CCE, separating cells on the 
basis of their sedimentation velocities, to samples of haematopoietic 
tissue. Sedimentation velocity varies according to cell size and 
density. A clear demarcation is reported between the RPA/’pre-CFU- 
S’ and CFU-S populations. This technique also suggests there may 
be a more primitive cell than the RPA/’pre-CFU-S’, responsible for 
long-term haematopoietic repopulation. Pioemacher and Brons 
[1988b; 1989a] observed similar evidence.
it is proposed that for successful haematopoietic regeneration, 
two vital classes of haematopoietic precursors are required In 
transplanted tissue. Firstly, the cells capable of the initial short-term, 
sustained proliferation, producing the committed haematopoietic 
progenitors, namely the CFU-S subpopulations and secondly, the 
cells capable of long-term sustained haematopoiesis. It is clear that a 
complex hierarchy exists within the haematopoietic stem ceil 
population and investigation into the behaviour and regulation of the 
various components of this very primitive compartment is limited by 
the assay techniques presently available. However, Sutherland el al
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[1989] and Ploemacher efS [1989b] report the development of 
assays of such primitive haematopoietic precursors responsible for 
the initiation of iong-term haematopoiesis, which should allow their
subsequent investigation.
1.7 Determination of the proportion of haematopoietic
stem ceils in S-phase,
The murine in vivo CFU-S haematopoietic transplantation assay 
[Till & McCulloch,1961] has allowed qualitative and quantitative 
investigation of the haematopoietic stem ceil compartment. One such 
factor investigated is the degree of haematopoietic stem cell 
proliferation. Celiuiar proliferation is intimately linked with DNA 
synthesis at S-phase in the cell cycle and this can be exploited by the 
use of S-phase specific cytotoxic agents. Proliferating cells take up 
the agent at S-phase and are killed. If such cells had colony-forming 
potential, this is not realised during any subsequent assay and by a 
comparison of colony numbers in the absence and presence of the 
cytotoxic agent, a measure of the proportion of colony-forming cells 
in S-phase and so proliferating, can be made. This is the basis of the 
’S-phase suicide assay.
Two S-phase specific agents widely used are tritiated thymidine 
(3H-TdR) and 1 -B-D-arabinofuranosyl cytosine (also known as: 
cytosine B-D-arabinoslde, cytosine arabinoside or cytarabine)(ARA- 
C). Tritiated thymidine fH-TdR) competes with native thymidine for 
incorporation into newly synthesizing DNA at S-phase. On 
incorporation, intense localized radiation induces lethal DNA lesions 
and the result is cell death [Becker ef a/,1965]. 1-B-D- 
arabinofuranosyl cytosine (ARA-C) is a nucleoside analogue, 
competing with native deoxycytidine for incorporation into newly
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synthesizing DNA at S-phase. Deoxy-c^dine kinase converts ARA-C 
to ARA-C triphosphate (ARA-CTP) [Wist ef a/,1976] and incorporated 
by the complex DNA-synthesizing enzymes into the elongating DNA 
molecule, it prevents subsequent nucleoside polymerization probably 
by stereochemically hindering its access to the 3’-OH group of the 
DNA macromoiecule. As such it acts as a ’chain-terminator’ and Its 
incorporation Is a lethal event for the cell [Millard & Okell,1975].
The kinetic behaviour of the haematopoietic stem cell population 
during chemotherapeutic and radiotherapeutic regimes and during 
haematopoietic transpiantation and embryonic development is of 
great interest. With respect to chemotherapeutic and
radiotherapeutic regimes, widely used in the treatment of 
malignancy, the survival and behaviour of the haematopoietic system 
is an important consideration and a major limiting factor in regulating 
the levels of use of such therapeutic agents.
1,8 The proportion of haematopoietic stem cells in
S-phase,
The CFU-S assay and S-phase suicide techniques have allowed 
the investigation of the behaviour of the haematopoietic stem cell 
population under different conditions, in normal unstressed 
haematopoietic tissue, the proportion of haematopoietic stem cells in 
S-phase is relatively low at approximately 10% [Becker ef a/,1965] 
[Figure 5]. The majority of stem cells in normal unstressed 
haematopoietic tissue, appear to be in a reversible, non-proliferative, 
’Gd-state’ within the cell cycle. This G^^-state may be of particular 
significance, perhaps allowing a genetic ’house-keeping’ mechanism 
to act and maintain the ’high quality' genetic integrity of the 
haematopoietic stem cell population. A rapidly proliferating cell
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system would be forced to express any genetic damage, the defects
possibly passed on to all subsequent progeny perhaps to effect 
aspects of their proliferation, differentiation or maturation.
The relatively large proportion of stem cells in a ’resting’ GoState 
also ensures the haematopoietic tissue has a very great ’functional 
reserve’. As haematopoietic output requires, the proportion of stem 
cells in S-phase can increase to meet the demand. During subiethai 
whole body X-irradiation, this mobilization of the Go-state, ’resting’ 
stem cells can be demonstrated. 1.5 Gy, 3.0 Gy and 4.5 Gy whole 
body X-^adiation doses reduce CFU-S numbers to approximately 
20%, 4% and less than 1% of normal levels respectively [Hendry & 
Lajtha,1972]. After such treatment the proportion of CFU-S In S-phase 
increases from approximately 10% to 40-50% [Guzman & Lajtha,1970] 
{Figure 5J. Haematopoietic stem ceil proliferation is increased In an 
attempt to both maintain the integrity of the damaged haematopoietic 
system and restore CFU-S numbers to pretreatment levels, through 
self-renewai. Once the haematopoietic system has been 
reconstituted, the proportion of the haematopoietic stem cell 
population in S-phase reduces to pretreatment levels.
A similar effect is observed if the haematopoietic system is 
stressed through the use of a haemoiytic agent - phenyl hydrazine 
[Rencricca ef a/,1970]. The anaemia induced by phenylhydrazine, is 
compensated by an increased haematopoietic output, met inturn by 
an increase in the proportion of haematopoietic stem cells in S- 
phase. An increase from approximately 10% to 30-50% in S-phase is 
reported [Rencricca ef a/,1970].
Similarly, during embryonic development a constant increase in 
haematopoietic output is required with growth. Haematopoiesis 
initiated in the murine (and human) yolk sac, develops in the foetal
liver, to eventually become established in the marrow ■ cavities
Figure 5: The proportion of haematopoietic stem cells
(CFU-S) in S-phase.
Normal bone marrow.
Approximately 10% of 
haematopoietic stem 
cells (CFU-S) in S-phase.
Regenerating or foetal
haematopoietic tissue.
30-40% of haematopoietic 
stem cells (CFU-S) in
S-phase.
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[Metcalf & Moore,1971]. The proportion of stem celis in S-phase In 
the foetal liver is relatively high at 30-40% [Thomas ef a/,1981] to 
meet the increasing demand for haematopoietic output.
The mechanism(s) by which the proportion of haematopoietic
stem ceils In S-phase Is modified to meet haematopoietic demand, is
of particular interest.
1,9 Evidence for the local of haematopoietic stem
cell proliferation.
The proportion of haematopoietic stem celis in S-phase, and so 
proliferating, is able to change to match haematopoietic output to 
demand. In unstressed haematopoietic tissue the proportion of stem 
celis in S-phase is relatively low at approximately 10%, while in 
haematopoietically stressed tissue, for example after cytotoxic drug 
treatment, irradiation or during foetal development, the proportion of 
stem cells in S-phase is increased at 30-40%. The mechanism(s) by 
which the proportion of haematopoietic stem cells in S-phase is 
modified has been elucidated through the use of part-body X- 
irradlation.
During whole body X-irradiation, haematopoietic survival is 
enhanced if either the spleen is exteriorized and shielded [Jacobson 
ef a/,1949], or if a hind iimb is shielded [Croizat ef a/,1970; Gidaii & 
Lajtha,1972]. Initially the shielded tissue acts as a stem cell 
’reservoir’, exporting stem ceils to the irradiated, haematopoietically 
deficient haematopoietic tissue [Hanks,1964]. Approximately 30% of 
the total hind iimb stem ceils, as measured by the CFU-S assay, may 
be exported within 6-12 hours of the initial Irradiation insult. The 
depletion of stem ceils in the shielded tissue, leads to an increase in 
the proportion of stem cells in S-phase, sufficient to restore stem cell
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numbers to pre-export levels, through self-renewal, after which the 
proportion of stem cells in S-phase reduces. This is in marked 
contrast to the stem ceils seeding into the haematopoietically-
deficient, irradiated tissues. Here the proportion of stem ceils in S- 
phase is high to develop the extensive haematopoietic regeneration 
required. Thus, within one animal, two distinct populations of 
proliferating stem cells can be demonstrated. Despite the major 
whole-body haematopoietic stress, the proportion of stem cells in S- 
phase in the shielded tissue remains low. This essentially rules out 
the existence of a body-wide stem cell proliferation regulation 
mechanism, with the haematopoietic stem ceil population essentially 
responding to local microenvironmental cues. In shielded tissue, 
once the Initial export depletion is corrected, the local
haematopoietic microenvironment is essentially normal, and the 
proportion of stem celis in S-phase is correspondingly low. 
Conversely, in the irradiated tissue, the local haematopoietic 
microenvironment is depleted and the proportion of stem cells in S- 
phase is correspondingly high, reflecting the local need for 
haematopoietic regeneration.
Similar evidence of a locally active proliferation regulation 
mechanism, is observed with the use of the haemoiytic agent 
phenylhydrazine [Rencricca ef a/,1970; Wright & Lord,1977]. 
Phenylhydrazine induces a marked haemoiytic anaemia and In 
response, the proportion of stem cells in S-phase the bone marrow is 
markedly increased. Stem cells are exported to the spleen from the 
bone marrow, however, In marked contrast, the proportion of stem 
cells in S-phase In the spleen Is low, despite the body-wide 
haematopoietic stress. Again, within one animal, two distinct 
populations of proliferating stem celis can be demonstrated, implying 
the involvement of a localized haematopoietic stem cell proliferation
18
regulation mechanism, the stem cells responding to local
micoenvironmental cues rather than body-wide regulatory signals.
1,10 The mechanism, of haematopoietic stem cell
proliferation regulation.
The putative, locaiiy active regulatory mechanism (s) reponsible 
for modifying haematopoietic stem ceil proliferation, were 
Investigated using crude ceii-free extracts of haematopoietic tissues 
[Lord ef a/,1976; Lord ef a/,1977; Wright & Lord,1977; Wright & 
Lord,1978].
Normal bone marrow extract (NBME), derived from a tissue in 
which the proportion of stem ceils In S-phase is low [Becker ef 
a/,1965], has the capacity to reduce the proportion of stem cells in S- 
phase from haematopoietically stressed or regenerating bone 
marrow, or foetal liver. This is evidence of a proliferation inhibitor 
[Lord ef a/,1976; Cork ef a/,1981] [Figure £|.
Conversely, haematopoietically stressed or regenerating bone 
marrow extract (RBME), (or foetal liver extract), derived from a tissue 
in which the proportion of stem ceils in S-phase is increased [Croizat 
ef a/,1970; Gidaii & Lajtha,1972; Rencricca ef a/,1970; Wright & 
Lord,1977; Thomas ef a/,1981], has the capacity to increase the 
proportion of stem cells in S-phase from normal unstressed bone 
marrow. This is evidence of a proliferation stimulator [Frindel ef 
a/,1976a; Lord ef a/,1977; Frindei ef a/,1978; Thomas ef a/,1981; 
Dawood ef a/,1990] [Figure 7].
The reduced proportion of stem cells in S-phase in normal bone
marrow is thus maintained by the presence of an endogenous 
proliferation inhibitor, while the increased proportion of stem celis in
S-phase in haematopoietically stressed or regenerating bone
Figure 6: Evidence for a stem cell proliferation inhibitor.
NBME------- 1
Regenerating or foetal 
haematopoietic tissue 
Approximately 30-40% 
haematopoietic stem cells 
(CFU-S) in S-phase.
Normal bone marrow 
extract. Derived from 
a tissue in which the 
proportion of stem cells 
(CFU-S) in S-phase is low 
(approximately 10%).
Proportion of stem cells 
(CFU-S) in S-phase 
reduced.
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marrow, or foetal liver, is maintained by the presence of an 
endogenous proliferation stimulator.
Significantly, the slowly proliferating stem celis of normal, 
unstressed haematopoietic tissues, remain slowly cycling, even if the 
endogenous inhibitor is washed away. Similarly, rapidly cycling stem 
celis from haematopoietically stressed, regenerating or foetal 
tissues, remain rapidly cycling, even if the endogenous stimulator is 
washed away [Lord ef a/,1979]. Haematopoietic stem cells thus 
remain either slowly, or rapidly cycling, unless acted upon by the 
opposing proliferation regulator. Removal of the existing regulatory 
activity is not sufficient to change the proliferative status of 
haematopoietic stem ceils.
As previously discussed, the local nature of stem ceil proliferation 
regulation is demonstrated by either part body X-irradiation, or the 
use of the haemoiytic agent phenylhydrazine. The existence of two 
distinct populations of cycling stem ceils within the one animal can 
be explained in part by examination of the respective local levels of 
proliferation inhibitor and stimulator. Unshielded, X-irradiated tissue 
contains rapidly cycling haematopoietic stem cells and this is 
consistent with the local presence of stimulator, in shielded tissue, 
containing slowly cycling haematopoietic stem cells, inhibitor is 
present. Similarly, in phenyl hydrazine-treated marrow, a source of 
rapidly proliferating stem celis, stimulator is demonstrable, while in 
phenyihydrazine-treated spleen, containing slowly cycling stem ceils, 
inhibitor is demonstrable [Lord ef a/,1979; Wright & Lord,1977; Wright 
& Lord,1978].
Use of Amicon Diafio Ultrafiltration, a technique separating 
factors by molecular weight, has isolated the /n/^j/^j/fejr activity to a 
50,000-100,000 dalton fraction of normal bone marrow extract, termed 
NBMBIV [Figure SJ. Sf//n^//aO0/'activlty has been similarly isolated to
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a 30,000-50,000 dalton fraction of regenerating bone marrow extract
(and also of haematopoietically stressed marrow and foetal liver 
extracts), termed RBMB-iii [Figure fl] [Lord ef a/,1977]. (1 dalton = 1 
atomic mass unit (amu) = 10'24g)
No significant /n/r/b/for activity is detected in the 50,000-100,000 
dalton fraction of RBME, or stf/nu/afor activity detected in the 30,000­
50,000 dalton fraction of NBME, implying that the two endogenous 
factors are not present simultaneously but act antagonistically to 
modify the proportion of stem celis in S-phase and tailor stem ceil 
proliferation and so haematopoietic output, to haematopoietic 
demand. Sf/mu/afer and inhibitor are not detected in non­
haematopoietic tissues, demonstrating their role is confined to the 
regulation of haematopoietic tissues [Riches ef a/,1981 a; 1981b].
1.11 Cellular sources of the haematopoietic stem cell
proliferation regulators.
In producing cell-free extracts of normal (NBME) and 
regenerating, haematopoietically stressed or foetal liver tissue 
(RBME), the haematopoietic cells are effectively washed and the 
proliferation regulators removed. As previously stated, this does not 
affect inherent stem cell proliferation [Lord ef a/,1979] - slowly cycling 
ceils remain slowly cycling and rapidly cycling cells remain rapidly 
cycling. If the washed cells are incubated after washing, resynthesis 
of the appropriate regulatory factor occurs. Over a 5 hour period, 
incubated at 37°C, washed, normal bone marrow will resynthesize 
inhibitor, [Wright & Lord,1978] and over a 3 hour period, incubated at 
37°C, washed, regenerating or haematopoietically stressed bone 
marrow, or foetal liver will resynthesize stimulator [Wright & 
Lord,1978]. Resynthesis of the proliferation regulators can be
Figure 8: Stem cell proliferation inhibitor and stimulator
Inhibitor:
Isolated to a 50,000-100,000 dalton 
Amicon ultrafiltration fraction 
of normal bone marrow 
conditioned medium. NBME-IV
Stimulator:
isolated to a 30,000-50,000 dalton 
Amicon ultrafiltration fraction 
of regenerating bone marrow
(or foetal haematopoietic tissue) 
conditioned medium.
RBME-III
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blocked by the action of cyclohexamlde, an inhibitor of protein
synthesis, demonstrating the production of the proliferation
regulators requires active protein synthesis [Wright ef a/,1980b;
1982].
Cellular fractionation studies of haematopoietic tissue 
demonstrate that the cells responsible for the production of the 
proliferation regulators are a non-stem cell population. Fractionation 
of normal murine bone marrow, demonstrates a cell population of 
1.052-1.062 g/ml density which are adherent, phagocytic, relatively 
radio-resistant, Thy 1.2', Fco, phosphodiesterase positive, is 
responsible for inhibitor production [Wright & Lord,1979; Wright ef 
a/,1980b] [Figure flj. Similar fractionation of regenerating murine 
marrow, demonstrates a cell population of 1.064-1.072 g/ml density 
which are adherent, phagocytic, relatively radio-resistant, Thy 1.2' , 
Fc+, is responsible for sf/mu/ator production [Wright & Lord,1979; 
Wright ef a/,1982] [Figure 9].
Microscopic examination of cells at these densities shows a wide 
variety of cell types present, and while two distinct cell densities exist 
for the inhibitor- and of/mwZafer-producing cell populations, it may be 
that a single cell-type is capable of producing either factor with it’s 
density varying accordingly. It is clear however, that the factor- 
producing cells are not stem cells. Virtually no stem cells are found at 
either density and similarly, no factor-producing cells are apparent at 
the density where stem cells are concentrated [Wright & Lord,1979; 
Wright ef a/,1980b; Wright ef a/,1982].
It is likely that the proliferation regulators are produced by cells of 
the monocyte-macrophage lineage within the haematopoietic tissue. 
Macrophages make up a large component of the haematopoietic 
stroma and are already demonstrated to play a major role in the 
regulation of granulopoiesis, erythropolesis, megakaropolesio and
Figure 9: Summary of inhibitor- and stimulator-producing cell populations.
Both inhibitor- and stimulator-producing cell populations are characterized as
Adherent
Phagocytic
Relatively radioresistant 
Thy 1.2 -ve 
Fc +ve
Phosphodiesterase +ve 
F4/80 +ve
Probably cells of the monocyte-macrophage lineage.
Inhibitor-producing cells 1.052 - 1.062 g/mi density. 
Stimulator-producing cells 1.064 - 1.072 g/ml density.
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lymphopoiesis. A monoclonal antibody F4/80, which is specific for 
murine macrophages has been used in association with a density-cut 
procedure and fluorescence activated cell sorting to select for F4/80 
positive and negative populations from murine marrow. An F4/80 
positive fraction contained both inhibitor- and sfZznuZator-producing 
cells and cells displayed the histochemical characteristics of 
macrophages. These purified macrophage populations can be 
cultured over an extended period and still synthesize inhibitor and 
stimulator [Simmons & Lord,1985; Wright & Lorimore,1987; Pojda et 
aZ,1988].
1,12 identification and characterization of the
haematopoietic stem ceil proiiferation inhibitor.
Since cells of the monocyte-macrophage lineage are probably 
responsible for the production of the stem cell proliferation 
regulators, a number of macrophage cell lines were screened for the 
production of either inhibitor or stimulator.
Crude conditioned medium from a murine macrophage cell line 
J774.2 was demonstrated to possess a 50,000-100,000 dalton activity 
which was capable of reversibly inhibiting stem cell proliferation 
[Graham et aZ,1990]. The activity was termed 'stem cell inhibitor 
(SCI). A 50,000 fold purification of the activity from crude J774.2 
conditioned medium was performed and a protein doublet of 8000 
daltons isolated [Graham et aZ,1990]. N-terminai analysis resolved 
amino acid sequences corresponding to a previously described 
superfamily of cytokines, the macrophage inflammatory proteins 
(MIPs) [Wolpe & Cerami,1989]. One component of the isolated 
protein doublet, a 69 amino acid polypeptide, was found to 
correspond to the previously described cytokine, macrophage
23
inflammatory protein - 1 aipha (MIP-1 alpha), and the second 
component of the protein doublet, was found to correspond to the 
previously described cytokine, macrophage inflammatory protein - 1 
beta (MIP-1 B). Antibodies directed against MIP-1 alpha were able to 
remove inhibitory activity from the purified stem cell inhibitor (SCI), 
the crude J774.2 conditioned medium and significantly from normal 
bone marrow extract (NBME), Indicating that the stem cell inhibitor, 
as purified SCI, crude J774.2 conditioned medium or NBME, and MIP 
1 alpha are antigenically and functionally identical. The complete 
genomic sequence of the murine haematopoietic stem cell 
inhlbitor/macrophage inflammatory protein 1 alpha has subsequently 
been determined [Grove ef a/,1990].
Use of the polymerase chain reaction and subsequent generation 
of an expression vector in COS cells has allowed the production of 
recombinant MIP-1 alpha and MIP-1 B. rMIP-1 alpha has native SCI 
activity while rMIP-1 B, although possessing a 67% amino acid 
homology with rMIP-1 alpha, shows no SCI activity, demonstrating a 
considerable degree of MIP-1 alpha specificity. Molecular probes 
have isolated the SCI/MIP-1 alpha gene to murine chromosome 11. 
This Is significant since the genes for interleukins 3-5 and 
granulocyte-macrophage and granulocyte colony-stimulating factors 
as well as the macrophage colony-stimulating factor-receptor lie 
within close genomic proximity. In humans molecular probes have 
isolated the SCI/MIP-1 alpha gene to chromosome 17 [Irving ef 
a/,1990].
Similar studies are likely to isolate and characterize the
haematopoietic stem cell proliferation stimulator.
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1.13 Demonstration of the ha ematopoietic stem ce II
proliferation regulators in in vitro long-term bone marrow
culture.
The modification of haematopoietic stem coll proliferation by the
proliferation regulators can be simulated using in vitro long-term 
bone marrow culture systems. The maintainance of long-term bone 
marrow culture is dependent on the formation of a healthy, adherent, 
'stromal' layer containing a variety of cell types including fibroblast 
and epithelial-like cells, fat cells and phagocytic, mononuclear 
macrophages. This adherent stromai layer provides a unique 
haematopoietic microenvironment, which allows the seeding and 
proliferation of haematopoietic stem cells and the production of 
haematopoietic progenitor cells [Dexter ef a/,1977a; 1977b; Spooner 
& mexter,1984; mhrshkird,1990]. To maintain long-term marrow 
cultures in vitro, a periodic removai of oid medium and replacement 
with fresh medium is required. Cells released into the medium by the 
actively haematopoietic layer, are removed with the old medium to be 
replaced by fresh, cell-free medium. This cellular depletion leads to a 
cyclical increase in the proportion of the haematopoietic stem cell 
population in S-phase, however, within a few days of the depletion, 
the celluiarity of the medium has increased sufficiently for 
haematopoietic output to return to normal levels, with a subsequent 
reduction in the proportion of stem cells proliferating [Dexter et 
a/,1977a; 1977b; Toksoz,1980; Cashman ef a/,1985].
The increased stem ceii proliferation in response to the cellular 
depletion of the culture, is induced by the endogenous production of 
sf/nH/Zaaorby the stromal layer. As cellular ^population occurs after 
5-7 days, ievels of endogenous stimuiator fall and levels of
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endogenous inhibitor Increase, with a resultant reduction in the 
proportion of stem cells in S-phase. It thus appears that this artificial 
in vitro model of haematopoiesis demonstrates the same subtle stem 
cell proliferation regulation mechanism as is observed in vivo.
The degree of stem celi proliferation in long-term bone marrow 
cultures can be artificially manipulated by the exogenous addition of 
either inhibitor or stimuiator. A number of chemotherapeutic drugs 
are S-phase specific, cytotoxic agents and, in use, damage cycling, 
normal tissues as well as the target cancerous tissues.
Haematopoietic tissue is especially sensitive to such agents and the 
potential for the use of the proliferation inhibitor to reduce the 
proportion of haematopoietic stem cells In S-phase, and so sensitive 
to the specific action of the cytotoxic agent, is significant. Such 
potential can be demonstrated using the in vitro, long-term bone 
marrow culture system. Treatment of long-term bone marrow cultures 
with cytosine arabinoside (ARA-C), an S-phase specific cytotoxic 
agent, leads to a long term depression of haematopoietic output. In 
contrast, cultures pretreated with exogenous proliferation inhibitor, 
prior to treatment with ARA-C, perform at least as well as control 
cultures (no ARA-C) [Lord ef a/,1987].
These in vitro results mimic results observed in vivo [Lord & 
Wright,1980]. Exogenous inhibitor was observed to ’protect’ 
haematopoietic stem cells in wvofrom the S-phase specific cytotoxic 
effects of tritiated thymidine (3H-TdR), hydroxyurea and ARA-C.
The use of long-term bone marrow culture systems reveals a 
subtle permissive stromal microenvironment is vital in the 
maintainance and regulation of haematopoiesis. Such a specialized 
microenvironment and evidence of very local haematopoietic stem 
cell-stromal cell interactions [Lambertsen,1984; Zipori,1989] is
26
somewhat reminiscent of the stem cell ’niche’ proposed by Schofield
[1978].
1.14 Regulation of the production of the haematopoietic
stem cell proliferation inhibitor and stimulator.
The mechanism of action of the proliferation regulators has been 
investigated. The proportion of stem cells in S-phase in normal 
unstressed haematopoietic tissue is relatively low and maintained by 
endogenous /n/w/Mo/' activity. In the absence of inhibitor, when cells 
are washed, the proportion of stem cells in S-phase remains low and 
washed, incubated cells resynthesize inhibitor. In regenerating, 
haematopoietically stressed or foetal haematopoietic tissues, the 
proportion of stem cells in S-phase is increased, maintained by 
endogenous of/mu/af^rr production. In the absence of stimuiator, 
when the ceils are washed, the proportion of stem cells in S-phase 
remains increased and washed reincubated cells resynthesize 
stimuiator. Thus, change in the proportion of stem cells in S-phase is 
not simply brought about by a removal of the existing regulatory 
factor. Changes in the proportion of stem cells in S-phase can only 
be induced by the presence of the opposing factor.
Distinct stimuiator and inhibitor producing cells can be Identified 
in all haematopoietic tissues. Both ceil subpopuiations are present 
regardless of the proliferative state of the haematopoietic tissue, with 
the potential to produce one or other factor, or both, however, only 
one proliferation regulator predominates at any one time. This, 
together with evidence that stimuiator and inhibitor are relatively 
stable activities (with no loss of potency after a week at 37°C) 
[Toksoz ef a/,1980] and do not directly Interact, the one not 
inactivating the other [Lord & Wright,1982| implies a distinct
27
regulatory mechanism must exist to coordinate inhibitor and 
stimuiator production and breakdown, to ensure the appropriate 
degree of haematopoietic stem ceii proliferation occurs.
Changes in inhibitor and stimuiator production, and so
changes in the degree of haematopoietic stem cell proliferation, are 
brought about by the action of the one factor on the celi producing 
the other. Isolated inhibitor-producing cells will resynthesize inhibitor 
if washed. However, in the presence of exogenous stimulator, no 
/nb/b/forsynthesis is observed [Figure 10}. Similarly, isolated 
stimuiator-produclng cells will synthesize stimulator if washed. 
However, In the presence of exogenous inhibitor, no stimulator 
synthesis is observed [Lord & Wright,1982; Riches & Cork,1987] 
[Figure 1t}.
This elegant interaction of factor with opposing factor-producing 
cell populations, however, does not allow for the proliferative 
flexibility demonstrated by the haematopoietic system. Regulation by 
this mechanism alone would see haematopoietic tissue effectively 
’locked’ into producing one factor at the expense of the opposing 
factor. Questions arise: When damaged, how does haematopoietic 
tissue and specifically the factor-producing cell population therin, 
’know’ to preferentially produce stimuiator and how is the 
subsequent change from /nb/b/for production brought about ? Also, 
once regenerated, how does the haematopoietic tissue and 
specifically the factor-producing cell population therin, ’know’ to 
cease sf/m^j^^for production and initiate /nb/b/for production and how 
is this change brought about ? In effect how is haematopoietic stem 
cell proliferation coordinated ? The answer appears to lie in a second 
regulatory mechanism intimately related to the haematopoietic stem 
cell population itself.
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1,15 Evidence for a haemaPopoietic stem ceii ifeedback
factor* coordinating stimulator and /nft/Mtor production,
A crude model for the existence of a putative stem cell 'feedback 
factor’ can be proposed: In normal unstressed haematopoietic tissue, 
stem ceil numbers are ’sufficient’ and Interact with the factor- 
producing ceil populations to initiate //?w?Mor production and/or 
suppress sf/nizZpfhr production. Conversely, in haomatopoiatlcplly 
stressed tissue, where stem cell numbers are insufficient, or 
depleted, the Interaction with the factor-producing ceils initiates 
sf/mu/ator production and/or suppresses iohilbi1^^r production. With 
increased stem celi proliferation and self-renewal, stem ceil numbers 
increase, become ’sufficient’ and interaction with the factor- 
producing cells once again initiates /nft/ft/for production and/or 
supresses stimulator production. In this way, a secondary regulatory 
mechanism can be envisaged to directly initiate, or suppress, 
production of one of the factors and so coordinate the proliferative 
state of the haematopoietic tissue.
Experimental evidence exists for such a secondary regulatory 
mechanism [Lord,1986]. A ’stem cell feedback facto? has been 
identified and extracted from stem celi conditioned medium as a 
30,000-50,000 daiton moiety. If added to pherylhydrpzire-troated, and 
so rapidly cycling, bone marrow, stem ceii feedback factor has the 
capacity to reduce the proportion of stem cells in S-phase although 
not itself being a proliferation inhibitor. A reduction in stimulator 
ievels and increase in inhibitor levels is observed. Whether the stem 
ceil feedback factor is actively preventing sf/ww/afor production and 
subsequently allowing /nft/d/tor production, or else is activating 
/nfr/ZMor production, which wiii inturn prevent sf/mu/ator production 
by the sf/mu/afor-producing celis, can be determined. Removai of the
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inhibitor-producing cell subpopulation from the phenyhydrazine- 
treated marrow, prior to the addition of stem cell feedback factor, 
demonstrates that stimuiator production is inhibited rather than 
inhibitor production initiated. The action of the stem cell feedback 
factor thus appears to actively suppress stimulator production by 
stimulator-producing cells thereby allowing inhibitor production 
[Figure 12[.
Stimulator production in regenerating haematopoietic tissue can 
be explained in terms of the putative stem cell feedback factor. In 
sublethaliy X-irradiated haematopoietic tissue, stem cell numbers are 
depleted. With stem cell depletion, levels of stem cell feedback factor 
will fall. The inhibition of stimulator production by the stimulator- 
producing celis is removed allowing the production of stimulator.
With the increase in endogenous stimulator, the proportion of stem 
cells in S-phase increases and stem cell numbers will be restored 
through self-renewal. With the restoration of stem ceil numbers to 
pre-irradiation levels, levels of stem cell feedback factor rise to 
actively suppress stimulator production by the stimulator-producing 
cells, allowing production of the proliferation inhibitor, with a 
subsequent reduction in the proportion of stem cells in S-phase. For 
such a feedback factor to operate, the levels of the factor must be 
proportional to the size of the stem cell population. In this manner, 
one can envisage an elegant feedback loop coordinating the 
production of proliferation regulators, and so the proportion of 
haematopoietic stem ceils in S-phase, to the required haematopoietic 
output.
However, high stem cell numbers, with a supposed high 
concentration of putative stem cell feedback factor, are not always 
consistent with slowly proliferating haematopoietic tissue. Similarly, 
low numbers of stem cells, with a low concentration of putative stem
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cell feedback factor, are not always associated with rapidly 
proliferating haematopoietic tissue. Consider eheryihydrpziro- 
treated bone marrow. Stem ceil numbers are not significantly 
reduced and a high putative stem cell feedback factor concentration 
should exist inducing iow stem cell proliferation. However, this is not 
the case. Where stem ceii numbers are high so too is the degree of 
stem ceil proliferation. It is also difficult to explain the increased stem 
cell proliferation observed in foetal haematopoietic tissues where 
again stem ceii numbers are relatively high. Stem celi numbers must 
not be the sole determining factor in this feedback mechanism. Lord 
and Wright [1982], suggest the localized ratio of stem celi numbers to 
factor-producing cells may be a more significant determinant.
1.16 The distribution of and inhibitor-
produclnq cells In the bone marrow.
As previously discussed, stem ceils are not uniformly, or 
randomly, distributed throughout normal bone marrow [Lord & 
Handry,1972; Lord ef a/,1975], rather a considerable degree of 
haematopoietic micrharchitoctura exists. Similarly, the distribution of 
inhibitor- and sf/oiz/pfhr-prhducirg ceils is not uniform, or random 
[Lord & Wright,1984]. Varying the size of axial cores of murine 
femoral marrow as axial, central and marginal regions, demonstrates 
that a well defined micro-organization of various ceii populations 
exists.
/nS7/b/fhr-erhducirg ceils are most abundant in the axial core of 
the femoral marrow, the numbers of such celis reducing as one 
approaches the endosteal surface of the bone. Conversely, 
sf/znu/Ph/*-producing cells are most abundant at the endosteal 
surface of the bone, in the marginal region of the marrow. The
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presence of increased numbers of sf/mu/afor-producing cells in this 
subendostea! region probably accounts for the high degree of stem 
celi proliferation observed in this region. Axial stem ceii proliferation 
is relatively low in comparison, consistent with the presence of
increased numbers of /nb/bbor-producing cells.
The slowly cycling stem cells derived from the axial marrow are of 
a ’higher quality' than those found in the subendosteai marrow. Such 
’high quality' stem cells possess a high self-renewal capacity and are 
better able to establish haematopoietic regeneration in
haematopoietically-deficient mice, in comparison to the subendosteai 
stem ceils. This implies that the stem ceil population is a 
heterogenous population, as previously discussed, and that axial 
stem ceils are more primitive haematopoietic precursors than those 
in the subendosteai marrow. It has been proposed that an age- 
related migration of stem ceils from the primitive, axial stem ceils to a 
more mature, subendosteai stem ceil population may occur. With this 
putative migration, the presence of decreasing numbers of inhibitor- 
producing ceils and increasing numbers of sf/mzzZafor-producing cells 
wiil alter the subtle microenvironmental cues to which the ceils are 
exposed.
1.17 The stem cell specifieity of stimulator and inhibitor
and variation in the sensitivity to the proliferation
regulators with stem ceii maturation.
The relative sensitivities of a number a haematopoietic 
precursors to the proliferation Znb/bbor and stimuiator have been 
investigated [Tejero ef a/,1984]. A comparison of day 9 CFU-S, mixed 
colony-forming cells (CFC-mix) (an in vitro cell population shown to 
possess characteristics which imply a close relationship to the in vivo
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CFU-S population) [Metcalf et a/,1978; Johnson,1980] and more 
mature, committed haematopoietic progenitors: granulocyte- 
macrophage colony-forming cells (GM-CFC) and erythroid burst­
forming units (BFU-E), has demonstrated that stimulator and inhibitor 
are only effective against the more primitive haematopoietic 
precursors, the day 9 CFU-S and in vitro CFC-mix. GM-CFC and BFU- 
E, show no stimulator or inhibitor sensitivity, implying that stimulator 
and inhibitor are stem cell-specific in nature, regulating the 
proliferation of the more primitive components of the haematopoietic 
system. The more mature GM-CFC and BFU-E haematopoietic 
progenitor cell populations possess their own specific regulation 
mechanism, related to end-cell feedback [Lord et al,1974a; 1974b]. 
Significantly, the haematopoietic stem ceil population proves 
insensitive to these more mature haematopoietic progenitor cell 
proliferation cues.
Within the heterogenous stem cell population there is a variation 
in the sensitivity to inhibitor and stimulator [Tejero ef a/,1984; Wright 
et a/,1985; Lorimore et a/1990] and this contributes to the evidence 
of an age-related organization of the stem cell population. Day 12 
CFU-S are believed to be a more primitive stem ceil population than 
day 7 CFU-S, and possess an increased sensitivity to the 
haematopoietic stem cell proliferation inhibitor and reduced 
sensitivity to the proliferation stimulator. As the day 12 CFU-S mature 
to day 7 CFU-S and subsequently to the in vitro CFC-mix, there is a 
progressive reduction in inhibitor sensitivity and a progressive 
increase in stimulator sensitivity [Tejero et a/,1984; Wright ef a/,1985; 
Lorimore et a/,1990] [Figure 73]. In effect, the more primitive 
haematopoietic stem celis prove a more difficult population to induce 
into S-phase than do the more mature CFU-S and in vitro CFC-mix.
Figure 13: The variation in stem cell sensitivity to
inhibitor and stimulator with maturation.
1) More primitive components of the haematopoietic 
stem cell population (day 12 CFU-S) display 
INCREASED inhibitor 
and
REDUCED stimulator 
sensitivity.
2) More mature components nt t he haematopoietic 
stem cell population (day 7 CFU-S and CFC-mix) display 
REDUCED inhibitor
and .
INCREASED stimulator
sensitivity.
3) Mature, commuted haematopoietic progenitor 
populations (GM-CFC and BFU-E) display 
NO sensitivity to either inhibitor or stimulator.
THEREFORE:
1) With stem cell maturation, sensitivity to inhibitor 
REDUCES and sensitivity to stimulator INCREASES.
2) Inhibitor and Stimulator are stem cell specific
proliferation regulators.
t
Relative
sensitivity
A diagramatic 
representation 
of the variation 
in inhibitor and 
stimulator 
sensitivity with 
maturation.
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In the light of this variation in proliferation regulator sensitivity
with maturation, as the stem cells undergo the putative migration 
from the axial marrow to the subendosteal marrow, is it the subtle 
changes in the proliferation regulator levels which are actually 
responsible for the induction of 'ageing* ? In effect, is the 
haematopoietic microenvironment 'maturing' the stem cells as they 
undergo their migration, developing a stem cell of limited self­
renewal and increased capacity for differentiation, with the reduction 
in endogenous inhibitor levels and an increase in stimuiator levels ? 
Alternatively, is it the natural maturation of the haematopoietic stem 
cell population with it's reduction in inhibttor sensitivity and increase 
in sfimyiafor sensitivity, which attracts it towards the stimuiator-rich, 
subendosteal microenvironment ? At present this is unclear.
1,10 The non-species specificity of the stem cel||-^^<^<^iii^i<t
proliferation regulators.
While the proliferation stimuiator and inhibitor are stem cell- 
specific in nature, there is evidence that they are non-species 
specific. 50,000-100-000 dalton extracts of normal human [Wright et 
ai,1900a], rat [Riches ef ai,1901 a; Cork ef ai,1901], guinea pig [Riches 
ef ai,1901b] and pig [Riches ef ai,1901b] bone marrow, have the 
capacity to reduce the proportion of stem cells in S-phase in 
regenerating murine marrow. Similarly, a 30,000-50,000 dalton extract 
of human foetal liver [Riches ef a/,1901 b; Cork ef ai,1902; Cork ef 
ai,1906] has the capacity to increase the proportion of stem cells in 
S-phase in normal murine marrow. Significantly, extracts of human 
foetal thymus, a non-haematopoietic tissue, show no proliferation 
regulator activity implying the production of stimuiator and inhibitor 
is restricted to haematopoietic tissues [Riches ef ai,1901 a; 1901b].
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Such evidence of species cross-reactivity, suggests a highly
conserved haematopoietic stem ceil regulatory system exists. The 
fact that human haematopoietic stem ceil proliferation regulators can 
be assayed in a murine system is of significance since there is no 
equivalent to the murine CFU-S assay with which to directly assay the 
human haematopoietic stem cell. Using the murine system, the 
relative levels of the endogenous proliferation regulators in human 
haematopoietic tissues can be assessed and the kinetic state of 
human haematopoietic stem cells infered.
1.19 Other haemoregulatory activities.
While discussion thus far has been restricted to the normal bone 
marrow-derived 50,000-100,000 dalton, stem cell proliferation 
inhibitor, and regenerating or maemetopoletlcally stressed bone 
marrow-, or foetal liver-derived 30,000-50,000 dalton, stem cell 
proliferation stimulator, it is acknowledged that a number of other 
positive and negative haemoregulatory activities have been 
identified. However, the effects of the majority of these factors is 
largely at the level of the haematopoietic progenitor ceil population 
rather than at the level of the haematopoietic stem cell population. 
The target cells of most of the characterized heamoraguletory 
activities, appear to be the bipotentiai granulocyte-macrophage, early 
erythroid or megakaryocyte progenitors (Reviewed by Axelrad [1990] 
and Graham & Pragnell [1990]). However, a haematopoietic stem cell 
proliferation inhibitor, distinct from the 50,000-100,000 dalton normal 
bone marrow extract (NBME-iV), has been identified.
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1.20 A low molecular weight haemarequiatory peptide.
Isolated from foetal calf bone marrow [Frindel & Guigon,1977] 
and from foetal calf liver [Gulgon ef a/,1984] as a crude dialysable 
extract and as a seml-purified factor, it has the capacity to prevent 
haematopoietic stem cell ’recruitment' into S-phase from the 
quiescent Go-state, following sublethai X-irradiation, or cytotoxic drug 
treatment [Gulgon & Frindel,1978]. It does not act to reduce the 
increased proportion of stem cells in S-phase in regenerating or 
haematopoieticaliy stressed bone marrow, or foetal liver, as does 
NBME-iV. Used in vivo, the foetal calf bone marrow extract has been 
demonstrated to 'protect’ mice from potentially lethal doses of the S- 
phase-specific agent cytosine arabinoside (ARA-C), by preventing 
the recruitment of quiescent stem cells into a cytotoxic drug-sensitive 
S-phase [Gulgon ef a/,1980; Gulgon ef a/,1981; Gulgon ef a/,1982; 
Wdzieczak-Bakala ef a/,1983; Gulgon ef a/,1989]. Use of foetal calf 
bone marrow, or foetal calf liver dialysate as a crude source of the 
proliferation inhibitor, implied the factor was of low molecular weight. 
Subsequent purification isolated a tetrapeptide of 487 daltons, with 
no carbohydrate and of amino acid sequence: Acetyl-N-Ser-Asp-Lys- 
Pro-OH (AcSDKP) [Lenfant ef a/,1989a] [Figure 14[, The purified and 
synthesized molecule has native, crude extract activity and 
administered at 1OOng per mouse (4ug per Kg body weight), shows 
no toxicity, but is sufficient to 'protect' mice from cytotoxic drug- 
induced haematopoietic damage. The tetrapeptide, isolated from 
foetal calf tissue is active in both murine and human haematopoietic 
tissues [Gulgon ef a/,1990], demonstrating a non-species specificity.
The small molecular weight tetrapeptide is possibly an active 
fragment of a higher molecular weight molecule, degraded in the
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complex purification procedure. Lenfant ef ai [1909a] using foetal calf 
liver as a crude source of the factor and a more gentle extraction and 
purification technique in an attempt to preserve any putative high 
molecular weight moiety, failed to find any evidence of such a 
molecule. This may imply the AcSDKP is active physiologically as a 
low molecular weight moiety.
The SDKP amino acid sequence has been identified in a number 
of existing characterized molecules [Lenfant ef ai,1909a; Pradelles et 
ai,1990]. The significance of the sequence in rat liver phenylalanine 
hydroxylase is unclear, however, the sequence is also found in 
tumour necrosis factor-aipha (TNF-alpha), a putative
haemoregulatory activity [Old,1905; Broxmeyer ef ai,1906; Munker ef 
ai,1907; Peetrie ef ai,1900; Slordal ef ai,1909], and thymosin &4. 
Thymosin 0-4 possesses a N-terminal 'AcSDKP-’ sequence and 
proteolytic cleavage would yield an AcSDKP moiety. An endogenous 
enzyme endoproteinase Asp-Nhas subsequently been isolated and 
is demonstrated to perform such a proteolytic cleavage of thymosin 
0-4 [Grillon ef ai,1990] [Figure 151- This may have significance since 
the thymus is reported to play a role in haematopoietic stem cell 
proliferation regulation [Frindel ef a/,1976b; Lepault ef ai,1979;
Lepault ef ai,1901; Fache ef a/,1902; Lepault ef ai,1900].
As a proliferation inhibitor, AcSDKP may act in antagonism to 
interleukin 3 (IL3)imulti-CSF, which has the capacity to stimulate the 
proliferation of multipotential haematopoietic precursors. However, 
AcSDKP does not inhibit IL3-dependent cell line proliferation, nor 
does it inhibit IL3-induced granulocyte-macrophage, or mast cell 
colony formation. No evidence of AcSDKP competition for IL3 
receptors is observed [Lenfant ef ai,1909c]. Reported mast cell 
colony suppression by semipurified extracts of AcSDKP was
Figure: 14: The low molecular weight haematopoietic
stem cell proliferation inhibitor - AcSDKP.
Acetyl - N - Ser - Asp - Lys - Pro - OH
AcSDKP
mw = 487 amu
Figure 15: Thvmosin B-4.
AcSDKP- DMAEIEKFDKSKLKKTETTQEKNPLPSKETIEQEKQAGES
A
”Endoproteinase Asp-N"
The possible mechanism of AcSDKP production from thymosin 6-4
by the proteolytic enzyme "Endoprotalnese Asp-N".
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considered due to a co-purifying activity distinct from the AcSDKP 
moiety [Lenfant et ai,1909b].
The effects of AcSDKP on haematopoietic stem cell and stroma 
interactions have also been investigated. MS-1-T, a murine bone 
marrow stromal cell line [Itoh ef ai,1909], shows a slight reduction in 
proliferation in the presence of AcSDKP, however, more significant is 
a marked increase in stem cell adhesion to the stromal layer in the 
presence of AcSDKP [Lenfant ef ai,1909c]. The physiological 
significance of this AcSDKP-mediated increase In stem cell adhesion 
to stromal tissue is unclear at present.
Other cell-cell interactions are modified by the presence of 
AcSDKP. In vitro, human Jurkat lymphoma T-cells and sheep 
erythrocytes form 'rosettes’ [Thierry ef ai,1990]. In the presence of 
AcSDKP, rosette formation is inhibited, a titratable effect allowing it's 
use as a bloassay of AcSDKP activity. Sheep erythrocytes possess a 
T11TS membrane glycoprotein which interacts with the human CD2 T- 
cell membrane glycoprotein to produce the rosette. A region of the 
CD2 glycoprotein which modulates rosette formation contains the 
amino acid sequence -Ser-Asp-Lys- (-SDK-). It is thought that 
addition of exogenous AcSDKP competes with the CD2 -SDK- 
sequence for membrane recognition sites, so preventing rosette 
formation in a dose-dependent manner. Peptide analogues of 
AcSDKP, with modifications to determine the minimal active 
sequence of the molecule, and changed amino acids, to determine 
the role of chemical side chains, have been produced and both 
acetylated and de-acetylated peptides have been assayed for activity 
in the rosette formation-inhibition assay. The analogue Ser-Asp-Lys 
(SDK) was found to be the most potent rosette formation-inhibitor, 
able to inhibit rosette formation at *10*i4M in comparison to the native 
AcSDKP molecule, inhibiting at 10'4m. Many of the analogues
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produced showed no rosette formation-inhibition even at 103M,
demonstrating that a very specific molecular interaction may be 
occuring. The specific requirements for an inhibiting moiecule in the 
rosette formation assay appear to be (1) the presence of three polar 
amino acid side chains and (2) the presence of a se/yA moiety within 
the peptide sequence [Thierry ef a/,1990].
The physiological role of AcSDKP In inhibiting such a T-cell 
interaction at the level of haematopoietic stem ceil regulation is 
unclear. It has been proposed that T-cells may mediate the inhibitory 
effects of the AcSDKP molecule in vivo, however, nude, athymic 
mice, with no T-cell population, still demonstrate an AcSDKP- 
associated 'protection' from the cytotoxic effects of cytosine 
arabinoside [Monpezat & Frindel,1989]. This implies that the action of 
AcSDKP Is T-cell independent.
The cellular specificity of AcSDKP has been investigated on a 
number of cell-lines in vitro. With specific ceil lines, it Is possible to 
synchronize cells within the cell cycle. Primary cultures of 
hepatocytes exist mostly in a unless appropriately stimulated
with epidermal growth factor, insulin and pyruvate. Similarly, 
fibroblast 3T3 cells can be arrested by serum-deprivation. 
Reintroduction of serum, stimulates growth. Factor-dependent cell 
lines (FDC) can be arrested by withdrawal of their appropriate factors 
and stimulated by their reintroduction. In all cases, either hepatocyte, 
3T3 or FDC cells, none of the stimulatory influences were overcome 
by AcSDKP inhibition. Also, addition of AcSDKP to rapidly cycling cell 
populations, failed to reduce proliferation, although a similar addition 
of transforming growth factor-beta (TGF-B), or interferon (IFN) does 
[Lauret ef a/,1989a].
A degree of proliferation inhibition of hepatocytes in vivo by 
AcSDKP has been reported. Hepatocytes triggered into cycle by
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deg^a^e enzyme activity, or partial hepetectomy, show a 50-70% 
proliferation inhibition by AcSDKP [Lombard ef a/,1990]. Since the 
pure primary hepatocyte culture showed no such proliferation 
inhibition, an explanation of this in vivo observation may be the 
presence of non-parenchymal liver cells in the heterogenous liver ceil 
population. These cells may repond to the AcSDKP and mediate 
subsequent hepatocyte proliferation, a mechanism already 
demonstrated to exist with the production of liver-active proliferation 
regulators.
The degree of AcSDKP 'protection' of the haematopoietic stem 
cell population in vivo with the use of S-phase specific cytotoxic 
agents, is extremely sensitive to the relative times of drug and 
AcSDKP administration. This allows a determination of the precise 
point in the cell cycle at which AcSDKP exerts its proliferation 'block' 
after a cytotoxic drug 'recruitment trigger' [Monpezat & Frindei,1989]. 
AcSDKP is only active at the Go-G1 transition and cells progressing 
into early Go and subsequently into S-phase prove insensitive to the 
inhibition of AcSDKP. This would explain the observed failure of 
AcSDKP to inhibit an already cycling cell population. If AcSDKP is 
administered before the influence of the cytotoxic drug initiates stem 
cell proliferation, the majority of stem cells undergo the. AcSDKP- 
associated 'recruitment block' and are spared. However, if AcSDKP is 
administered after the cytotoxic drug-associated ’proliferation trigger’ 
Is effective, with most of the stem cells mobilized into Go, then it is 
too late for the action of the AcSDKP-assocleted 'recruitment block’ 
to act. Even if the proportion of stem cells in S-phase appears 
relatively low at drug administration, the majority of stem cells will 
subsequently progress to S-phase and cytotoxic drug-induced death 
with the associated haematopoietic damage [Monpezat & 
Frindel,1989].
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AcSDKP is not an Immunogenic moiety, however, an amino acid 
extension of the tetrapeptide Is immunogenic and an antiserum
produced cross-reacts with AcSDKP [Lauret ef ai,1909b]. Although 
the antiserum is of low affinity for AcSDKP, it's use in vivo Is reported 
to increase the proportion of stem ceils In S-phase dramatically 
[Frindel & Monpezat,1909]. This demonstrates the AcSDKP moiety is 
produced in vivo and is active physiologically as an endogenous 
stem cell proliferation inhibitor. If the Inhibition is removed by the 
presence of a neutralizing antibody, inhibited stem cells are allowed 
to enter S-phase and proliferate. Use of the neutralizing antiserum 
has also been demonstrated to remove the AcSDKP-associated, 
’protection' of stem cells against the action of S-phase specific 
cytotoxic drugs. The effects of both the addition of exogenous 
AcSDKP and it’s removal by the use of a neutralizing antiserum have 
thus been demonstrated and strongly imply a physiological role for 
the tetrapeptide.
With the development of the AcSDKP antiserum, enzyme 
immunoassay of AcSDKP has been developed [Pradelles ef ai,1990] 
and is reported to detect levels of AcSDKP down to 15 femto Molar 
(15x10‘14M). Using immunoassay the presence of AcSDKP in normal 
mononuclear blood cells [Pradelles ef a/,1990] and a similar molecule 
in human placental extract [Lopez ef a/,1991], have been 
demonstrated. The quantitative and qualitative immunoassay of 
AcSDKP should now allow the biosynthesis of the molecule to be 
investigated, the producer-cells to be identified and levels of 
endogenous AcSDKP in various haematological disorders to be 
determined. Interestingly, use of enzyme immunoassay implies a 
number of AcSDKP-like molecules may exist, perhaps suggesting 
evidence for a novel family of very low molecular weight, potent, 
haemoregulatory activities.
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De novo synthesis of AcSDKP has been followed in vivo in mice
and in vitro in long-term murine bone marrow cultures [Wdzieczak- 
Bakala ef a/,1990] using tritiated proline (pH]-proline). pH]-proiine 
competes with native proline for Incorporation into newly synthesized 
AcSDKP. Newly synthesized AcSDK-[3H]P was detectable, secreted 
by bone marrow stroma and pH]-proiine pulse labelling gives some 
evidence that AcSDKP may be derived from a larger precursor and 
undergoes enzymatic maturation to form biologically active AcSDKP 
[Wdzieczak-Bakala ef a/,1990].
Cyclical changes are reported in the proliferative state of the 
haematopoietic stem cell population In long-term bone marrow 
cultures with refeeding [Wdzieczak-Bakala ef a/,1990]. This is 
considered due to the removal of endogenous AcSDKP with the old, 
spent medium and replacement with fresh AcSDKP-deficient medium. 
The removal of endogenous AcSDKP removes the inhibition of stem 
ceil proliferation, allowing the proportion of stem cells in S-phase to 
increase. Proliferation levels remain relatively high until the levels of 
endogenous AcSDKP are restored by resynthesis and stem cell 
proliferation inhibition restablished. (This compares with the 
previously discussed observations of Dexter ef a/[1977], Toksoz 
[1980] and Cashman ef a/[1985], who also demonstrated such 
cyclical proliferation changes in long-term bone marrow cultures at 
refeeding. They concluded such cyclical changes were due to cellular 
depletion and subsequent variations in endogenous levels of NBME- 
IV and RBME-Ill. How the two distinct proliferation regulation systems 
relate and possibly interact will be of considerable interest.)
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1,21 The haematopoietic colonv-stimulatinq factors.
The in vivo CFU-S assay [Till & McCulloch,1961] has greatly 
improved the understanding of haematopoietic stem cell regulation 
and behaviour, however, the assay has considerable drawbacks 
amongst which is the large numbers of mice required to obtain 
statistically significant results. The development of an in vitro, 
clonogenic assay of a similarly primitive, high proliferative potential, 
self-renewing, multipotential haematopoietic precursor, would be a 
considerable development. A number of in vitro clonogenic assays 
already exist which utilize semi-solid agar, or methylcelluiose culture 
techniques, to support the growth of haematopoietic colony-forming 
cells. A consequence of the development of such in vitro assays was 
the recognition that haematopoietic progenitor cells are unable to 
survive, or proliferate, unless specifically stimulated. A group of 
specific regulatory glycoproteins, stimulating haematopoietic 
progenitor cell proliferation and certain aspects of mature cell 
function, have been isolated as haematopoietic coiony-stimuiating 
factors (CSFs). The best characterized haematopoietic colony- 
stimulating factors are those regulating the proliferation and 
maturation of the granulocyte-macrophage progenitors, although 
similar regulatory factors exist for progenitors of the erythroid, 
eosinophil, megakaryocyte, mast and lymphoid lineages within the 
haematopoietic system.
A number of granulocyte-macrophage colony-stimulating factors
have been identified In both human and murine heematopolesls and 
these will be briefly discussed:
Murine granuiocyte coiony-stimuiating factor (G-CSF) is 
synthesized by a wide variety of tissues and is a 25,000 dalton 
glycoprotein [Nicola ef a/,1983]. Active at 10*i2M, it stimulates the
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proliferation of iineage-commltted granulocyte progenitors within 
haematopoietic tissue and has a considerable capacity to induce 
terminal differentiation [Metcalf & Nicola,1983]. The molecule has 
considerable tertiary structure maintained by intra-molecuiar 
disulphide bonds, without which biological activity is lost. One copy 
of the G-CSF gene is present in the murine genome, isolated to 
chromosome 11. Murine G-CSF displays a 70% amino acid sequence 
homology with its human equivalent, a glycoprotein of 20,000 
daltons, the gene of which has been isolated to human chromosome 
17. G-CSF displays cross-species activity. [Nagata ef a/,1986; Nomura 
ef a/,1986; Tsuchiya ef a/,1986; Nagata,1989].
Murine macrophage colony-stimulating factor (M-CSF/CSF-1) is 
synthesized by fibroblasts and is found in embryonic yolk sac and 
pregnant mouse uterus extract (PMUE) [Stanley & Heard,1977; 
Johnson & Burgess,1978]. Purified to homogeneity from mouse L-celi 
conditioned medium as a 70,000 dalton, dimeric glycoprotein 
[Burgess ef a/,1977; Waheed & Shadduck,1982; Burgess ef a/,1985], it 
is active at 1O'13-io33m, stimulating predominantly committed cells of 
the monocyte-macrophage lineage to proliferate and differentiate. 
The intact 70,000 dalton dimer is heavily glycosylated (*The purpose 
of this carbohydrate moiety, present to a varying degree in all native 
colony-stimulating factors, but not necessary for biological activity 
(non-glycosylated, recombinant factors still demonstrate activity), is 
to confer solubility, stability and resistance to proteolytic degradation 
to the CSFs. As such, the CSFs are extremely resilient, resisting 
denaturation and enzymatic degradation.) and consists of two 
identical subunits, of approximately 14,000 daltons, linked by inter- 
molecuiar disulphide bonds. Mercaptoethanol disruption of the 
disulphide bonds yields two haematopoieticaliy inactive subunits.
One copy of the gene for murine M-CSF/CSF-1 is present and has
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been isolated to chromosome 3 [Gisselbrecht ef a/,1909] and murine 
M-CSF/CSF-1 displays an 00% amino acid sequence homology with 
it’s human equivalent, a dimeric glycoprotein of 70,000-90,000 
daltons, which consists of two identical 21,000 dalton subunits. The 
gene for human M-CSF/CSF-1 has been isolated to chromosome 5 
[Pettenati ef a/,1907; Ladner ef a/,1900] and M-CSF/CSF-1 displays a 
cross-species activity.
Murine granulocyte-macrophage colony-stimulating factor (GM- 
CSF), synthesized by a wide variety of tissues, was purified to 
homogeneity from mouse lung conditioned medium, as a 25,000 
dalton glycoprotein [Burgess ef a/,1977]. Active at 10' 12M, it 
stimulates primarily the proliferation and differentiation of both 
bipotental granulocyte-macrophage progenitors and lineage- 
committed granuiocyte and macrophage progenitors from 
haematopoietic tissue. The molecule has considerable tertiary 
structure maintained by intra-molecular disulphide bonds. 
Mercaptoethanol-treated GM-CSF has no biological activity [Gough et 
a/,1905]. Murine GM-CSF has a single gene localized to chromosome 
11 [Gough ef ai,1904] and displays a 50% amino acid sequence 
homology with it’s human equivalent, a glycoprotein of 10,000-24,000 
daltons. The gene for human GM-CSF has been localized to 
chromosome 5. GM-CSF is a species specific factor [Yang ef a/,1900; 
Miyatake ef a/,1905].
Murine interleukin 3 (\L3)/mu/tipotentiai coiony-stimuiating factor 
(multi-CSF), is synthesized by antigenimitogen stimulated T-cells and 
is produced constitutively by the myelomonocytic leukaemic cell line 
WEHI-3B [Warner ef a/,1969; Metcalf ef a/,1969; Lee ef ai,1902; Baziil 
ef ai,1903; Ciark-Lewis ef a/,1905; McNiece ef a/,1905]. Purified to 
homogeneity [ihle ef a/,1902], IL3/Multi-CSF is a glycoprotein of 
23,000 daltons, acUve at -O'^-O'1 iM. -t stimulates -he proHferatton
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and maturation of multlpotentiel haematopoietic precursors, 
bipotential and lineage-committed granulocyte/macrophage 
progenitors and committed erythroid, eosinophil, mast cell and 
megakaryocte progenitors from haematopoietic tissue [Ihle ef 
a/,1983; Hapel ef a/,1985]. A single copy of the IL3/multi-CSF gene 
exists in the murine genome, localized to chromosome 11. IL3/multi- 
CSF has a 30% amino sequence homology with it's human 
equivalent, a glycoprotein of 15,000-25,000 daltons, the gene of which 
is isolated to chromosome 5 [Yang ef a/,1988; Yang ef a/,1989]. 
IL3/multi-CSF is species specific.
These granulocyte-macrophage colony-stimulating factors are 
complemented in haematopoietic regulation by a rapidly expanding 
family of haematopoieticaliy active factors. A number of these factors 
will be briefly discussed:
Erythropoietin (Epo) [Stephenson ef a/,1971; Miyake ef a/,1977; 
Jacobs ef a/,1985] is a glycoprotein which stimulates the proliferation 
and differentiation of relatively mature, llnaega-committad erythroid 
progenitor cells. Earlier erythroid progenitors are stimulated if a 
’ burst promoting activity (BPA) is added prior to Epo. Both GM-CSF 
and IL3/multi-CSF possess such BPA activity. The single gene for 
murine Epo has been isolated to chromosome 7 and the mature gene 
product has considerable tertiary structure, maintained by intra­
molecular disulphide bonds, without which, biological activity is lost.
Interleukin f (iLI) exists as I L1 alpha and beta. It is primarily 
active in the mediation of the inflammatory response, however, it also 
demonstrates haematopoietic activity [Bagby,1989; Henney,1989]. 
IL1, initially identified as ’hemopoietirrh [Jubinsky & Stanley,1985; 
Mochizuki ef a/,1987] has no colony-stimulating activity. It's major 
function appears to be an induction of expression of other genes, 
including those for interleukin 6 (IL6) [Walther ef a/,1988], the colony-
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stimulating factors [Sieff ef a/,1987; Segal ef a/,1987; Lee etai, 1987; 
Kaushansky ef a/,1988; Fibbe ef a/,1988] and their receptors. It is 
proposed that IL1 mediates it's effects by modifying the accumulation 
of mRNA of the appropriate gene. Subsequent translation of this 
reservoir of mRNA, rapidly yields a considerable amount of protein. 
While mRNA is normally very short lived, IL1 appears to increase it’s 
stability, prolonging the life of the proteln-template and aiiowing a 
considerable flexibility In both the amount and rate of protein output, 
as required. IL1 has also been Implicated as a regulator of some 
leukaemic populations [Sakai ef a/,1987; Griffin ef a/,1987]. Murine 
IL1-alpha and IL1 -B are both non-species specific and demonstrate a 
62% and 30% amino acid homology respectively, with their human 
equivalents.
Interleukin 4 (IL4) is ^^-(^^1/stimulating factor-T (BSF-1) and 
stimulates the proliferation and maturation of B-lymphocytes. It 
induces immunoglobulin synthesis, B-lympocyte surface receptor 
production and the production of cytotoxic T-lymphocytes. It also 
stimulates the proliferation and differentiation of mast cells, although 
IL4 receptors are detected on a wide variety of cell types [Yokota ef 
a/,1986; Mosmann ef a/,1986]. The gene for human IL4 has been 
isolated to chromosome 5 [LeBeau ef a/,1989; van Leeuwen ef 
a/,1989] and IL4 is species specific [Mosmann ef a/,1987].
Interleukin 5 (IL5) Is B-ceii growth factor-UF (BCGF-HI). It is a 
dimeric, non-species-specific factor stimulating B-lymphocyte 
proliferation and maturation. It also stimulates the proliferation and 
maturation of lineage-committed eosinophil progenitors from 
haematopoietic tissue [Yokota ef a/,1987; Clutterbuck & 
Sanderson,1988]. Some colonies stimulated by IL5 are mixed 
basophil/eosinophil colonies [Yokota ef a/,1987] which suggests a 
bipotentiai progenitor may exist for these lineages. IL5 also promotes
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the action of mature eosinophils [Yamaguchi ef a/,1900]. The gene for
ILS has been isolated to murine chromosome 11 and human 
chromosome 5 [LeBeau ef ai,1909, van Leeuwen ef a/,1909].
Interleukin 6 (IL6) or interferon beta-2 (IFN-B2) stimulates B- 
lymphocyte differentiation and stimulates the production of cytotoxic 
T-lymphocytes [Wong & Clark,1900]. The gene for human IL6 has 
been isolated to chromosome 7, and the gene product, mature IL6, is 
produced by a number of cell types including fibroblasts, especially 
in the presence of IL1 [Walther ef a/,1900]. This has both 
immunological and haematopoietic significance. Murine IL6 has the 
capacity to stimulate the limited proliferation of bipotentiai 
granulocyte-macrophage progenitors and is of considerable interest 
since it is also proposed to be active at the level of the primitive 
haematopoietic stem cell and enhances the capacity of IL3 to 
stimulate the proliferation of multipotential precursors [ikebuchi et 
ai,1907; Ogawa & Clark,1900].
(*A number of excellent reviews of haematopoietic growth factors 
exist: [Metcalf,1904; 1905; 1906; Sieff,1907; Morstyn & Burgess,1900; 
Nicola,1909; Platzer,1909; Golde,1990; Metcalf,1990; Whetton,1990].)
With the exception of M-CSFiCSF-1 and ILS, which are dimers, the 
other factors discussed, are single subunit glycoproteins. Despite 
their similar molecular weights, general molecular nature and 
overlapping biological specificities, each factor is encoded by a 
single unique gene, binds to a unique receptor with no cross­
reactivity and shows no extensive amino acid sequence homology 
with any other factor. M-CSF/CSF-1, G-CSF, IL1 and IL5 are 
remarkably well conserved between species and are abie to cross- 
react. GM-CSF, IL3imulti-CSF and IL4, however, differ significantly 
between species and do not cross react. In the mouse the GM-CSF, 
IL3imulti-CSF, G-CSF and IL5 and the M-CSFiCSF-r receptor
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(identified as the c-fms oncogene product [Sherr ef a/,1985]) genes 
have been mapped to chromosome 11 (*The gene for the purified 
haematopoietic stem cell proliferation inhibitor, MiP-1 alpha has 
significantly also been mapped to murine chromosome 11 [Graham 
ef a/,1990]). in humans the GM-CSF, IL3/multi-CSF, M-CSF/CSF-1, IL5 
and M-CSF/CSF-1 receptor [Groffen ef a/,1983] genes have all been 
mapped to chromosome 5. This is significant since part of murine 
chromosome 11 is homologous to the long arm of human 
chromosome 5. Another part of murine chromosome 11 is 
homologous to human chromosome 17, where the gene for G-CSF 
has been isolated (human MIP-1 alpha has also been mapped to 
chromosome 17 [Irving ef a/,1990]). This probably reflects a distant 
evolutionary relationship.
1,22 A novel multiporeatial qrc^vwt^ faato^r eaooVea bvthe
SMocus is a iiqand of a receptor encoded bv the M-locus.
The haematological significance of the ’Steel' (Si) locus of murine 
chromosome 10 and the ’dominant white spotting' (W locus of 
murine chromosome 5, has long been realised. Mice bearing 
mutations in either loci present with considerable haematological 
dysfunction characterized by severe anaemia and mast cell 
deficiency. In the case of SAmutants, haematopoietic dysfunction is 
the result of a defective haematopoietic microenvironment while W- 
mutants possess inherently defective haematopoietic stem cells 
[Dexter & Moore,1977]. While 5/and Ware distinct genetic loci they 
possess a related haematological function and recent studies have 
identified and characterized the products of both loci.
The product of the 'Steel' (Si) locus of murine chromosome 10 
has been identified as a 31,000 dalton glycoprotein mo'iety [Copeland
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ef a/,1990; Huang ef a/,1990; Williams ef a/,1990; Witte,1990; Zsebo ef 
a/,1990a; 1990b]. Administered to SAmutant mice it restores normal 
haematopoiesis, reversing both the severe anaemia and the mast cell 
deficiency [Zsebo ef a/,1990b]. The glycoprotein, isolated from rat 
buffalo liver cell line conditioned medium [Zsebo ef a/,1990] and a 
murine bone marrow stromal cell line supernatant [Williams ef 
a/,1990], strongly synergizes with Interleukins 1,3,6 [Zsebo ef 
e/,1990a; 1990b] and 7 [Martin ef a/,1990], erythropoietin [Nocka ef 
a/,1990], GM-CSF and G-CSF [Bernstein ef a/,1991; Bertoncello ef 
a/,1991; Broxmeyer ef a/,1991], increasing both the number and size 
of colonies In semi-solid agar culture. The glycoprotein appears to 
act in part, by potentiating the growth factor responsiveness of the 
relatively mature, lineage-committed haematopoietic progenitors, 
although the factor is itself a relatively potent colony-stimulating 
activity. The glycoprotein also appears to be a relatively potent 
stimulatory activity for haematopoietic colony-forming cells surviving 
5-fluorouracii treatment, which are considered relatively primitive 
haematopoietic precursors and possibly components of the 
haematopoietic stem cell population [Zsebo ef e/,1990e]. The 
glycoprotein has subsequently been termed 'stem cell factor* (SCF) 
[Zsebo ef a/,1990a] and ’ mast cell growth factor* (MGF) [Williams ef 
a/,1990]. Interestingly the activity of SCF/MGF is reported to be 
compromised by the presence of transforming growth factor-beta 
(TGF-B) [McNiece ef a/,1991], a previously characterized 
haematopoietic inhibitor [Axelrad,1990; Graham & Pragnell,1990].
The genomic sequences of murine, rat and human SCF/MGF have 
been determined [Copeland ef a/,1990; Martin ef a/,1990; Zsebo ef 
a/,1990b; Williams ef a/,1990; Huang ef a/,1990] and recombinantly 
expressed. Recombinant expression In E.CoA, producing a non- 
glycosylated factor, demonstrates the glycosylation of SCF/MGF is
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not essential for activity. Native SCF/MGF is heavily glycosylated and
this may assist solubility and protect from enzymatic degradation. 
There is also some evidence that native SCF/MGF exists as a dimeric 
molecule [Zsebo et ai,1990a]. •
The product of the ’dominant white spotting’ (W) locus of murine 
chromosome 5 is a transmembrane tyrosine kinase receptor. The 
145,000 datton activity [Flanagan & -.€^6^1990; Wiillams ef^^O; 
Huang ef a/,1990] is the product of the c-k/f proto-oncogene [Chabot 
ef a/,1900; Geissler ef ai,1900] and mutations of the W-locus usually 
produce a kinase-deficient Inactive moiety.
Significantly SCF/MGF has been identified as a ligand for the c- 
kif-derived tyrosine kinase receptor [Witte,1990; Flanagan & 
Leder,1990; Zsebo ef a/,1990a; 1990b; Williams ef a/,1990; Huang ef 
ai,1990] and SCF/MGF has thus also been termed ’c-kk ligand’ (KL), 
although other c-k/f ligands may exist.
The importance of SCF/MGFiKL and c-k/f proto-oncogene 
receptor interaction in haemoregulation is becoming clear. The 
action of SCF/MGFiKL both alone, and in conjunction with other 
growth factors, may prove to be of clinical significance, perhaps 
stimulating haematopoietic recovery after bone marrow 
transplantation or assisting in the management of hypoproliferative 
haematopoietic disorders.
1,23 T^o development of an in vitro haematopoietic stem
ceil assay.
Interleukin 3 (IL3)imulti-CSF has the capacity to stimulate the 
proliferation and differentiation of coiony-forming ceiis of different 
lineages from haematopoietic tissue. It also has the capacity to 
stimulate the proliferation of muitipotential haematopoietic
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precursors which demonstrate self-raoawel and have allowed a 
limited in vitro investigation of haematopoietic stem cell behaviour 
[Metcalf ef a/,1978; Humphries ef a/,1979a; Humphries ef e/,1979b; 
Jvhnsvn,1980; Nekeheta & Ogeva,1982; Koike ef e/,1986e].
Recent developments in in v/fro techniques have however, 
isolated a coiony-forming cell population from haematopoietic tissue 
which is characterized by a high proliferative potential, a self-renewal 
capacity and a multipotency. This high proiiferative potential coiony- 
forming cell (HPP-CFC) population, demonstrates many behavioural 
and regulatory similarities to the in vivo CFU-S population, previously 
taken as the haematopoietic stem cell assay. The potential of the 
HPP-CFC assay as an in vitro assay of the haematopoietic stem cell 
population wili be discussed.
1,24 The in viiro high prollierative potential colony­
forming ceil (HPP-CFC) essee.
The novei aspect of the in vitro HPP-CFC assay is it's use of 
combinations of cvlony-stlmuletlog factors. Bradley and Hodgson 
[1979] first reported the stimulation of colony-forming cells with a 
high proliferative potential, from murine bone marrow, using a 
combination of crude factors derived from pregnant mouse uterus 
extract (PMUE) and human spleen conditioned medium (HUSPCM). 
PMUE alone, stimulated the proliferation of lineage-committed 
haematopoietic progenitor cells with limited proliferative potential. 
HUSPCM alone demonstrated no colony-stimulating activity. Only on 
combination of the two extracts were the HPP-CFC demonstrated. 
This illustrates haematopoietic growth factor ’synergisrri - on 
combination, factors produce a more than additive effect. Bradley 
and Hodgson [1979] demonstrated that the HPP-CFC population
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isolated by the combination of PMUE and HUSPCM was a distinct, 
previously undetected population of colony-forming cells, through 
the use of 5-fluorouracil (5FU). The PMUE-stimulated colonies proved 
especially sensitive to 5FU, implying a relatively rapidly cycling, 
colony-forming cell population was being demonstrated. This would 
be consistent with these cells being lineage-committed 
haematopoietic progenitor cells. The PMUE and HUSPCM-stimulated 
HPP-CFC population, however, proved relatively insensitive to 5FU, 
implying that the HPP-CFC population was relatively slowly cycling, 
consistent with its being a more primitive haematopoietic precursor 
population.
Characterization of PMUE has demonstrated it to be a crude 
source of M-CSF/CSF-1 [Das ef a/,1980], however, identification of 
the synergizing factor in HUSPCM has proved more problematic. 
Other factors found to synergize with M-CSF/CSF-1 have been 
obtained from rat and mouse spieen and from human placenta 
[Kriegler ef a/,1982] and other factors have come to light [Kriegler ef 
a/,1984; Stanley ef a/,1986; McNiece ef e/,1987a; Song ef a/,1985; 
Quesenberry ef a/,1987; McNiece ef a/,1989a; Kriegler ef a/,1990]. 
Subsequent analysis of these synergizing factors has demonstrated 
at least three distinct types of activity exist, each stimulating a 
discrete HPP-CFC subpopulation.
Interleukin 1 (hemopoietin-1), has been demonstrated to 
synergise with M-CSF/CSF-1 to stimulate an HPP-CFC population and 
whiie not completely replacing the synergism obtained from a 
number of crude conditioned media, it does not itself possess 
colony-stimulating activity, which is consistent with the findings of 
Hodgson and Bradley [1979] and their use of HUSPCM. Other 
sources of an interleukin 1 -like synergistic factor, termed 'synergistic 
factor-T (SF-1), have been identified as spleen and placental
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extracts, medium conditioned by bladder carcinoma ceii line 5637
and medium conditioned by murine EMT-6 cells [Bradley & 
Hodgson,1979; Kriegler ef ai,1902; kriegler ef ai,1904, Bartelmez & 
Stanley,1905; Stanley ef a/,1906; McNiece ef a/,1907a].
Interleukin 3 (IL3)/multi-CSF, produced constitutively by the 
murine myelomonocytic leukaemic ceil line WEHI-3B [Warner ef 
ai,1969], has been purified and characterized [ihle ef ai,1902, Ihle ef 
ai,1903] and demonstrated to synergise with M-CSFiCSF-1 to 
stimulate HPP-CFC proliferation [Bartelmez ef a/,1905]. Interleukin 3- 
like factors constitute the second group of synergizing factors.
A third distinct class of non-IL1-like and non-IL3-like synergizing 
factors has been demonstrated and are yet to be isolated and 
characterized. Present In TC-1 murine bone marrow stromal cell line 
conditioned medium [Song ef ai,1905; Quesenberry ef a/,1907], 
synergism with M-CSFiCSF-1 demonstrates a third discrete HPP-CFC 
population.
A developmental hierarchy appears to exist within the 
heterogenous HPP-CFC population with the HPP-CFC stimulated by 
SF-1/IL1-like activity and M-CSFiCSF-1, termed HPP-CFO1, 
considered the more primitive haematopoietic HPP-CFC. These HPP- 
CFC-1 are proposed to mature to IL3/multi-CSF and M-CSF/CSF-1 
sensitive HPP-CFC, termed HPP-CFO2, which are inturn considered 
to mature to the TC-1 and M-CSFiCSF-r sensitive HPP-CFC, termed 
HPP-CFC3 [Bradley ef a/,1905; McNiece ef ai,1906; 1907b].
The development of highly purified and recombinant 
haematopoietic colony-stimulating factors has allowed the role of 
individual growth factors in synergizing interactions to be 
investigated. A number of haematopoietic colony-stimulating factors 
have been demonstrated to synergize:
G-CSF and M-CSFiCSF-1 [McNiece ef ai,1900a],
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GM-CSF and M-CSF/CSF-1 [McNiece ef a/,1988b; Falk & 
Vogei,1988; Eckmann ef a/,1988; Pragnell ef a/,1988; Bot ef a/,1990; 
Lorimore ef a/,1990],
G-CSF and GM-CSF [McNiece ef e/,1988a; Bot ef a/,1990],
G-CSF and IL3/multi-CSF [McNiece ef aA^Sa],
GM-CSF and IL3/multi-CSF [McNiece ef e/;1988a; 1989b],
IL3/multi-CSF and M-CSF/CSF-1 [Chen & Clark,1986; Koike ef 
e/,1986V; McNiece ef e/,1987V; Williams ef a/,1987; Bartelmez ef 
a/,1989; Morris ef a/,1990],
IL6 and G-, M-, GM-, or IL3/muiti-CSFs, or IL4 [Rennick ef a/,1989]
IL1 and G-CSF [Moore & Warren,1987]
IL1 and IL3/multi-CSF, or IL1 and iL3/multi-CSF and M-CSF/CSF-1 
[Bartelmez ef a/,1989].
The relationship between these HPP-CFC subpvpuletlvos is as
yet unclear, however, a number of techniques may allow a
hierarchical structure within the heterogenous HPP-CFC population 
to be investigated.
1.25 Evidence of a.n age-related in vitro HPP-CFC
hierarchy.
As previously discussed Bradley and Hodgson [1979], 
lnvestlgetad the kinetic state of the HPP-CFC isolated by a 
combination of PMUE and HUSPCM using 5FU. Similar studies have 
been performed and raeeel evidence of an ega-releted hierarchy 
within the HPP-CFC population and an HPP-CFC maturation scheme 
has subsequently been developed.
HPP-CFC-1 isolated by the synergism of IL1-like activity and M- 
CSF/CSF-1 are relatively resistant to 5FU treatment. A depletion of 
50% 2 days after 5FU treatment Is reported [Bradiey ef a/,1985]. in
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comparison HPP-CFC-2, Isolated by a synergism of IL3-like activity 
and M-CSF/CSF-1, prove more sensitive to 5FU treatment. A 
depletion of 99% 2 days after 5FU treatment is reported [Bradley et 
a/,1985]. This evidence implies that the proportion of HPP-CFC-1 in S- 
phase is lower than the proportion of HPP-CFC-2. Also, recovery after 
5FU treatment by HPP-CFC-1 is rapid and complete, while HPP-CFC-2 
take longer to recover [Bradley ef e/,1985]. From this the conclusion 
that HPP-CFC-1 is a more primitive haematopoietic precursor 
population, slowly proliferating and more able to self-renew than the 
HPP-CFC-2, has been drawn. Replating experiments have shown that 
HPP-CFC-1 produce HPP-CFC-2 [McNiece ef a/,1987b], implying a 
maturation of the one to the other, and a subsequent maturation of 
HPP-CFC-2 to HPP-CFC-3 is also suggested. HPP-CFC-3, prove even 
more sensitive to 5FU treatment than HPP-CFC-2, impiying they are a 
more rapidly cycling population stiil. (*This maturation scheme would 
correlate particularly well with observations that primitive 
haematopoietic precursors have an age-related, transient sensitivity 
to IL3 [Koike ef a/,1986a]). A subsequent maturation of the more 
mature HPP-CFC-3 to the lineage-committed haematopoietic 
progenitor cell population could then be envisaged. Such an age 
related hierarchy is somewhat reminiscent of that previously 
discussed within the CFU-S population.
Direct and significant correlations between the in vivo CFU-S and 
in vitro HPP-CFC populations have been made. HPP-CFC-2 when 
injected into tethally X-irradiated mice give rise to day 13 CFU-S 
[McNiece ef a/,1987b], a CFU-S population considered a relatively 
primitive component of the- haematopoietic stem cell compartment. 
This Implies that the HPP-CFC-2, and the HPP-CFC-1 from which they 
are derived, must also be relatively primitive components of the 
haematopoietic stem cell compartment, likely to possess marrow,
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platelet and erythroid repopulating capacity. There Is evidence,
however, that the HPP-CFC-1 and HPP-CFC-2, do not contain the 
ceils responsible for long-term haematopoietic recovery, the ’pre- 
CFU-S’, discussed previously [Bertoncello ef a/,1909a]. In vitro 
attempts to isolate such a cell population are being developed 
[Iscove & Yan,1990; Pioemacher ef a/,1909b] and investigations have 
isolated what may be a ’ pre-HPPCFCOT precursor, which forms 
colonies in in vivo diffusion chambers, termed ’CFU-D'. CFU-D are 
reported to generate in vitro HPP-CFC-1, HPP-CFC-2 and in vivo day 
12 CFU-S, and possess a very high proliferative potential [Niskanen 
ef a/,1990] [Figure 16\.
A number of techniques have been developed which enrich HPP- 
CFC from haematopoietic tissues, many of which are developments 
of the previously discussed techniques, used to enrich CFU-S 
populations. The Qa-m7 antigen is present on 90% of relatively 
primitive, day 13 CFU-S and HPP-CFC express relatively high levels of 
this antigen, allowing their enrichment using flow cytometric 
techniques. Specifically, use of 5FU marrow, to deplete the marrow of 
more mature haematopoietic progenitor cell populations [Bertoncello 
ef ai,1907], allows a 20% enrichment of HPP-CFC-1 and HPP-CFC-2. 
HPP-CFC-1 and HPP-CFC-2 also bind wheat germ agglutinin (WGA+) 
and can be enriched using Rh-123. Use of Rh-123 has demonstrated 
that highly quiescent stem cells are Rh-123 dull [Visser & de 
Vries,1900; Ploemacher & Brons,1900c; 1900d], amongst these day 
16 CFU-S, pre-CFU-S, and long term haematopoietic repopulating 
cells. More rapidly proliferating, more mature stem cells, for example 
day 8 CFU-S, are Rh-123 bright. HPP-CFC-1 have been resolved as a 
Rh-123 dull subpopulation, while HPP-CFC-2 are resolved as a Rh- 
123 bright subpopulation [Bertoncello ef a/,1909a], which reinforces 
evidence of an age-related HPP-CFC hierarchy. Use of the Sca-1+,
Figure 16: Possible maturation scheme within
the high proliferative potential colony-forming
cell (HPP-CFC) population.
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Thy-1l°, lineage-negative ceil ’fingerprint’ by Sprangrude ef a/[1988], 
also appears to select HPP-CFC, specifically the more primitive HPP- 
CFC-1 subpopuiation. Thus techniques developed primarily to enrich 
the in vivo CFU-S populations and resolve subpopulations therin, are 
also proving to select the in vitro HPP-CFC and to resolve the HPP- 
CFC-1 and HPP-CFC-2 subpopulations therin. This is further evidence 
of a very ciose correlation between the in vivo CFU-S and the in vitro 
HPP-CFC populations.
A significant development of the in vitro HPP-CFC assay has been 
the isolation of a coiony-forming cell of high proliferative potential 
from human haematopoietic tissue [McNiece ef a/,1989]. While the in 
v/ve CFU-S assay [Till & McCulloch,1961] has allowed a quantitative 
and qualitative analysis of haematopoietic stem cell behaviour and 
regulation, it is strictly a murine assay. An equivalent assay of a 
primitive human haematopoietic precursor does not at present exist, 
although as previously discussed the human stem cell proliferation 
regulators can be assayed in the murine system. The potential of an 
in vitro assay of a primitive human haematopoietic precursor is thus 
significant. The human HPP-CFC reported [McNiece ef e/,1989b] is 
considered equivalent to the murine HPP-CFC-2 subpopulation and 
should allow a direct investigation of human haematopoietic stem cell 
behaviour in normal, regenerating, haematopoieticaliy stressed and 
foetal haematopoietic tissues and also potentially the behaviour of 
stem cells in haematopoietic disorders.
1.26 Refinement of the In vitro HPP-CFC technique 1 - Tl^e
"CFU-A" assay.
While demonstrating many functional similarities to the in vivo 
CFU-S popuiation, recent reports aiso demonstrate that the in vitro
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HPP-CFC population aiso shares many significant behavourai and 
regulatory similarities to the in vivo CFU-S population. As previously 
discussed, the synergism between certain colony-stimulating factors 
stimulates the proliferation of a number of different HPP-CFC 
subpopulations. GM-CSF and M-CSF/CSF-1 have been demonstrated 
to synergize [McNiece ef ai,1900b; Faik & Vogei,1900; Eckmann ef 
a/,1900; Pragnell ef a/,1900; Bot ef a/,1990; ef ai,1990] and
this synergy and the high proliferative potential coiony-forming cell 
stimulated by this combination of colony-stimulating factors, form the 
basis of the "CFU-A- assay [Eckmann ef ai,1900; Pragnell ef ai,1900; 
Lorimore ef a/,1990].
Eckmann ef ai[1900], Pragnell ef a/[1900], and Lorimore ef a/ 
[1990] have demonstrated that CFU-A stimulated by a combination of 
GM-CSF and M-CSFiCSF-1 from murine haematopoietic tissue are 
muitipotentiai precursors, giving rise to cells of the granulocytic, 
macrophagic, erythroid and megakaryocyte lineages and to 
immature, undifferentiated blast ceils. CFU-A are also reported to 
give rise to day 12 CFU-S, considered a relatively primitive 
component of the haematopoietic stem cell population, when 
injected into lethaily irradiated recipient mice. This agrees with the 
report of McNiece ef ai [1907b], who demonstrated the production of 
day 13 CFU-S on the transplantation of putative HPP-CFC-1 to lethaily 
X-irradiated mice. As well as a considerable proliferative potential, 
CFU-A also exhibit a self-renewai capacity, demonstrated by repiating 
experiments.
Perhaps of greatest significance has been the demonstration that
the CFU-A popuiation shows kinetic properties that mimic those of 
the in vivo CFU-S popuiation in both normal and haematopoieticaliy 
stressed tissues. CFU-A aiso show a sensitivity to the previously 
CFU-S-characterized stem cell proliferation inhibitor and stimulator.
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In normal, unstressed bone marrow, the proportion of
haematopoietic stem cells in S-phase, as measured by the in vivo 
CFU-S assay is relatively low at approximately 10%. The proportion of 
i(n vitro CFU-A in S-phase from such tissue is also relatively low at 
approximately 10%. This contrasts with the relatively high proportion 
of more mature, haematopoietic progenitor cells in S-phase at 30­
40%. in regenerating or haematopoieticaliy stressed haematopoietic 
tissue, the proportion of in vivo CFU-S in S-phase increases to 30­
40% and a similar Increase in the proportion of CFU-A in S-phase is 
observed.
The changes in the relative proportion of haematopoietic stem 
cells in S-phase are brought about by stem cell specific proliferation 
regulators - inhibitor and stimuiator. Significantly, the in vitro CFU-A 
population shows a sensitivity to these stem cell-specific proliferation 
regulators with stimuiator increasing the proportion of CFU-A in S- 
phase and inhibitor reducing the proportion of CFU-A in S-phase. 
(Use of the in vitro CFU-A assay assisted in the identification and 
characterization of the stem cell proliferation inhibitor as MiP-1 alpha 
[Graham ef ai,1990].)
As previously discussed, a variation in stem cell sensitivity to the 
proliferation regulators occurs with maturation. The more primitive 
haematopoietic stem cells (day 12 CFU-S) prove more sensitive to 
the proliferation inhibitorXhan to the proliferation stimulator, while 
more mature haematopoietic stem cells (day 8 CFU-S), prove more 
sensitive to the proliferation stimulator Xhan the proiiferation inhibitor. 
Lorimore ef ai[1990] have shown that both inhibitor and stimuiator 
are tltratabie activities using the in vitro CFU-A assay and that the in 
vitro CFU-A popuiation shows a greater inhibitor Xhan stimuiator 
sensitivity. This is somewhat anaiogous to the day 12 CFU-S, an 
exampie of a relatively primitive haematopoietic precursor, and
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further evidence that the in vitro CFU-A population is indeed a 
reiatively primitive haematopoietic precursor within the 
haematopoietic stem celi compartment.
Lorimore et ai [1990] have also explored the spatiai distribution of 
the CFU-A population within femoral marrow. The non-random, non­
uniform distribution of CFU-S within femoral marrow has been 
discussed. Axial cores of active murine haematopoietic tissue from 
femora, demonstrate the majority of slowly cycling, ’high quality’, 
relatively primitive stem cells lie axially, while the majority of more 
rapidly cycling, ’lower quality’, more mature stem ceils lie in the 
subendosteal marrow. Analysis of the CFU-A distribution 
demonstrates that the majority of CFU-A lie in a region deep to the 
subendosteal region, implying their being at least one step removed, 
and so more primitive than, the more rapidly cycling, more mature, 
subendosteal stem cell population. Radiation sensitivity and density 
separation characteristics of the in vitro CFU-A are also comparable 
to the in vivo CFU-S population [Lorimore ef a/,1990].
in conclusion, there is considerable evidence that the in vitro 
CFU-A HPP-CFC subpopuiation is a reiatively primitive 
haematopoietic precursor and that the in vitro CFU-A assay is indeed 
an assay of a component of the haematopoietic stem cell population. 
As such it should greatly assist investigation of the regulation and 
behaviour of the haematopoietic stem celi population.
1.27 Refinement o1f the in vitro,HPP-CFC technique 2 - The
"HPP-CFC,L3+csf..," assay.
A high proliferative potential colony-forming cell population can 
be isolated in vitro from murine haematopoietic tissue by a
synergistic interaction between interleukin 3 (IL3)/multl-CSF and M-
61
CSF/CSF-1 [Chen & Clark,1906; Koike ef ai,1906b; McNiece et al, 
1907b; Williams ef a/,1907; Bartelmez ef a/,1909; Morris ef a/,1990] 
termed “HPP-CFCjc+csf-A a maJ"or objective of this research project 
will be the characterization of baiiaviour and
regulation. Using a combination of WEHI-3B myelomonocytic 
ieukaemic cell line conditioned medium, as a crude source of murine 
interleukin 3 (iLaj/multi-CSF [Warner ef ai,1969; Metcalf ef a/,1969; 
Ihie ef a/,1902; Lee ef a/,1902; Baziii ef a/,1903; Ciark-Lewis ef a/,1905; 
McNiece ef a/,1905] and L929 fibroblast cell line conditioned medium, 
as a crude source of murine M-C5F/C5F-1 [Stanley & Heard,1977; 
Burgess ef a/,1977; Waheed & 5hadduck,T902; Burgess ef a/,1905] 
the number, cellular composition and proportion of HPP-CFC1L3+tof.i 
in S-phase in normal and regenerating, or haematopoietically- 
stressed, murine haematopoietic tissue, will be investigated and 
comparison made with the behaviour of the in vivo CFU-S [Till & 
McCulloch,1961] and in v/fre CFU-A (PPP-CFCGM.tot+cot-1) [McNiece 
ef a/,1900b; Falk &Vogel,1900; Eckmann ef ai,1900; Pragnell ef 
a/,1900; Bot ef a/,1990; Lorimore ef ai,1990]. Correlation between in 
v/vo CFU-S, in vitro CFU-A and in vitro PPP-CFC1L3+CoF.i behaviour 
would be evidence for the primitive nature of the PPP-CFC^cs^ 
population.
PPP-CFC1L3+CsF1 sensitivity to the stem cell-specific proliferation 
regulators inhibitor and sfimu/atorwUl be investigated and if 
demonstrable would further reinforce the evidence for the HPP- 
CF^L3+c3sif-i being a primitive haematopoietic precursor population, 
possibly a component of the heterogenous haematopoietic stem cell 
compartment. The relative sensitivity of PPP-CFC^cs^i to both 
inhibitor and sf/mu/ator may allow the position of the popuiation 
within the heterogenous, age-reiated haematopoietic stem cell 
hierarchy to be determined.
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If Similar behavioural and regulatory characteristics are 
determined for the CFU-S, CFU-A and HPP-CFC|L3+csf_1 populations, 
the potential of the in vitro HPP-CFC^^+GsF.i assay as a technique with 
which to investigate haematopoietic stem cell behaviour and 
regulation In aberrant haematopoiesis will be developed. Specifically, 
the assay will be used to investigate stem ceil behaviour and 
regulation in the neoplastic proliferative disorder of the 
haematopoietic system - myeioid ieukaemia. A number of X- 
irradiation induced, murine, serially passaged, myeloid leukaemias 
have been established in this laboratory [Hepburn ef ai,1987] and will 
be used as models with which to investigate such aberrant 
haematopoiesis.
1.28 Leukaemia and leukaemia associated inhibition of
normal haematopoiesis.
’Leukaemia', a term applied to a group of malignant 
haematopoietic proliferative disorders, is characterized by the 
abnormal production of white blood cell precursors. Leukaemias 
differ In both cell lineage (neoplastic proliferation is usually restricted 
to one celi lineage), and degree of cellular differentiation (with poorly 
differentiated cells usually indicative of a rapidly progressing, 
aggressive, ’acutd leukaemia, while more differentiated ceils usually 
indicate a slowly progressing, less aggressive, "chronid leukaemia). 
The abnormal white blood cells produced enter, and circulate in the 
bloodstream to extensively infiltrate the haematopoietic system, liver, 
spleen and many other tissues. Often disease progression is 
associated with hepatic and splenic enlargement (hepato- and 
splenomegally) as the organs become diffusely Infiltrated by 
ieukaemic cells. One particularly significant aspect of most
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leukaemias is a leukaemia-associated suppression of normal 
heemetopoiesis. A consequence of this suppression of normal 
haemetopoiesis is that death may result from anaemia, haemorrhage 
or infection due to a lack of functional erythrocytes, platelets and 
granulocyte-macrophages. This leukaemia-associated suppression 
of normal haemetopoiesis is of particular interest and may explain the 
'proliferative advantage’ developed by the Ieukaemic cells. The 
selective inhibition of normal haematopoiesis by putative leukaemia- 
associated inhibitory activities can be envisaged. In such a system, 
the ieukaemic cells would be insensitive to such inhibition and be 
able to proliferate at the expense of normal haematopoietic tissue. 
Evidence for such leukeemla-essocleted inhibitory activities has been 
reported.
Olofsson and Olsson [1980a; 1980b; 1980c], Olofsson ef a/ [1984] 
and Olofsson and Sailefors [1987], report the isolation of a 500,000­
600,000 dalton, heat stable glycoprotein, produced by acute and 
chronic myeloid ieukaemic ceils and the HL60 promyelocytic 
Ieukaemic cell line. The factor, "Leukaemia Associated Inhibitor'
(LAI), is reported to inhibit normal bipotential granulocyte- 
macrophage progenitor cell proliferation, while Ieukaemic cells prove 
insensitive to the inhibition.
Broxmeyer ef£/[l978], Bognaki ef e/[1981], Broxmeyer et at 
[1981; 1982; 1983], Jacobs [1983], Sala ef e/[1986] and Broxmeyer ef 
e/[1989], report the isolation of a 550,000 dalton moiety, , active at 
10*17~10" 19% and suppressing normal granulocyte-macrophage 
progenitor cell proliferation. Produced by Ieukaemic cells, which 
themselves prove insensitive to it’s inhibitory activity, "Leukaemia- 
associated inhibitory Activity' (LiA), has subsequentiy been reported 
to be acidic isoferriti‘n. Whether LAi or LiA possess inhibitory activity 
at the level of haematopoietic stem cell proliferation is unclear.
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1,29 Aims and objectives.
In this study, medium conditioned by the radiation-induced, 
serially passaged, murine, myeloid leukaemias will be investigated 
using the in vitro HPP-CFC1L3+csm assay. The respective levels of 
endogenous inhibitor and stimulator will be determined and 
abnormalities investigated. Any abnormalities may represent a 
manipulation of endogenous proliferation regulator production 
and/or action by the developing leukaemia allowing it a proliferative 
advantage over, and at the expense of, normal haematopoiesis.
A possible explanation of the development of the Ieukaemic 
proliferative advantage over normal haematopoiesis may be a change 
in the sensitivity of the ieukaemic cells to inhibitor. A leukaemogenic 
change at the level of the stem cell population may, amongst other 
properties, remove or reduce stem cell sensitivity to inhibitor. As a 
result, despite the relatively high endogenous levels of inhibitor in the 
normal haematopoietic tissue, Ieukaemic stem ceil proliferation will 
occur. Existing haematopoietic feedback mechanisms may detect the 
excessive, inappropriate white blood cell production and lead to an 
increase in inhibitor levels. However, despite increased inhibitor 
levels, the ini7iM/tor-insensitive Ieukaemic proliferation will continue at 
the expense of the normal, inhibttor-sens'Xive haematopoietic tissue.
Another possibility may involve the production of leukaemia- 
associated inhibitory activity, similar to LAI and LIA. This factor may 
possess inherent inhibitory activity to directly suppress 
haematopoietic stem cell proliferation, or it may act indirectly to 
block the production and/or action of the endogenous proliferation 
regulators. With ieukaemic progression the composition of the blood 
becomes abnormal. Such abnormalities are normally corrected by an 
intricate haematopoietic feedback mechanism, adjusting
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haematopoietic output to restore the composition of the blood. Part 
of this restorative mechanism is an increase In haematopoietic stem 
celi proliferation induced by stimulator. In effect, with Ieukaemic 
progression the haematopoietic system is ’stressed’ but apparently 
fails to respond and the quality of the peripheral blood deteriorates. 
The putative leukaemia-associated activity may act to block the 
production and/or action of stimuiator. The suppression of normal 
haematopoiesis may be a result of a failure of haematopoietic 
stimulation. Interestingly, if stimulator is produced but inactivated, it 
may act to prevent iniiid/for production, so that during subsequent 
HPP-CFCIL3+F5F-1 assay of the ieukaemic ceil conditioned medium 
neither factor is detectable.
Another possibility may be the production of a leukaemia- 
associated factor which is a stimulatory activity to which only the 
Ieukaemic cells are sensitive. Again Ieukaemic proliferation at the 
expense of normal haematopoiosis would be observed. Whether 
such a factor would be detectable using the in vitro PPP-CFC1L3+Cot_ i 
assay using normal haematopoietic tissue remains to be seen.
A basic understanding of the mechanism by which Ieukaemic 
cells develop a proliferative advantage over normal haematopoietic 
tissue, would be a considerable step towards the development of 
more effective disease therapy and management. Depending on the 
mechanism of action of the Ieukaemic proliferation, it may prove 
possible to overcome the leukaemia-associated deterioration of the 
blood ’quality’, by the exogenous addition of stimuiator. if normal 
haematopoietic output could at least be maintained then the life 
threatening aspects of the leukaemia-associated anaemia, 
haemorrhage and infection may become less problematic and allow 
some degree of disease management, although not achieving a 
’cure’. The potential loss of proliferative advantage by the Ieukaemic
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system may in itself hamper disease progression and assist survival.
This always assumes that exogenous stimuiator does not promote 
leukaemia proliferation.
if a difference in normal and Ieukaemic sensitivity to inhibitor 
could be demonstrated, then this could be exploited. 
Chemotherapeutic and radlotherape-uhc regimes are most effective 
against proiiferating celi populations. If Ieukaemic proliferation were 
determined to be insensitive to inhibitor, exogenous inhibftor applied 
prior to therapy would reduce the proportion of normal 
haematopoietic stem ceils in S-phase, while leaving a cycling 
Ieukaemic population as specific targets for such agents. This 
ertiiicial manipulation of the haematopoietic system to a therapeutic 
advantage has great potential, but will rely on the development of an 
understanding of Ieukaemic proliferation regulation.
In addition to the investigation of leukaemia, a further objective of 
this research project will be an Investigation of the low molecular 
weight stem cell proliferation inhibitor, the tetrapeptide AcSDKP. 
Using the in vitro HPP-CFCagacsF-i assay, the mechanism of action of 
AcSDKP (kindly supplied by Dr. Maryse Lenfant, ICSN, CNRS, Gif-sur- 
Yvette, France) will be investigated to determine whether the peptide 
possesses inherent inhibitory activity or acts indirectly by interacting 
with the production and/or action of inhibitor and/or stimulator. 
Various peptide analogues of AcSDKP (kindly supplied by Dr.
Lenfant) will also be investigated to determine the minimal active 
amino acid sequence of the parent molecule and to determine 
whether more potent heemoreguletory moieties exist.
Chapter 2
Materials
and
Methods
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2.1 Mice and Pousinq,
Experiments and procedures were performed on CBA/H strain 
mice bred inhouse at the University of St.Andrews Animal Facility, in 
accordance with the Pome Office Animai (Scientific Procedures) Act 
1906. Mice were exposed to a 12 hour iight/dark cycie and kept at an 
ambient temperature of 21-23°C. Animal house feed SDS RMI(C) % 
pellets (Special Diet Services, Essex) and chlorinated water (20mg 
sodium dichioroisocyanurate/l) (Presept Disinfectant Tablets, 
Surgikos Ltd.) were allowed ad libitum.
2.2 Experimental Tissue.
Haematopoietic tissue was obtained from the marrow cavities of
murine femora. 9-12 week old CBA/H strain mice were killed by ether 
inhalation overdose and intact femora dissected and removed to a 
sterile plastic petridish. Tissue was transfered to a sterile laminar flow 
cabinet and desiccation avoided by covering tissue with sterile 
medium. Muscle tissue was scraped from the femora using a scalpel 
blade and the ball jcont removed. A 1ml syringe charged with sterile 
medium and fitted with a 23 gauge (G) needle was inserted through 
the articular cartilage of the femur using a gentle ’drilling’ action. 
Minimal trabecular bone allows a discharge of medium from the 
syringe to drive haematopoietic tissue from the marrow cavity as a 
’plug’ into sterile medium. Repeated flushing of the marrow cavity 
ensured maximal haematopoietic tissue was removed.
Microscopic analysis confirms that a single cell suspension was 
produced by a gentle repeated drawing of the marrow ’plug’ through 
a 1ml syringe fitted with a 23G then a 25G needle. Excessive, or 
overvigorous, syringing should be avoided since this leads to ceil
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membrane damage, cell-cell adhesion and ’clumping’. Celiularity was 
determined using an electronic particle counter (Coulter Counter 
Model ZM, Coulter Electronics.) and dilutions performed in 
appropriate medium.
2,3 Determination of the Celiularity of Single Cell
Suspensions,
The celiularity of single cell suspensions was determined using 
an electronic particle counter (Coulter Counter Model ZM, Coulter 
Electronics). Cells are suspended in an isotonic, electrically 
conductive medium (isoton ii, Coulter Electronics). The medium 
passes through a small aperture (1OOpM diameter) and an electrical 
current is recorded. Cells in the medium produce a temporary 
impedance to the electrical current proportional to the cellular 
volume. Electronic circuitry reads the impedance as a ’pulse’ and as 
a given volume of cell suspension (0.5mi) is drawn through the 
orifice, the number of pulses generated corresponds to the number 
of cells in that volume and the size distribution of the cells 
corresponds to the size distribution of the electrical pulses. With high 
counts a correction for ’coincidence counting’, where more than one 
celi passes through the orifice at any one time, is made. Cell 
’clumping’ is a major source of potential error and as cells tend to 
settle with time, gentle inversion of the counting vial ensures a 
homogeneity of cell suspension.
Coulter Counter settings were optimized by prior calibration with 
the cell type of interest. Settings were adjusted until criteria for an 
accurate cell count were met. A calibration curve was produced 
[Figure 77] and settings chosen on the ’plateau region’ to exclude
Figure 1i: Coulter Counter Titration Curves For:
0 10 20 30 40 50 60 70 80 90
Lower Threshold Setting.
Lower Threshold Setting.
Lower Threshold Setting.
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cell debris and platelets while giving an accurate cell count, which 
can be verified by use of a hemocytometer.
The following settings proved appropriate for the accurate 
determination of the cellularlties of single cell suspensions of bone 
marrow and spleen and thymus tissue :
Current,! = 130 (1.3mA), Full Scale^S = 10mA, Lower 
Threshold,TL = 30, Attenuafion,A = 1 and Preset Gain,PG = 2.
Routinely six counts were made and the average of three similar 
values taken. A background count. In the absence of cells, was taken 
and subtracted from this average count. From dilutions made, the 
cellularity of the original suspension was determined.
40pl, or 1OOfil of single cell suspension were added to 20mls of 
Isoton II (Coulter Electronics). Prior to counting, 3 drops of a red 
blood cell-lysfng solution (Zaponin, Coulter Electronics) (25ml acetic 
acid/l) was added to allow a nucleated cell count and the Coulter vial 
gently inverted. 0.5ml, Zaponized, single cell suspension was Coulter 
counted and with the use of a x1OOO, or x400 dilution factor 
respectively, the cellularity of the source single cell suspension can 
be determined.
2,4 Cellular Staining and Cytology.
Cytology was performed on cytocentrlfuged (Cytospin 2, 
Shandon) preparations. Single cell suspensions of tissue were 
produced, cellularity determined and adjusted to 2-5x1 O5cen/mL 0.5ml 
of single cell suspension was added to a Cytospin funnel and spun 
(x000 rpm, 10 mins.). Cells deposited on the slide were air dried and 
Jenner-Giemsa stained
Fix in methanol (ISmins.)
Jenners stain (BDH) (^mins.)
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6.8pH buffer rinse 
Giemsa stain (BDH) (1Omins.)
6.8pH buffer rinse
Slides were allowed to air dry and preparations can be mounted
using a mounting medium (DePeX, BDH) and coverslip.
Alternatively, more rapid staining was achieved using the Diff-
Qulk staining system (Merz + Dade AG, Switzerland). Slides were 
prepared and air dried. Staining was performed by dipping slides 
repeatedly for 35 seconds In each of a fixative solution (Fast green in 
methanol), stain solution I (Eosin G) and stain solution ii (Thiazine 
dye). Continuous immersion of slides gives unsatisfactory results. 
Excess solution was allowed to drain after each dip and between 
each solution. Slides were rinsed in pH 6.8 buffer and allowed to air 
dry. Preparations can be mounted using a mounting medium (DePeX, 
BDH) and coverslip.
2,5 ProProtion of Medium Co nditioneo Bd WEHI 3B
Mveiomonocvtic Leukaemic Cell Line and L929 Fibroblast
Cell Line,
WEHi 3B myBloooncytic leukaemic cell line is a non-adherent cell 
line, growing as a single cell suspension. WEHI 3B cell line-
conditioned medium is a crude source of interleukin 3 (IL3)imulti-CSF 
[Warner ef ai,1969; Metcalf ef a/,1969; ihle ef 0,1982; Lee ef ai,1982; 
Bazill ef ai,1983; Clark-Lewis ef a/,1985; McNiece ef ai,1985]. L929 
fibroblast cell line is an adherent cell line growing as a monolayer. 
L929 conditioned medium is a crude source of macrophage colony- 
stimulating factor (M-CSF/CSF-1) [Stanley & Heard,1977; Burgess ef 
a/,1977; Waheed & Shadduck,1982; Burgess ef ai,L985]. Both WEHi 
3B and L929 cell lines were maintained in culture at 37°C In
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Dulbeccos medium supplemented with 50 i.U./ml benzyl penicillin, 50 
pg/ml streptomycin sulphate, 2 mM L-glutamine and 10% (v/v) foetal
calf serum.
Medium was considered ’conditioned’ after a 3 day incubation 
with either WEHi single cell suspension, or confluent L929 
monolayer. Half the incubation medium was removed and replaced 
with fresh medium and incubation continued for three days before a 
second harvest. A maximum of 3 harvests of conditioned medium 
from one L929 monolayer were taken before passaging and 
restablishment of a fresh monolayer. In effect each harvest of WEHI 
conditioned medium acts as a passage.
Conditioned medium removed was centrifuged (x1OOO rpm, 15 
mins.) to remove cells and initially bulk frozen (-20°C). Once a 
sufficient volume of conditioned medium was produced, the whole 
was thawed, MilliPore filtered (0.22 pM), aliquoted and frozen (-20°C). 
The ’potency’ of each batch of conditioned medium was assessed by 
performing a titration of the colony-stimulating activity in both the in 
vttro GM-CFC (2.9) and HPP-CFC (2.10) assays. Individual aliquots 
were not refrozen once thawed.
Cell lines were stored cryopreserved in liquid nitrogen (-196°C) 
until required. 1ml aliquots of 5-10x1Ca cell/ml in supplemented 
Dulbeccos medium, 10-20% (v/v) foetal calf serum and 5-10% (v/v) 
DMSO (Dimethyl Sulphoxide, AnalaR, BDH), were placed in cryotubes 
(Cel-Cult, Sterilin), chilled on ice then transfered to the gas-phase 
compartment of an N2 freezer. After 12 hours cryotubes can be 
transfered to the liquld-phase compartment of the N2 freezer.
When required cells were rapidly thawed from the N2 freezer at 
37°C, washed and suspended in supplemented Dulbeccos medium 
with 10% (v/v) foetal calf serum In 25 cm2 tissue culture flask (Cel-
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Cult, Sterilin) and incubated at 37°C to restablish the cell line before 
passaging.
Passaging of the non-adherent WEPI cell line was continuous as 
conditioned medium was harvested. L929 cell line grows as a 
monolayer and requires trypsin digestion to produce a single cell 
suspension prior to passaging. Medium was completely removed and 
the monolayer washed with 0.05% trypsin (Sigma) in phoshate 
buffered saline and 0.5M EDTA (Ethylenodiamino tetraacetic Acid, 
Sigma). A wet film of trypsin was left over the monolayer and 
incubated at 37°C for 5 minutes. Addition of medium was sufficient to 
disrupt the monolayer and produce a single cell suspension.
Collularltios prior to passage were determined using a Coulter 
Counter Model ZM at settings:
WEPI 3B: Current,! = 700 (0.7mA), Full Scale, FS = 1mA, Lower 
Threshold, Tc = 30, Attenuation = 16, Preset Gain = 2.
L929: Current,! = 700 (0.7mA), Full Scale, FS = 1mA, Lower 
Threshold, Tc = 20, Attenuation = 32, Preset Gain = 2.
Medium conditioned by AF1-19T cell line was aiso produced. 
AF1-19T normal rat kidney cell line, transformed with the malignant 
histiocytosis sarcoma virus (MHSV) is a crude source of GM-CSF 
[Pragnell ef a/,1900; Kriegler ef ai,1990]. AF1-19T is an adherent cell 
line growing in culture as a monolayer. It was maintained in culture 
and passaged similarly to L929 cell line. AF1-19T cell line conditioned 
medium was prepared similarly to the L929 cell line conditioned 
medium, aliquoted and stored at -20°C.
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2,6 Recombinant haematopoietic colony-stimulating
factors.
In specific experiments more rigorously defined conditions were 
applied through the use of recombinantly derived haematopoietic 
colony-stimulating factors:
Murine interieukin 3 (IL3)/multi-CSF was kindly supplied by 
Genetics Institute, Massachusetts, £.S.A, as a crude conditioned 
medium from recombinantly engineered CHO cells.
Human macrophage coiony-stimulating factor (M-CSF/CSF-1) 
was kindly supplied by Genetics Institute, as a crude conditioned
I
medium from recombinantly engineered CHO cells.
Murine granuiocyte-macrophage coiony-stimuiating factor (GM- 
CSF) was kindly supplied by both Genetics Institute, as a crude 
conditioned medium from recombinantly engineered COS cells and 
Immunex, Washington, U.S.A., as a lyophilized protein sample.
Human interleukin 1 (IL1) was kindly supplied by both Genetics 
Institute, as a crude conditioned medium from recombinantly 
engineered COS cells (IL1 alpha) and Immunex, as lyophilized 
protein samples (IL1 alpha and beta).
2,7 Determination of the activity of recombinant
haematopoietic colony-stimulating factors.
The relative activities of recombinant murine interleukin 3 
(IL3)/multi-CSF, human M-CSF/CSF-1 and murine GM-CSF were 
determined using two distinct assay systems:
1) The in eitro granuIenyte-ryacrLehage aglony1torming cnl! assaa
[Figure 18[ (2.9) and,
Figure 18: GM-CFC titration of recombinant
colony-stimulating factors.
Incubated 
7 days.
A volume of 
appropriately 
diluted recombinant 
colony-stimulating 
factor.
Number
of
colonies
Colony number 
determined. 
(Colony = 
more than 50 cells)
Dose-response
curve
established.
▼
Dilution of recombinant 
colony-stimulating factor.
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2) The in eitro vntioted thymidine (3H~TCP- uptake assaa [Figure 
19[i The ir vitco tritiated thymidine (3H-TdR) uptake assay was used 
to measure ceilular proliferation of murine femoral bone marrow in 
the presence of a range of dilutions of haematopoietic colony- 
stimulating factors. 3H-TdR competes with native thymidine for 
incorporation into newly synthesizing DNA at S-phase and 
proiiferating cells are thus radioactiveiy labelled. (The specific activity 
of the CH-TdR used (105 GBq/mmol) is not sufficient for its 
incorporation to result in S-phase death of the ceil.)
A single celi suspension of normal, murine, femoral marrow was 
produced in RPMI medium (Gibco) supplemented with 50 I.U./ml 
benzyl penicillin, 50 pgiml streptomycin sulphate, 2 mM L-glutamine 
and 10% (v/v) foetal calf serum (Gibco), cellularity determined and 
adjusted to 7x105 cellsiml. 100 pi, 7x105 cells/mi was aliquoted into an 
appropriate number of flat-bottomed wells of a 96 well microtitre 
plate (Nunc).
A range of haematopoietic coiony-stimulating factor dilutions 
were prepared and 100 pi added to appropriate cell-containing wells. 
The final dilution of colony-stimulating factor in the 200 pi total 
volume was determined and cells incubated for 4 days In a 37°C, 5% 
COg in air, fully humidified atmosphere. At t=4 days, 25 pi of 300 
KBq/mi CH-TdR (Amersham) was added to each well and incubation 
continued for 0 hours.
At t=0 hours, cells were harvested using a Titertek cell harvester 
(Skatron, Norway) onto glass-flbre filter paper sheets (Titertek). After 
thorough oven-drying, individual filter discs were placed in 
scintillation vials and 2mls of scintillant ^p^hase ’Safe’, FSA 
Laboratories, Loughborough) added. 3H-TdR uptake by proliferating 
cells was determined using a liquid scintillation counter (LKB1214 
Rackbeta). Each vial was counted for a five minute period and a
Figure 19: Tritiated thymidine uptake assay
as a measure of cellular proliferation.
◄-
100 jil, appropriately 
diluted recombinant 
haematopoietic 
colony-stimulating
factor.
100 pi, 7x10scelliml.
Incubated 
4 days.
25 nl, 300 KBq 
tritiated thymidine 
added.
Incubated 
8 hours.
▼
Cells harvested and tritiated 
thymidine uptake determined 
using liquid scintillation.
Tritiated thymidine ™ Cellular 
uptake proliferation
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'counts per minute' (CPM) value determined. The CPM figure reflects 
3H-TdR incorporation which inturn reflects cellular proliferation. 
Cellular proliferation was subsequently related to the dilution of 
colony-stimulating factor and a dose-response curve established.
2,8 Murine thymocyte proliferation assay of
interieukin 1 activity,
[Figure 20 Thymic tissue was removed from 2-3 week old GBA/H 
mice. A single ceii suspension of thymocytes was produced in RPMI 
medium (Gibco) supplemented with 501U./mi benzyl penicillin, 50 
ag/mi streptomycin sulphate, 2 mM L-glutamine and 10% (v/v) foetal 
calf serum (Gibco), celiuierlty determined and adjusted to 102 cell/ml.
a) Titration oo co^^<^^l^^\^^lim A.
Ooncanaveiin A (Con A) will Itself stimulate thymocyte
proliferation. A suboptimei concentration of Con A was required to 
allow subsequent interleukin 1 titration.
10071107 thymocytes/ml were added to an appropriate number 
of flat-bottomed wells of a 96 well microtitre plate (Nunc) and 50 pi of 
variously diluted Con A added. The final concentration of Con A in 
the 150 pi total volume was determined and ceils incubated for 3 days 
in a 37°C, 5%COg in air, fully humidified atmosphere. At t=3 days, 25 
pi of 300 KBq/mi 3H-TdR (Amersham) was added to each well and 
incubation continued for 16 hours. At t=16 hours, ceiis were 
harvested and 3H-TdR incorporation determined by scintillation 
counting. 3H~TdR incorporation, related to cellular proliferation was 
subsequently related to Con A concentration and a dose-response 
curve established [Figure 21],
Figure 20: The murine thymocyte assay of interleukin 1.
1) A suupppulation of t hhmocctes (T-lymphocctes), exppsee 
to interleukin 1 produce interleukin 2 receptors.
2) A subp euplafipnof on yon ocytecinterant wite the 
Concanayalin P (Con P) antigen and release interleukin 2.
3) inteeleukin 2 stimulates interleukin 2 (exeptofrbearlng 
cells to undergo proliferation.
4) Thymocyte ctoli(urstioni dote cted cy tripy( ed 
thymidine incorporation, is related to interleukin 1 levels.
Figure 21 : Concanavalin A titration.
50 gi, appropriately 
diluted Con A.
100 pi, 107 thymocytes/ml
Incubated 
3 days.
▼
Cells harvested and tritiated thymidine 
uptake determined by liquid scintillation.
Tritated thymidine 7 Thymocyte 
uptake proliferation
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b) Tiiration oo inteiTeukin 1.
tOOpI, 10C thymocytes/ml were added to an appropriate 
number of flat-bottomed wells of a 96 well microtitre plate (Nunc) and 
50 pi of Con A sufficient to produce a final concentration of 1.5 pg/ml 
in a 200 pi total volume was added. 50 pi of variously diluted 
Interleukin 1 (alpha or beta) was added to appropriate wells and the 
final dilution of interleukin 1 in the 200 pi total volume determined. 
Cells were Incubated for 3 days in a 37°C, 5%C02 in air, fully 
humidified atmosphere. At t=3 days, 25 pi of 300 KBq/mi ^-TdR 
(Amersham) was added to each well and Incubation continued for 16 
hours. Att= 16 hours cells were harvested and CH-TdR incorporation 
determined by scintillation counting. Cp-TdR incorporation, related to 
cellular proliferation was subsequently related to the dilution of 
interleukin 1 and a doso-respoHSo curve established [Figure 22].
2-9 Ir Vitro GryHulochto-Mycroehyyo ColoHg-Formmy Cell
(GM-CFC)Aooyg^
A single cell suspension of haematopoietic tissue was produced
in Dulbeccos medium (Gibco) supplemented with 50 l.U./ml benzyl 
penicillin (Glaxo), 50 pgiml steptomycin sulphate (Evans), 2 mM L- 
glutamine (Flow Laboratories) and 20% horse serum (Gibco). 
Cellularity was determined and adjusted to 5x103 cell/ml. 1ml, 5x103 
cell/ml and 1ml, melted 3% (w/v) agar (Difco BactoAgar) were added 
to 0mls of warmed (37°C), supplemented Dulbeccos medium. 1ml 
aliquots of the lOmls, 5x104 cell/ml in 0.3% agar produced, were 
plated in 30mm plastic, non-tissue culture grade, triple vent, 
petridishos (Sterilin), over a volume of haematopoietic colony- 
stimulating activity. Routinely medium conditioned by WEHI3B 
myelomoHOcgtic leukaemic cell line was used (a crude source of
Figure 22: Interleukin .1 titration.
50 jxl, appropriately 
diluted interleukin 1.
◄--------- 50 p,l, appropriately
diluted Con P.
100 nL 107tCymocytxe/ml
Incubated 
3 days.
▼
Cells harvested and tritiated thymidine 
uptake determined py liquid scintillation.
Trltated thymidine ™ Thymocyte 
uptake proliferation
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interieukin 3 (IL3)/multi-CSF). After titration, lOOpI WEHI 3B
conditioned medium/1 mi single ceil suspension in 0.3% agar plated,
was found to have an optimal colony stimulating activity (10% v/v final
concentration).
A titration of medium conditioned by L929 fibroblast cell line, a
crude source of macrophage coiony-stimuiating factor (M-CSF/CSF- 
1), medium conditioned by AF1-19T ceil line, a crude source of GM- 
CSF and of recombinant coiony-stimuiating factors was performed 
using this technique.
The agar was allowed to set and cultures were incubated in a 
37°C, 5%CO2 in air, fully humidified atmosphere for 7 days. Colonies 
were assayed on day 7 using a binocular dissecting microscope, set 
up to give dark field illumination and colonies in excess of 50 ceiis 
counted. Collections of less than 50 ceiis were considered ’clusters' 
and were not counted [Figure 23[.
2.10 /n vitro High Proliferative Potential Colony-Forming
Ceii (HPP-CFC) Assay.
This assay utilizes a combination of haematopoietic colony- 
stimulating factors and employs a biiayer agar culture technique. A 
’feeder’ layer containing the colony-stimulating factors underlies a 
cellular layer. Coiony-stimuiating factors diffuse from the underlying 
’feeder’ layer to influence the proliferation and differentiation of ceiis 
within the cellular layer.
Underlaver : A combination of haematopoietic coiony-stimuiating 
factors was added to a volume of 37°C Dulbeccos medium 
supplemented with 50 1U./ml benzyl penicillin, 50 pg/ml steptomycin 
sulphate, 2 mM L-glutamine and 20% horse serum, sufficient to 
produce a total of 9mis and 1ml, 5% (w/v) melted agar (Difco
Figure 23: The granulocyte-macrophage
cciony-forming cell (GM-CFC) assay.
1 ml melted 3% agar
1ml 5x10 5 cellsiml
8mls warmed Dulbeccos medium 
supplemented with benzyl penicillin, 
streptomycin sulphate, L-glutamine
and 20% horse serum.
1ml aliquots of 5x104cell/ml in 
0.3% agar, plated in 30mm petridishes
over a volume of colony-stimulating
activity.
Colony-stimulating
activity.
Incubated for 7 days at 37°C
in a 5%C02 .fully humidified
atmosphere.
Colonies assayed at day 7 
using dark field illumination. 
A "colony" is defined as 
greater than 50 cells.
7 days
▼
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BactoAgar) was added. 1ml/2ml aliquots of the 10ml medium In 0.5%
agar containing the combination of colony-stimulating factors were 
plated in 30mm/50mm plastic, non-tissue culture grade, triple vent, 
petridiohes. The agar was allowed to set and these ’feeder’ layers 
were stored in a 37°C, S^tCOg in air, fully humidified atmosphere until 
required.
Routinely medium conditioned by WEHI 3B mye1omonocgtic 
leukaemic cell line (a crude source of ' Interleukin 3 (IL3)imulti-CSF) 
and medium conditioned by L929 fibroblast ceil line (a crude source 
of M-CSF/CSF-1) were used in combination. Titration of conditioned 
media both singly and in combination demonstrated 10% (v/v) of 
each in combination produced optimal HPP-CFC proliferation. Thus, 
1mi each of WEHI 3B and L929 conditioned media were added to 
7mls of supplemented Dulbeccos medium and 1 ml, 5% (w/v) agar 
added. In specific instances different combinations of conditioned 
media were used and in other cases, recombinant colony-stimulating 
factors were investigated.
Cellular laver : A single ceil suspension of haematopoietic tissue 
was produced in Dulbeccos medium supplemented with 50 l.U./ml 
benzyl penicillin, 50 pgiml oteptomgcin sulphate, 2 mM L-glutamine 
and 20% horse serum. Experimental evaluation demonstrates that the 
cellularity of tissue plated to produce sufficient HPP-CFC-derlved 
colonies at assay, varies according to the source of the tissue.
Normal haematopoietic tissue was diluted to 2.0-2.5x105 cell/mi, while 
haematopoietic tissue from mice subjected to whole body X- 
irradiation (2.13) was diluted to 5.0x104 cell/ml.
1ml, 2.0-2.5x105 normal bone marrow cells/mi, or 5.0x105 whole 
body X-irradlated bone marrow cellsiml and 1ml, 3% (w/v) melted 
agar were added to 0mls, 37°C, supplemented Dulbeccos medium. 
1ml/2ml aliquots of the 10ml, 2.0-2.5x10'' normal bone marrow
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ceils/ml, or 5.0x103 whole body X-lrredleted bone marrow ceils/mi In 
0.3% agar, were plated in 30mm/50mm petridishes over the 
previously prepared 0.5% agar 'feeder' layers containing the colony- 
stimulating iectors. The agar was allowed to set and cultures 
Incubated in a 37°C, 5% COg in air, fully humidified atmosphere for 14 
days, a period of incubation which, during evaluation, proved optimal 
for HPP-CFC proliferation.
Colonies were assayed unstained using a binocular dissecting 
microscope set up to give dark field illumination. Alternatively, 12-24 
hours prior to assay, O.5mil1.OmI of an autoclaved solution of 1mg 
INT/ml 0.9% (w/v) NaCI was added to each 30mm/50mm culture dish 
and incubation continued. (INT = 2(4-iodophenyl)-3-(4-nitrophenyi)- 
5-phenyitetrazolium chloride, BDH/Sigma) [Bol ef a/,1977]. As viable 
ceiis proliferate in vitro, in response to coiony-stimuiating factors, 
they convert the colourless tetrazolium sait to a water insoluble red 
formazan which precipitates inside ceiis. The contrast of colonies 
was increased sufficiently to allow macroscopic assay.
Colonies in excess of 2 mm diameter were established during 
evaluation as the population of colony-forming cells of interest a 
criterion applied by Pragneii ef a/[1988], Eckmann ef and
Faik and Vogel [1988]. Colony size was determined using a 1mm grid 
on a clear acetate sheet underlay [Figure 24\.
2,11 Fixation and Staining of GM-CFC and HPP-CFC-
Derived Colonies.
Colonies can be fixed after assay using an overlay of a 10% (v/v) 
formalin solution and can be stored at +4°C, in a humidified 
atmosphere. Alternatively, the colony-containing agar disc can be 
removed from the petridish and mounted on a glass slide:
Eigure 24: The high proliferative potential colony-forming
cell (HPP-CFC) assay.
Underlayer.
1ml melted 5% agar
1ml WEHI conditioned medium
1ml L929 conditioned medium
7mls warmed Dulbeccos medium 
supplemented with benzyl penicillin, 
streptomycin sulphate, L-glutamine
and 20% horse serum.
Cellular layer.
1 ml melted 3% agar.
1ml 2x105normal 
i 5x10® X-irradiated 
cellsiml
8mls warmed Dulbeccos medium 
supplemented with benzyl penicillin, 
streptomycin sulphate, L-glutamine
and 20% horse serum.
Jb Culture layer Ki
'XXXXXXXXXXXXXXXXXXXXXXXXXXX
sssssssssssssssss sssssssss
/•xxxxxxxxxxxxxxxxxxxxxxxxxxx
1ml/2ml, 2x105normal i 5x1 O4 X-irradiated 
cellsZml in 0.3% agar are plated in 30mmi 
50mm plastic petridishes over the 0.5%
agar feeder layer containing 10% (viv) 
each of WEHI and L929 conditioned media.
Assayed after 14 days incubation.
HPR-CFC-derived colony defined as 
a colony in excess of 2mm diameter.
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Cultures were cooled (+4°C) to solidify the 0.3% coiony-
contalning agar. Potridioheo were then carefully submerged in a 
+4°C, isotonic solution (Isoton II, Coulter Electronics). If already 
fixed with 10% formalin, +4°C water may be used. A 25G needle was 
run around the edge of the agar disc and the 0.3% agar culture layer 
floated free from the petridish. In the case of the PPP-CFC assay, the 
0.3% agar culture disc can aiso be floated free from the 0.5% agar 
’feeder’ layer.
The freo-floatiHg 0.3% agar disc was captured on a methanol- 
cleaned 2“x3" glass slide and carefully removed from the solution. An 
filtereaper disc (Whatman 541,5.5cm) was placed over the agar disc 
to remove excess fluid and the whole allowed to air dry. Once dry the 
filter paper disc was easily removed.
If already stained with INT, PPP-CFC-derived colonies were 
apparent in the othe-rwise unstained agar disc. Unstained GM-CFC 
and PPP-CFC-derived agar discs can be Jenner-Giemsa stained (2.4). 
After staining, colonies macroocopically stain dark blue in a blue­
staining agar disc. Resolution for microscopic iHhootigytioH proved 
relatively poor due to the residual thickness and background staining 
of the agar. Slides can be mounted using DePeX (BDP) mounting 
medium and a glass coversiip.
2,12 Use of Metlhvloellulose as a Semi-Solid Support
Medium for GM-CFC and HPP-CFC Culture,
In specific cases where colony repiating experiments, cytological 
investigation, or collularitg determination of colonies was of interest, 
the 0.3% agar support medium was replaced with 0.9% 
methylceilulose (Methocei MC4000, Fluka). Mothyiceiiuiooe allows 
colonies of interest to be ’plucked’ from the culture environment
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using a 1mi syringe and 23G needle, in replating experiments, sterile
conditions were maintained. Single ceii suspensions were produced 
from single colonies in appropriate medium and repiated for 
subsequent GM-CFC or HPP-CFC assay. For cytological investigation 
cytocentrifuge preparations were produced (2.4) and colony 
celiularities were determined using a Coulter Counter.
Aliquots of 2% (w/v) methyiceiiuiose in Dulbeccos medium 
supplemented with 50 l.U./mi benzyl penicillin, 50 pg/ml streptomycin 
sulphate and 2 mM L-giutamine were stored at -20°C. For use, 
aliquots were thawed at room temperature.
Smis, 2% methyiceiiuiose in supplemented Dulbeccos medium 
was added to 5mis, 10.0x1 O’* subiethaily X-irradiated, regenerating 
bone marrow (RBM) ceii/mi, or 5.0x1 O’* normal bone marrow (NBM) 
ceii/mi, single ceil suspension in supplemented Dulbeccos medium 
with 40% (v/v) horse serum. 1ml aliquots of the 1OmIs, 5.0x1 O’* RBM 
ceii/mi, or 2.5x1 O’* NBM ceii/mi, in supplemented Dulbeccos medium 
with 20% (v/v) horse serum produced, were plated in 30mm non­
tissue culture grade, triple vent, plastic petridishes, over an optimal 
volume of coiony-stimuiating activity for subsequent GM-CFC assay, 
or over a 0.5% agar 'feeder' layer containing a combination of coiony- 
stimuiating factors, for subsequent HPP-CFC assay. Colonies were 
assayed after 7/14 days incubation in a 37°C, 5%C02 in air, fully 
humidified atmosphere and visualised using a binocular dissecting 
microscope set up to give dark field illumination.
2,13 Determination of the Proportion of Colony-Forming
Ceiis In S-phase,
The degree of cellular proliferation was determined through the 
use of an S-phase "suicide" assay. Ceiis were incubated with a
02
nucleoside analogue which competes with the native nucleoside for 
incorporation into newly synthesizing DNA at S-phase. When the 
complex DNA-synthesizing enzyme system incorporates the 
nucleoside analogue into the elongating strand of DNA, the molecule 
acts as a "chain-terminator" preventing the subsequent 
polymerization of further nucleosides probably through 
stereochemical hinderaHco, so preventing further DNA synthesis. A 
failure of DNA synthesis at S-phase is a lethal event and the cell will 
die. if the cell is a colony-forming ceil, during subsequent colony­
forming cell assays, the colony-forming potential is not realised. By a 
comparison of the number of colonies formed from ceils treated with, 
or without, the S-phase specific cytotoxic agent, a measure of the 
proportion of colony-forming cells in S-phase was obtained. The S- 
phase specific cytotoxic agent used was Cytosine B-D- 
ArabiHofuranoslde (Cytosine Arabinoside, ARA-CXSigma), a 
deoxycytidine analogue [Cork ef yi,190T; Thomas ef yi,1901; Riches 
ef yi,1901; Wright ef a/,1902; 1905; Cork ef y/,1906]■
A single cell suspension was produced in appropriate medium, 
cellularity determined and adjusted to 5x106 cell/ml. Two 1mi samples 
of 5x106 ceil/mi were produced in plastic, conical, centrifuge tubes. 
ARA-C, stored iyophilized at +4°C was solubilized in appropriate 
medium immediately prior to use as 250 pgimi. To one 1ml sample of 
5x106 cell/ml, lOOpi of the 250 pg ARA-C/ml was added, producing a 
final concentration of 25 pg ARA-C/ml (^O'M). (100pi, 250 pg ARA- 
C/mi was added per 1ml of cell suspension) To the other 1ml sample 
of 5x106 cell/ml, lOOpI of medium alone was added as a control. 
Samples were incubated for 1 hour at 37°C with frequent vortex 
mixing. After 1 hour, cells were washed: 7mls fresh medium was 
added to each sample and the ceil suspension centrifuged (x1OOO 
rpm, 15 mins i). Supernatant was removed to waste, the ceil pellet
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resuspended in 8mis of fresh medium and recentrifuged (x1OOO rpm, 
15 mins.). Supernatant was removed to waste and the ceii pellet 
resuspended in 1mi of fresh medium as a single ceii suspension. 
Washing confines the action of the S-phase specific cytotoxic agent 
to the 1 hour Incubation and not subsequent culture. Ceiiularity was 
determined using a Couiter Counter and adjusted as appropriate for 
subsequent GM-CFC (2.9) or HPP-CFC (2.10) assay [Figure 25\,
2,14 The Pi^r^c^i^^^ti^in of Medium Conditioned By Normal
Bone Marrow,
Normal bone marrow conditioned medium was used as a crude 
source of stem ceii proliferation inhibitor. Normal bone marrow was 
obtained as femorai marrow from CBA/H mice and suspended as a 
single ceii suspension in Dulbeccos medium supplemented with 50 
i.U./ml benzyl penicillin, 50 pg/ml streptomycin sulphate, 2 mM L- 
glutamine and 20% (v/v) horse serum, in specific cases, the 20% 
horse serum was ommitted to allow the production of a serum-free 
conditioned medium. Ceiiuierity was determined using a Couiter 
Counter and adjusted as required, usually within a 15-20x10® ceii/mi 
range. The single ceii suspension was incubated at 37°C, with 
frequent vortex mixing for a 4-6 hour period [Lord ef a/,1976; 1977; 
1979; Wright & Lord,1979; Wright ef e/,1980a; 1980b; Lord & 
Wright,1982;1984; Tejero ef a/,1984; Simmons & Lord,1985; Lord ef 
e/,19S7; Wright & Lorimore,1987; Pojda ef a/,1988]. After incubation, 
the single ceii suspension was centrifuged (x1OOO rpm, 15 mins.). The 
supernatant was retained, twice recentrifuged (x2000 rpm, 15 mins. 
and X3000 rpm, 15 mins.), aliquoted and frozen (-20°C). individual 
aliquots were not refrozen once thawed and prior to use were
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centrifuged (x3000 rpm, 15 mins.), MHliPore filtered (0.22 pM) and
diiuted as required [Figure 26[.
2,15 The Producltion of Medium Conditioned By
RoyoHorytlHq/Cgc1iHg bone marrow,
Regoneratlng/ogciing bone marrow conditioned medium was 
used as a crude source of stem ceii proliferation stimulator. In mice, 
0.2 Gray (Gy) whole body X-lrradiation is sufficient to iethally damage 
the haematopoietic system and death occurs after 14 days due to 
haematopoietic failure. Use of 4.5 Gy whole body X-irradiation, 
subiothallg damages the haematopoietic system and haematopoietic 
regeneration occurs. Regenerating femorai bone marrow was 
harvested from mice 7 days after 4.5 Gy whole body X-irradiation, as 
a source of cycling bone marrow and medium conditioned by the 
regenerating marrow as a crude source of the stem ceii proliferation 
ofi/Hu/ytor [Wright & Lord,1977; Lord ef aZ,1977; Tejero ef y/,1904; 
Wright ef yi,1905].
Mice were irradiated in a perspex cassette placed a fixed distance 
from an X-ray source. X-rays were produced from a Siemens 
Stabilipan at 250KVp and 14mA and filtered through a 0.5mm copper 
(Cu) filter. A dose rate was established using a Farmer Dosimeter 
(Nuclear Entorpriooo, Reading) with an ionization chamber placed 
inside a wax mouse ’ghost’ and Irradiated identically to the mice. A 
dose rate of 0.01 Gy/min was established and a given dose obtained 
by varying the length of exposure.
Regenerating/cycling femoral bone marrow was obtained and 
suspended in Dulbeccos medium supplemented with 50 i.U./mi 
benzyl peHiciiiln, 50 pgimi streptomycin sulphate, 2 mM L-glutamine 
and 20% (v/v) horse serum. In specific cases the 20% horse serum
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was ommitted to aliow the production of a serum-free conditioned 
medium. Ceiiuiar-ity was determined using a Coulter Counter and 
adjusted as required usuaiiy within a 15-20x106 cell/ml range. The 
single celi suspension was incubated at 37°C with frequent vortex 
mixing for a 1-3 hour period. After Incubation, the single cell 
suspension was centrifuged (xfOOO rpm, 15 mins.). The supernatant 
was retained, twice recentrifuged (x2000 rpm, 15 mins. and x3000 
rpm, 15 mins.), aliquoted and frozen (-20°C). individual aliquots were 
not refrozen once thawed and prior to use were centrifuged (x3000 
rpm, 15 mins.), MiliiPore filtered (0.22pM) and diluted as required 
[Figure 27\.
2,16 Assay of Medium Conditjgned by Normal Bone
Marrow,
Normal bone marrow conditioned medium is a crude source of
stem ceii proliferation inhibitor. The activity was demonstrated 
against haematopoietic tissue in which the proportion of stem ceils in 
S-phase was increased. CBA/H mice were subjected to a 2Gy, 
sublethai whole body X-^adiation dose (X-ray unit: Siemens 
Stabilipan at 250KVp, 14mA and 0.5mm Cu filter. Dose rate =
0.81 Gy/min.). Regenerating femorai marrow was harvested 3 days 
after irradiation [Lord ef a/,1977; Wright ef a/,1985].
A single ceil suspension of regenerating/cycling femorai marrow 
was produced in Dulbeccos medium supplemented with 50 i.U./mi 
benzyl penicillin, 50 pg/mi steptomycin sulphate, 2 mM L-giutamine 
and 20% (v/v) horse serum. In specific cases the 20% horse serum 
was ommitted for incubation under serum-free conditions. Ceiis were 
washed once in appropriate medium to remove any endogenous 
regulatory activities, resuspended as a single ceii suspension and
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celluiarity determined. Ceiiuierlty was adjusted to 5x106
cycling/regenerating marrow ceiis/mi.
Aliquots of normal bone marrow conditioned medium (2.14), 
stored at -20°C, were thawed, centrifuged (x3000 rpm, 15 mins.) and 
MiliiPore filtered (0.22pM). The concentration of the proliferation 
inhibitor is related to the number of celis from which it is derived and 
dilution in appropriate medium produces a conditioned medium of 
the required 'potency*.
1ml, 5x106 cycling/regenerating marrow ceiis/mi was incubated 
with 1ml of appropriately diiuted normal bone marrow conditioned 
medium, or medium as a control, in paired, plastic, conical centrifuge 
tubes, for 4 hours at 37°C with frequent vortex mixing. "
The proportion of ceiis in S-phase was investigated by a further 1 
hour incubation in the absence or presence of ARA-C (2.13), and 
ceils were washed, plated and subsequently cultured in the in vitro 
HPP-CFC assay (2.10) [Figure 21
2.17 Assay of medium conditioned by
reqenereting/cycilng bone marrow.
Regenerating/cycling bone marrow conditioned medium is a 
crude source of stem cell proliferation stimuiator. The activity was
demonstrated against haematopoietic tissue in which the proportion 
of stem ceils in S-phase was reduced. Such haematopoietic tissue 
was obtained as normal femoral bone marrow [Wright et a/,1977; 
Wright & Lord,1979; 1982; Wright efe/,1982; Lord & Wright,1984; 
Tejero ef a/,1984; Wright ef a/,1985; Wright & Lorimore,1987j.
A single cell suspension of normal CBA/H femoral marrow was 
produced in Dulbeccos medium supplemented with 50 i.U./mi benzyl 
penicillin, 50 pg/mi steptomycin sulphate, 2 mM L-giutamine and 20%
Figure 28: Assay of medium conditioned by normal bone marrow.
Regenerating/ 
cycling bone 
marrow.
. . i i i ..11 .... i 
mi. —
. i . i .. i11
Normal bone 
marrow 
conditioned 
medium.
i
Incubated 
4 hours.
Incubated 
1 hour ± ARA-C
THEN
Cells washed 
and HPP-CFC 
assay performed.
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(v/v) horse serum. In specific cases the 20% horse serum was 
ommitted for incubation under oorum-treo conditions. Ceils were
washed once in appropriate medium to remove any endogenous 
regulatory activities, resuspended as a single ceii suspension and 
celluiyritg determined. Ceiiulyrity was adjusted to 5x106 normal
marrow ceiis/mi.
Aliquots of regeneratiHgicgc1iHg bone marrow conditioned 
medium (2.15), stored at -20°C, were thawed, centrifuged (x3000 rpm, 
15 mins.) and MiliiPore filtered (0.22 pM). The concentration of the 
proliferation stimuiator was related to the number of cells from which 
it was derived and dilution in appropriate medium produces a 
conditioned medium of the required ’potency’.
1mi, 5x106 normal marrow ceiis/mi was incubated with 1mi of 
appropriately diiuted regenerating/cycling bone marrow conditioned 
medium, or medium as a control, in paired, plastic, conical centrifuge 
tubes, for 2 hours at 37°C with frequent vortex mixing.
The proportion of cells in S-phase was investigated by a further 1 
hour incubation in the absence or presence of ARA-C (2.13), and 
cells were washed, plated and subsequently cultured in the in vitro 
HPP-CFC assay (2.10) [Figure 29\.
2.10 Derivation of primary, murine, myeloid
Primary myeloid leukaemias were induced in CBA/H, male mice 
subjected to 3Gy whole body X-irradiation (X-ray unit: Siemens 
Stabilipan at 250KVp 14mA and 0.5mm Cu filter. Dose rate =
0.01 Gy/min.) No spontaneous leukaemias were observed In 
unirradiated controls [Meldrum & Mo1o,1902; Mole ef yi,1903; 
Hepburn ef yi,1907]. When mice showed ruffled fur, weight loss, 
stiffness of movement, lethargy and pale feet, they were killed by
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ether inhalation overdose. At autopsy, leukaemias were characterized
by histological examination of biood, femorai bone marrow, spieen, 
sternum and iiver. Spleen and femorai marrow ceiis were injected 
intraperltoneally, or intravenously, into syngeneic mice to establish 
serial in vivo passage of the leukaemia [Hepburn ef a/,1987]. Two 
distinct morphologies subsequently developed depending on the 
number of leukaemic cells injected at passage. Leukaemias 
passaged at a low ceii dose, maintain a near-primary morphology and 
character [Hepburn ef a/,1987]. Leukaemias passaged at a high ceii 
dose, show a marked increase in aggressiveness, probably due to 
selection pressure on more rapidly growing leukaemic cells within 
the leukaemic population as a whole [Hepburn ef a/,1987].
Spieen and marrow cells from primary myeloid leukaemias and 
subsequent passages can be cryopreserved in liquid nitrogen (in 
supplemented medium, 10-20% (v/v) foetal calf serum and 5-10%
(v/v) CMSO) and rederived as required by rapid thawing, washing and 
either intravenous, or intraperitoneai injection into syngeneic 
recipients [Hepburn ef a/,1987].
2.19 In vivo passage of murine, myeloid leukaemias.
Syngeneic mice injected intraperitonealiy, or intravenously, with 
either a high, or low, cell dose of leukaemic cells, were checked daily. 
When mice show ruffled fur, weight loss, stiffness of movement, 
lethargy and pale feet, they were killed by ether inhalation overdose. 
At autopsy a large pale spleen was evident and was taken as 
indicative of leukaemic progression. Conformation of the disease 
was established by the production of a spieen 'touch-preparation'. 
The spleen was cut in two and the cut surface gently touched onto a 
glass slide. Cells deposited were air dried and either fixed and
09
Jenner-Giemsa, or Diff-Quik stained (2.4). Microscopic analysis
showed the opionomegai1y was the result of marked leukaemic
infiltration.
A crude leukaemic spleen cell suspension was produced in 
Fischers medium supplemented with 50 i.U./ml benzyi peniciiiln, 50 
jg/ml streptomycin sulphate and 2 mM L-glutamine using a 1 mi 
syringe with no needle attatched. Allowed to stand for a short time, 
large pieces of debris and extracellular matrix settle out of the 
suspension. A single ceii suspension of leukaemic spleen was 
produced through subsequent removal of cellular supernatant from 
the crude ceii suspension and use of 23G and 25G needles. 
Coiiuiaritg was determined using a Couiter Counter, adjusted as 
required and injected either iHtraperitonoaliy, or intravenously, at 
either a high, or low, cell dose. Cytocentrifugo preparations (2.4) of 
the leukaemic spieen cell suspension confirm the nature of the cells 
injected.
2.20 Production of medium conditioned by. leukaemic
bone marrow.
Syngeneic mice injected intryperitoHealiy? or iHtraveHouoly5 with 
either a high, or low, cell dose of leukaemic cells, were checked daily. 
When mice show ruffled fur, weight loss, stitfHooo of movement, 
lethargy and pale feet, they were killed by ether inhalation overdose. 
At autopsy a large pale spleen was evident and was taken as 
indicative of leukaemic progression. Leukaemic bone marrow was 
obtained as femoral marrow and suspended as a single ceil 
suspension in Dulbeccos medium supplemented with 50 i.U./mi 
benzyl penicillin, 50 jig/mi otroptomgciH sulphate, 2 mM L-glutamine 
and 20% (v/v) horse serum, in specific cases the 20% horse serum
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was ommitted to allow production of a serum-free conditioned 
medium. Cellularity was determined using a Coulter Counter and 
adjusted as required to within a 15-20x106 celi/ml range. The single 
ceii suspension was Incubated at 37°C with frequent vortex mixing for 
1-3 hours. After incubation the single ceii suspension was centrifuged 
(x1OOO rpm, 15 mins.). The supernatant was retained and 
recentrifuged (x2000 rpm, 15 mins. and x3000 rpm, 15 mins.), 
aiiquoted and frozen (-20°C). Individual aliquots were not refrozen 
once thawed and prior to use were centrifuged (x3000 rpm, 15 mins.), 
MiliiPore filtered (0.22 pM) and diiuted as required. Cytocentrifuge 
preparations of the ieukaemic bone marrow confirms the nature of 
the ceiis incubated [Figure 30[.
2.21 Assay of medium conditioned bv leukaemic bone
marrow.
The nature of haematopoietic stem cell proliferation regulation in 
myeloid leukaemic bone marrow was unknown. Medium conditioned 
by ieukaemic bone marrow was assayed against both
regenerating/cyciing bone marrow (2.16) to Investigate the 
presence/absence of proliferation inhibitor, and normal bone marrow 
(2.17), to investigate the presence/absence of proliferation stimulator 
[Figure 3T\.
2.22 lnvyetiggtinq t he effeets oo ieekaemic boon mLarow
conditioned medium on inft/Mfor and/or sf/m/afor action.
Normal bone marrow (NBM) conditioned medium, a crude source 
of inhibitor i2.14) and medium conditioned by regenerating marrow 
(RBM) from mice 7 days after a 4.5 Gy whole body X-irradietion dose,
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as a crude source of stimulator (215), were produced. Conditioned
medium was thawed, centrifuged (x3000 rpm, 15 mins.), MilliPore
filtered (0.22 ^M) and diiuted so as to be derived from 15x106
NBM/R.BM celis/mi.
Appropriate ieukaemic marrow conditioned medium (2.20) was 
thawed, centrifuged (x3000 rpm, 15 mins.), MilliPore filtered (0.22 |JM) 
and diluted so as to be derived from 15x106 ceiis/mi.
inhlbftorvias assayed against regenerating bone marrow (RBM) 
from mice 3 days after a 2 Gy whole body X-irradiation dose (2.16). 
RBM ceiis were washed once in supplemented Duibecco's medium 
and resuspended as 5x106 RBM cells/ml in either Ieukaemic 
conditioned medium or normal medium [Figure 33J.
Stimuiatorvias assayed against normal bone marrow (NBM) 
(2.17). NBM celis were washed once In supplemented Duibecco's 
medium and resuspended as 5x10® NBM ceils/ml in either Ieukaemic 
conditioned medium or normal medium [Figure 32T.
1 mi, 5x106 NBM/RBM ceiis/mi in either Ieukaemic conditioned 
medium or normal medium, was aiiquoted into each of two paired 
centrifuge tubes and assay of inhibitor and stimulator performed by 
the addition of 1 mi of the appropriate normal, or regenerating, bone 
marrow conditioned medium (2.16 & 2.17). The proportion of cells in 
S-phase was determined during the last hour of incubation In the 
absence or presence of ARA-C (2.13). Ceiis were washed and 
cultured in the HPP-CFC assay (2.10).
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2.23 Investigation of the effects of leukaemic bone
marrow conditioned medium on inhibitor mnd/or
stimulator production.
Normal bone marrow (NBM) was obtained from CBA/H mice and 
regenerating bone marrow (RBM) from mice 7 days after a 4.5 Gy 
whole body X-^adiation dose. A single ceii suspension of NBM/RBM 
was produced in Duibecco's medium supplemented with 50 i.U./ml 
benzyl penicillin, 50 pg/mi streptomycin sulphate, 2 mM L-giutamine 
and 20% (v/v) horse serum.
Appropriate ieukaemic bone marrow conditioned medium (2.20), 
stored at -20°C, was thawed, cenrifuged (x3000 rpm, 15 mins.), 
MilliPore filtered (0.22 pM) and appropriately diluted In supplemented 
Duibecco's medium so as to be derived from 15x106 cell/ml.
NBM/RBM celis were washed once In supplemented Duibecco's 
medium and resuspended as a single cell suspension In either 
Ieukaemic conditioned medium, or medium. Celluiarity was 
determined and adjusted to within 15-20x106 NBM/RBM ceii/mi and 
NBM and RBM ceiis were subsequently Incubated for 7 and 5 hours 
respectively, to allow inhibitor and stimulator resynthesis [Figures 34 
&35\.
At t=7, or 5 hours, the single ceil suspension was centrifuged 
(xOOO rpm, 15 mins.), supernatant retained and repeatedly 
centrifuged (x2000 rpm, 15 mins. and 3000 rpm, 15 mins.). Medium 
conditioned by NBM/RBM cells in the absence and presence of 
Ieukaemic conditioned medium was aliquoted and frozen (-20°C).
Incubated 7 hours
Inhibitor resynthesized.
Washed normal 
bone marrow
Incubated 7 hours
+ leukaemic bone marrow 
conditioned medium.
Inhibitor resynthesized ?
Washed normal 
bone marrow
Figure 34: Investigating the effects of leukaemic bone marrow
conditioned medium on inhibitor production.
Incubated 5 hours
Stimulator resynthesized.
Washed regenerating 
bone marrow
Incubated 5 hours
+ leukaemic bone marrow 
conditioned medium.
Stimulator resynthesized ?
Washed regenerating 
bone marrow
Figure 35: Investigating the effects of leukaemic bone marrow
conditioned medium on stimulator production.
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2.24 The low molecular weight, hyomoroyu1ytorg
totraeoptido AcSDKP and trieoptido yHyloguoo,
Tetrypeptide AcSDKP and a number of tripeptido analogues were 
synthesized [Thierry ef a/,1990] and kindly supplied by Pr^Maryse
Lenient and DroJosaine Thierry (Institut de Chimie des Substances 
Naturalles, CNRS, Gif-sur-Yvette, France). Peptides were supplied as 
lyophiiized HPLC fractions and stored at -20°C.
Samples were dissolved it a volume of -serum-free Dulbecco’s 
medium sufficient to produce 100 ng peptideimi (Approximately 10'S 
Molar, M), aiiquoted and frozen (-20SC). (*Serum is reported to 
enzymatically degrade the peptides (AcSDKP is reported to have a 
half-life of approximately 20 hours in 10% (v/v) heat inactivated foetal 
calf serum) and serum albumin is reported to adversely bind the 
peptides [M.Lonfant, personal communication]). Dissolving the 
peptides in the absence of serum protein, peptide manipulation was 
kept to a minimum and performed in plastic containers. Dissolved 
peptides were stored frozen (-20°+) in polypropylene crgotuboo 
(Nunc.). Individual 100 ng/mi peptide aliquots were not refrozen once 
thawed and were stored at +4°C until required.
2.25 lHhootigytioH of the direct effecte of the low
molecular weight eoetidoo oh GM-CFC and HPP-CFC
proliferation.
Direct stimulatory and/or inhibitory action of the low molecular 
weight peptides on both GM-CFC and HPP-CFC was investigated. 
Normal bone marrow (NBM) was obtained from the femora of 0-12 
week old CBA/H mice and regenerating bote marrow (RBM) from 
mice 3 days after a 2 Gy whole body X-irradiation dose. A single cell
94
suspension of NBM/RBM was produced in Duibecco's medium 
supplemented with 50 l.U./mi benzyl penicillin, 50 pg/mi streptomycin 
sulphate and 2 mM L-giutamine, ceils washed once, to remove 
endogenous regulatory activities, and resuspended in serum-free, 
supplemented Duibecco’s medium. Cellularity was determined and 
adjusted to 5x106 Nbm/RBM celis/mi.
100 ng/mi aliquots of appropriate peptide, stored at -20°C, were 
thawed and stored at +4°C. 1 mi, 5x106 NBM/RBM ceils/ml was 
added to each of two paired centrifuge tubes and incubated for 3 
hours at 37°C with the addition of sufficient peptide to produce a final 
concentration of 1 ng/mi (approx. 10*M), or medium as control, at 
t=0,1 and 2 hours.
The proportion of celis in S-phase was determined by the 
addition of ARA-C, or medium, during the final hour of incubation 
(2.13). Cells were subsequently washed and cultured in the GM-CFC 
(2.9) and HPP-CFC (2.10) assays [Figure 36].
2,26 Mof the effects of low molecular weight
peptides on inhibitor and/or se/mt/efor action.
Normal bone marrow conditioned medium, a crude source of 
inhibitor(2.11) and medium conditioned by marrow from mice 7 days 
after a 4.5 Gy whole body X-irradiation dose, a crude source of 
stimuiator (12.15), were produced under serum-free conditions in 
Duibecco's medium supplemented with 50 l.U./mi benzyl penicillin, 50 
pg/mi streptomycin sulphate and 2 mM L-giutamine.
inhibitor and stimulaterwere assayed as detailed (2.16 & 2.17) 
with the addition of a duplicate pair of centrifuge tubes to which 
appropriate peptide, to a final concentration of 1 ng/mi (approx. 10* 
9M) was added att=0 and at each subsequent hour of incubation.
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The final hour of Incubation was performed in the absence or
eroooHco of ARA-C to determine the proportion of cells It S-phase
(2.13). Cells were washed and subsequently cultured In the HPP-CFC
assay (2.10) [Figure 37\.
2,27 lnveHhiootion oft Qe ine irtct offeots of the low 
molecular weight peptides on inhibitor mndlor stimulator
production.
Normal bone marrow (NBM) was obtained from 0-12 week old 
CBA/H mice and regenerating bone marrow (RBM) from mice 7 days 
after a 4.5 Gy whole body X-Irradlatlon dose. A single cell suspension 
of NBM/RBM was produced In serum-free Dulbecco’s medium 
supplemented with 50 l.U./ml benzyl penicillin, 50 pg/ml streptomycin 
sulphate and 2 mM L-glutamlne. Cells were washed and 
resuspended, cellularity determined and adjusted to 15-20x106 
NBM/RBM cells/mi.
100 ng/ml aliquots of appropriate peptide, stored at -20°C, were 
thawed and stored at +4°C. NBM/RBM ceiis were incubated for 7/5 
hours at 37°C, with either the addition of sufficient peptide to produce 
a final concentration of 1 ng/mi (approx. 10'9M), or an equivalent 
volume of medium, at t=0 and at every subsequent hour of 
Incubation.
After Incubation, the NBM/RBM single ceii suspension was 
centrifuged (x1OOO rpm, 15 mits.), supernatant retained, repeatedly 
ceHtritugoC (x2000 rpm, 15 mits. and x3000 rpm, 15 mits.) and frozen 
(-20°C). Medium conditioned by the NBM/RBM suspension it the 
absence and presence of peptide was suboeqettlg assayed for 
stimulator and inhibitor (2.16 & 2.17) [Figures 38 & 3$].
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Incubated 7 hours
--------------------------- ► Inhibitor resynthesized.
Washed normal 
bone marrow
Incubated 7 hours
--------------------------- ► Inhibitor resynthesized ?
+ PEPTIDE
Washed normal 
bone marrow
Figure 38: Investigating the effects of the haemoregulatory
peptides on inhibitor production.
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Chapter 3
Results.
Section 1
The characterization of the 
in vitro HPP-CFCil3+csf-i 
assay.
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3,1 CnaryctorizytiQH of the eQtOHcg of medium 
CQHCitiQHoC by ceil IIhos ihC rocQmblHyHtIg-CorihoC
nyomytQeQiotic cQlQHg-otimuIytlHq factors,
3,1.1 , Characterization of the colonv-st^mulatinq 30^7^7 of medium
conditioned bv WEHI SB. L929 and AF1-19T cell lltes.
Procedure:
The colony-stimulating potential of medium conditioned by WEHI 
SB myoIomQtQcytic Ieukaemic cell lite, L929 fibroblast cell line and 
AF1-19T malignant histiocytosis sarcoma virus-transformed rat 
kldtey cell line was assessed by titration using the in vitro 
granulocyte-macrophage colony-forming cell (GM-CFC) assay (2.9).
0,50,100,150 and 200jul volumes of each conditioned medium 
were assayed with 1 ml, 5x104 normal bone marrow cells/mi In 0.3% 
agar, producing a final conditioned medium concentration of 0, 5,10, 
15 and 20% reopectlholg. At assay, "colonies" were defined as a 
collection of in excess of 50 coils. Collections of loss than 50 cells 
were defined as l,<tluotoro" and were not counted. The number of 
colonies stimulated was related to the concentration of conditioned 
medium and dose-response curves established. .
Results:
It the absence of conditioned medium, no cellular proliferation 
was observed. Increasing the concentration of the conditioned 
medium. Initially produced a proportional Increase in colony 
numbers, reaching a maximum, plateau value beyond which no 
significant lHcroaso It colony numbers was observed.
The optimal ho1umo/cQHcentratlon of conditioned medium was 
determined as the minimum which proved capable of stimulating 
near maximal colony numbers, A100 411/10% (v/v)
97
volume/concentration of conditioned medium appeared to fulfill this
criterion [Figures 40a & 40b].
3.1.1.1 WEHI 313 melomonoccVic leukaemic cell Ilne conditioned
medium.
Medium conditioned by WEHI 3B myelomonocytic leukaemic cell 
line is a crude source of interleukin 3 (IL3)/multi-CSF [Ihle et 
a/,1982](1.21) and stimulates the proliferation of colony-forming cells 
of a variety of haematopoietic lineages In the GM-CFC assay. At 
assay this was observed In the variety of both colony sizes and 
colony morphologies. Colony sizes varied considerably between 
'colonies' clearly In excess of 50 cells, to 'clusters' of 10-15 cells, 
while colony morphologies varied between compact 'tight' colonies, 
less compact 'loose' colonies and colonies of both a 'tight' and 
’loose' morphology ( | mixed' colonies). At assay, no distinction was 
made as to colony morphology, colony size (In excess of 50 cells) 
was the only criterion applied [Piate 1, Slide C].
3 batches of WEHI 3B cell line conditioned medium were used. 
Each batch was similarly titrated and no significant variation in 
colony-stimulating potential between Individual batches was 
observed [Figure 40].
3.1.1.2 cell Ilne conditioned medium.
Medium conditioned by the L929 fibroblast cell line is a crude 
source of macrophage colony-stimulating factor (M-CSF/CSF-1) 
[Burgess ef a/,1977](1.21). Primarily It stimulates the proliferation of
lineage-committed macrophage progenitors within murine 
haematopoietic tissue. At assay colonies varied In cellularlty between
98
those clearly in excess of 50 cells to 'clusters’ of 10-15 cells, while 
colony morphology showed little variation. L929 cell line conditioned 
medium-stimulated colonies were characterized by a relatively 
compact nature [Plate 1, Slide B & Piate 2, Siide 4].
2 batches of L929 cell line conditioned medium were used. Both 
batches were similarly titrated and no significant variation in colony- 
stimulating potential was observed [Figure 40b].
3.1.1.3 AFl1'11TceH I Ine conditioned medium.
Medium conditioned by AF1-19T malignant histiocytosis sarcoma 
virus-transformed rat kidney cell line, Is a crude source of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) 
[Kriegler ef a/,1990]. Primarily it stimulates the proliferation of 
lineage-committed granulocyte and macrophage progenitors and 
also bipotentlal granulocyte-macrophage progenitors within the 
murine haematopoietic tissue. This is consistent with the variety of 
colony morphologies observed at assay. The ’potency’ of AF1-19T 
cell line conditioned medium proved consistently low, this may be a 
direct consequence of the specles-speclficity of GM-CSF. AF1-19T is 
a rat-derived cell line, while the haematopoietic tissue under assay Is 
murine. A100 yt/10% (v/v) volume/concentration of AF1-19T cell line 
conditioned medium was used. 1 batch of AF1-19T conditioned 
medium was used during the project [Figure 40c].
\
Figure 40a: GM-CFC titration of
WEHI 3B cell line conditioned medium.
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3.1.2 areeraCierlzei|OL^eties^OtentyOerstombrnen1it<dsrlvei
haematopoietic colonv-stimuletlne factors.
Procedure:
The haematopoietic activity of the recombinantly-derived colony- 
stimulating factors was unknown and was investigated by use of both 
the in vitro GM-OFC assay (2.9) and the tritiated thymidine uptake 
assay (2.7).
Recombinant murine interleukin 3 (rmulL3)/multl-OSF and 
recombinant human macrophage colony-stimulating factor (rhuM- 
CSF/CSF-1) were kindly supplied by Genetics institute as medium 
conditioned by engineered CHO cells. Recombinant murine
granulocyte-macrophage colony-stimulating factor (rmuGM-OSF)
f
was kindly supplied by both Genetics Institute, as medium 
conditioned by engineered COS cells and Immunex, as a lyophiiized 
protein sample.
The material was serially diluted prior to in vitro GM-CFC and 
tritiated thymidine uptake assay. For comparison, a 10% dilution of 
WEHI or L929 cell line conditioned medium was used as a crude 
source of Interleukin 3 (^ymulti-CSF or M-OSF/OSF-1 respectively.
In the GM-OFO assay 100 pi volumes of appropriately diluted 
factor were incubated with 1 ml, 5x106 normal bone marrow cells/ml 
In 0.3% agar. The final factor concentration was thus xO.1 that added. 
5 dishes were produced per factor dilution. In the tritiated thymidine 
uptake assay, 100 pl volumes of appropriately diluted factor were 
Incubated with 100pi, 7x105 normal bone marrow cells/mi. The final 
factor concentration was thus xO.5 that added. 4-12 microtitre wells 
were produced per factor dilution.
For each recombinant factor, GM-OFO and tritiated thymidine 
uptake data were related to factor dilution, and dose-response curves
100
established. The optimal voIume/cQnceHtratlQH of recQmblHyntIg-
Cerlhod factor was CotorminoC as that which stimulated near maximal
colony numbers/cellular proliferation.
Results:
3.1.2.1 Recamt^^na^Hiv~-(er^ve<( murine interleukin 3 emulL3V/mul1ii
CSF.
With reference to both GM-CFC and trltiatod thymidine uptake 
titration data of rmuiL3 (Genetics Institute), at optimal dilution of 
1:500 (of Gonotics Institute rmuiL3 sample) was determined [Figure
41a].
3.1.2.2 Recoonb^^atniyh-(enver( human macrophage colQnv-
stlmulatito factor trhuM-C5FVC5F-1■
With reference to both GM-CFC and tritiatied thymidine uptake 
titration data of rhuM-CSF (Genetics institute), at optimal 
concentration of 30 unlto7ml was determined [Figure 41b],
3.1.2.3 R^r^t^o^fc^ir^^i^tl^-c^^ri^^^r( murint gsrnuloQthe-mnatophhge
colony-stimulating factor frmuGM-CSF).
Extensive in vitro GM-CFC titration of rmuGM-CSF (Immunex) had 
been previously pertQrmeC In this laboratory and at optimal 
concentration of 40 unitsVmi determined.
(*- rhuM-CSF (Genetics instutu^e) and rmuGM-CSF (Immunex) 
were supplied as samples of specified units of activity. The ^^10^ 
of ’units’ it each case was supplied, although subsequent titration of
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tho factors allowed the ’potency’ of tho factors to be determined. 
’Units’ were retained as reference values to assist in factor dilutions.)
3.1.3 ,Chotr^aterization oo the aat^lht¥ oo recoonfoiriHtni^y-3erivvrl human
interleukin 1 frnuIL1).
I L1 activity is determined by measuring the tritiated thymidine
incorporation by thymocytes cultured for 3 days in the presence of an 
appropriate concentration of concanavailn A and serially diluted IL1. 
IL1 activity is defined in units with 1 unlt/mi concentration being that
which stimulates 50% maximal thymocyte proliferation.
3.1.3.1 ,711^^00 oo A (Con Al^Saa,
Procedure:
A100 ul volume of Con A at a concentration sufficient to produce 
a final concentration of 0-15 pg/ml, was added to 100 pl, 107 
thymocytes/ml, to determine the concentration of Con A which would 
not itself stimulate thymocyte proliferation, but which would best 
potentiate the interleukin 1-assoclated thymocyte proliferation.
Result:
A 1.5 pg/ml concentration of Con A was determined as a 
concentration which would best potettiate the IL1-aso0Ciyted 
thymocyte proliferation [Figure 41c].
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3,1,3.2 TTir£^tic^r^.Qfr€^c^c^r^t^ir^g^r^tIiy^-c^€^rry^€^ci human i nterleukin 1
(rhulL1U2.8bL
Procedure:
A 50 pi volume of appropriately diluted interleukin 1 (rhuILI-alpha 
(Genetics Institute and Immunex) and IL1-beta (Immunex)), sufficient
to produce a final concentration of 0-100 units/mi was added to 100 
pi, 107 thymocytes/m! and 50 pi Con A at a concentration sufficient to 
produce a final concentration of 1.5 pg/mi, and the whole incubated 
for 3 days.
Results:
An optimal interleukin 1 (rhuILI-alpha (Genetics Institute and 
Immunex) and IL1-beta (immunex)) concentration of 5 units/mi was 
determined as active in the thymocyte proliferation assay [Figure
4101.
3.1.3.3 GM-CFC activitt oo recoml^Inntnlyvcierivvr:l hh^r^g^n » nterle^kin 1
frhulLf).
Procedure:
100 pi volumes of appropriately diluted rhylM-alpha (Genetics 
Institute and immunex) and ^011.1^^ (Immunex), sufficient to
produce a final concentration of 0,5,10 and 20 units/mi were 
incubated with 1 mi, 5x104 normal bone marrow ceils/ml in 0.3% agar, 
and incubated for 7 days (2.9).
Result:
Interleukin 1, as either rhuILI-alpha (Genetics Institute or 
Immunex) or rhulL1-betc (Immunex), failed to demonstrate colony- 
stimulating activity over the 0-20 unit/mi concentration range 
assayed.
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3.1.4 Evidence of interleukin 1 activity in the WEHi 3B, L929 or AF1-
19T cell line conditioned media.
3.1.4.1 Investigation of the capacity of WEHI 3B, L929 and AF1-19T
cell line conditioned media to stimulate thymocyte proliferation.
Procedure:
100 ul of appropriately diluted WEHI 3B, L929 or AF1-19T cell line 
conditioned medium, sufficient to produce a final concentration of 0, 
5,10,15 and 20% (v/v) was incubated with 100 pl, 107 thymocytes/ml, 
to determine the capacity of each conditioned medium to stimulate 
thymocyte proliferation.
Results:
WEHI 3B, L929 and AF1-19T cell line conditioned media, do not 
stimulate thymocyte proliferation over the 0-20% (v/v) concentation 
range assayed [Figure 41e].
3.1.4.2 Investigation of the interleukin 1 activity of WEHI 3B, L929 and
AF1-19T cell line conditioned media.
Procedure:
50 ul appropriately diluted WEHI 3B, L929 or AF1-19T cell line 
conditioned media, sufficient to produce a final concentration of 0,5, 
10,15 and 20% (v/v) was incubated with 100pl, 107 thymocytes/ml 
and 50pl Con A, at a sufficient concentration to produce a final 
concentration of 1.5pg/ml. Con A-potentiated, thymocyte 
proliferation would be indicative of interleukin 1 activity in the 
conditioned media.
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Results:
No evidence of Con A-potentlated thymocyte proliferation was
observed implying that over a 0-20% (v/v) concentration, the 
conditioned media demonstrate no interleukin 1 activity [Figure 41f[,
3.2 Characterization of haematopoietic colony-stimulating
factor synergism.
Specific colony-stimulating factors are able to interact when 
combined, to stimulate the proliferation of a colony-forming ceii 
population characterized by a high proliferative potential. This high 
proliferative potential colony-forming cell (HPP-CFC) population is 
only observed in the presence of combinations of colony-stimulating 
factors and is distinct from the colony-forming ceii population 
stimulated in the presence of a single colony-stimulating factor. This 
ability of specific colony-stimulating factors to "synergize" was 
investigated using both crude conditioned medium and 
recombinantiy-derived factors.
Procedure:
’Optimal’ dilutions of crude and recombinant colony-stimulating 
factors (3.1), were combined in the in vitro HPP-CFC assay (2.10). 
Any synergism between colony-stimulating factors was investigated, 
in the case of colony-stimulating factor synergism, large, 
macroscopic colonies were evident at assay.
The iii-defined nature of medium conditioned by WEHI 3B, L929 
and AF1-19T cell lines is such ruat, while they may prove to be crude 
sources of interleukin 3 (IL3)/muiti-CSF, M-CSF/CSF-1 and GM-CSF 
respectively, other factors may be present, and responsible for 
establishing synergistic interactions. Use of the rigorously defined, 
recombinantiy-derived factors was hoped to demonstrate the factors
Figure 41e: Stimulation of thymocyte 
proliferation by WEHI 3B, L929 or
AF1-19T coHCltloHeC meda.
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responsible for the stimulation of the HPP-CFC population were
indeed interleukin 3 (IL3)/muiti-CSF, M-CSF/CSF-1 and GM-CSF. 
Results:
3.2.1 Synergism between interleukin 3 (ILSVmuiti-CSF and
macrophage coionv-stlmuiatlna factor (M-CSF/CSF-11.
Interleukin 3 (lL3)/mu!ti-CSF, as both medium conditioned by the 
WEHi 3B ceii line and rmulL3, and M-CSF/CSF-1, as both medium 
conditioned by the L929 ceii line and rhuM-CSF were observed to 
synergize. Medium conditioned by the WEHI 3B ceii line and rhuM- 
CSF, and rmulL3 and medium conditioned by the L929 cell line, were 
also observed to synergize [Plate 1, Slide D & Plate 2, Slide 0|.
3.2.2 Svnergism between granuiocvte-macrophaae coionv-
stimuiating factor (GM-CSF) and macrophage coionv-stimuiating
factor (M-CSF/CSF-1).
GM-CSF as both medium conditioned by the AF1-19T cell line and 
rmuGM-CSF, and M-CSF/CSF-1 as both medium conditioned . by the 
L929 ceii line and rhuM-CSF were observed to synergize.
Significantly, despite the relatively low colony-stimulating activity of 
the medium conditioned by the AF1-19T ceil line (3.1.1), it proved 
sufficient to synergize with both crude and recombinantiy-derived 
sources of M-CSF/CSF-1. rmuGM-CSF and medium conditioned by 
the L929 ceii line were also observed to synergize [Plate 2, Slides B & 
q.
106
3.2.3 Synengsm heeween i nterieukin 3 alL3)/multi-CSF and
granulocyte-macrophage coionv-stimuiating factor fGM-CSFL
interleukin 3 (IL3)/multi-CSF as both medium conditioned by the 
WEHI 3B ceii line and as rmulL3, and GM-CSF as both medium 
conditioned by the AF1-19T ceii line and rmuGM-CSF were observed 
to synergize. Both medium conditioned by the WEHI 3B cell line and 
rmuGM-CSF, and rmulL3 and medium conditioned by the AF1-19T 
ceii line were also observed to synergize.
3.2.4 Colon v-stimulating lacKo syneegism with ^0^00^0 1 (ILH-
interleukin 1 as either Genetics Institute rhuiLI-alpha, or Immunex 
rUuiL1-clpUc or -beta, did not demonstrate a synergistic interaction
with interleukin 3 (IL3)/muiti-CSF, as either WEHI 38 ceii line 
conditioned medium or rmulL3, M-CSF/CSF-1, as either L929 ceii line 
conditioned medium or rhuM-CSF, or GM-CSF, as either AF1-19T ceii 
line conditioned medium or rmuGM-CSF. The pattern of colony
growth observed In the presence of interleukin 3 (iL3)/mulrl-CSFJ M- 
CSF/CSF-1 or GM-CSF (as either crude conditioned media or
recombinan^y-derived factors) was unchanged in the presence of 
interleukin 1.
3s3 .6!Ucrctrer^ce^na^J^UeJn_^Vitro
HPP-CpC|73+0^s^F_t_assay.
Before setting the strict criteria by which the HPP-CFC, mcSF_f
derived colonies were assayed, it proved necessary to optimize the in
vitro culture conditions. Many aspects of the HPP-CFC,f+CS7i assay
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were adaptations of the GM-CFC assay and thus may not have been 
optimal in the HPP-CFCIL3+cSy^ ssayy.
3.3.1 . The o|rtimal cell dose for
HPP:FCFK)U3:C2e4_yooaY.
Procedure:
The number of normal murine bone marrow cells plated in the 
0.3% agar culture layer of the bilayer HPP-CFC,^+^-1 assay, was 
titrated over a range Sxio3-ix105 normal boto marrow ceiis/mi.
Result:
Prior to tho specific CotlHltiOH of HPP-CFCJL3+C2r_1-<(e^ived 
colonies, a celluiarity of 2.0-2.5x104 normal bote marrow cellsiml was 
found to give ’countable’ numbers of HPP-CFC colonies. A lower 
ceiluiarltg gave proportionately lower HPP-CFC1L3_fffi numbers, 
while higher cellularities lead to colony ’overcrowding’ and made 
subsequent colony-counting difficult. HPP-CFClLa+csm were aiso 
demonstrable it normal, tot-haematopoietic, murlto spleen, 
although to achiovo colony numbers comparable to those of 2.0- 
2.5x104 normal boto marrow cells (approximately 25 HPP-CFC 
colonies), 10® spieen ceils were required. HPPPKf+fsw m also 
demonstrable it haematopoietic, murine foetal liver, with 5.0-10.01004 
foetal llvor ceiis producing colony numbers comparable to 2.0- 
2.5x103 normal bone marrow ceils.
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3.3.2 The cancentratton of calony-sttmuiattnq factors to induce
optimal HPPP-FCltC, pr proliferation.
Procedure:
The concentration of colony-stimulating factors inducing optima!
HPP-CFCIL3+csm proliferation was investigated. As previously 
demonstrated, the characteristic HPP-CFC populations are only 
observed in the presence of combinations of colony-stimulating
factors.
Results:
Titration of medium conditioned by the WEHI 3B cell line, as a
crude source of interleukin 3 (IL3)/multi-CSF, against a fixed 
concentration of medium conditioned by the L929 cell line (10% v/v), 
as a crude source of M-CSF/CSF-1, demonstrated that a GM-CFC- 
derived 'optimal' concentration of colony-stimulating factor, was not 
a prerequisite for synergism. HPP-CFC|L3+Ctf.| were demonstrable at 
markedly sub-optlmai WEHI 3B ceii line conditioned medium 
concentrations (as determined by the GM-CFC assay). Increasing the 
concentration of the WEHI 3B cell line conditioned medium, did not 
significantly increase the absolute number of HPP-CFC^L3+Gso.1, 
although the degree of cellular proliferation per HPP-CFC^+qsF.1- 
derived colony was increased, producing a stronger iNT-staining 
colony at assay. This finding correlates with the observation that 
medium conditioned by the AF1-19T ceii line demonstrated little 
colony-stimulating activity in the GM-CFC assay, although proving 
capable of synergism to stimulate the proliferation of the 
HPP-CFCgm.C3piC^m "GFU-A" population.
A concentration of 10% (v/v) each of WEHI 3B ceii line 
conditioned medium and L929 ceii line conditioned medium (as 
crude sources of interleukin 3 (ILSymuiti-CSF and M-CSF/CSF~1
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respectively) was determined as that which would promote HPP- 
CFC!L3+csf-i Proliferation.
3.3.3 The optimal time of assay of
HPP:CFClL3+CSM.
Procedure:
The time of assay of the HPP-CFCIL3+csf1 population was 
determined by performing a time study. Cultures of 2.5x104 normal 
bone marrow cells/ml in 0.3% agar were incubated over a ’feeder’ 
layer containing 10% (v/v) of WEHI 3B cell line (as a crude source of 
interleukin 3 (IL3)/multi-CSF), or L929 cell line (as a crude source of 
M-CSF/CSF-1), or a 10% (v/v) combination of each conditioned 
medium. Cultures were assayed after 8,10,12 and 14 days.
Results:
While a different pattern of colony growth was determined at as 
early as day 8 when comparing WEHI 3B, L929 and combined 
conditioned media stimuli, day 14 was chosen as a time which was 
considered to allow the full proliferative potential of the HPP- 
CFC|L3+csf-i to develop and so increase the contrast between the 
HPP-CFC|L3+csfand non-HPP-CFCIL3+GSF_1-derived colonies [Plate 3].
3.3.4 The development of a criterion to define the
HPP-CFC,L3+CSF1 population.
Procedure:
A criterion was required by which colonies derived from HPP- 
CFC, l3+csf-i cou|d be defined. The unique aspect of the HPP-CFC- 
derived colonies Is their relatively large size in comparison to non- 
HPP-CFC-derived colonies. Non-HPP-CFC-derived colonies, as
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stimulated by the presence of single colony-stimulating factors in the
HPP-CFC assay system, were rarely observed to exceed a 2mm 
diameter, while HPP-CFC-derived colonies, as stimulated by the
presence of a synergistic combination of colony-stimulating factors, 
were found to exceed a 2 mm diameter.
Result:
A size criterion: "colonies In excess of a2mm diameteF was thus
adopted as the definition of an HPP-CFC^c^derlved colony [Plate
4 & Plates 5A & 5BJ.
3.3.5 The cell^aa composition ao the HPP-CFCh , , aSF1-derived 
colonies.
Procedure:
In specific experiments the semi-solid 0.3% agar in the bilayer 
HPP-CFC assay was replaced by 0.9% methyiceiluiose (2.12). The 
use of merhyiceiluiose allowed an investigation of the cellular 
composition of the HPP-CFC^^^deeived colonies to be made. 
Individual colonies were ’plucked' from the methyiceiluiose after 14 
days incubation in the presence of 10% (v/v) each of WEHI 3B and 
L929 cell line conditioned media (as crude sources of interleukin 3 
(IL3)/muiti-CSF and M-CSF/CSF-1 respectively) and cytospin 
preparations produced.
Results:
Jenner-Giemsa staining of ceils derived from individual HPP- 
CFC^csi-^derived colonies revealed the majority of colonies were 
composed largely of macrophages. This would be consistent with the 
presence of the M-CSF/CSF-1 (as medium conditioned by the L929 
ceil line). The macrophages observed were characterized by a 
heavily vacuolated cytoplasm [Plate 64]. In some cases, in
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association with the mature macrophages, populations of immature
ceils were observed [Plate 6B[. in other cases, a morphoioglcaiiy 
distinct population of cells, characterized by a less vacuolated 
cytoplasm containing granules and with pale staining nuclei, were 
observed [Plate 6C].
3.3,6 The ceHularitv d 14 day HPP-CFCIL3; CCM-derived fcoonies.
Procedure:
I
The HPP-CFC|i+CSpi-derived colonies ranged in size from 
approximately 2-5mm in diameter. The use of 0.9% methyiceUuiose
allowed the ceiiularity of individual colonies to be determined. 
Individual HPP-CCCdgid-derived colonies were 'plucked' fom HPP- 
CFC assay at day 14 and ceii counts performed of. single cell 
suspensions of each colony using a Coulter Counter.
Result:
An average ceiiularity of 6.0(±04))x’104 celis/14 day HPP- 
CF:F^L3^HctP1 “derived colony was determined (n=6).
For comparison, a number of non-HPP-CFC-derived colonies, 
stimulated by either WEHI 3B (as a crude source of interleukin 3 
(IL3)/muitl-CSF) or L929 (as a crude source of M-CSF/CSF-1) cell line 
conditioned media, were investigated. Individai colonies were 
'plucked' from HPP-CFC assay at day 14, pooled and a ceil counts 
made of the resultant single ceii suspension using a Coulter Counter. 
An average ceiiuiariry of 1.4x10- ceiis/14 day WEHi 3B ceii line 
conditioned medium-stimulated colony and 0.6x10- ceiis/14 day L929 
cell line conditioned medium-stimulated colony, was determined.
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3.4 Reaui1telir^BF,L3+CSF frequency
in normal and sublerUclIvX-irrcdicred CBA/H mice.
3.4.1 Femur cellularities in normal and sublethaliy X-irradiated CBA/H
mice.
Procedure:
Femoral bone marrow was obtained from CBA/H mice as detailed 
(2.2). The majority of femoral marrow was expelled from the femoral 
cavity as a ’plug’ by the initial flush of medium, however repeated 
flushing of the femoral cavity with medium ensured maximal marrow 
recovery. Average femur ceUuiarities were determined by suspending 
the marrow of a known number of femora in a known volume of 
medium. A Coulter Count was performed on the resultant 
appropriately diluted, single ceii suspension (2.3).
Result:
An average femoral ceiiularity of 14(±1)x106 ceils (±SEM)(n=54) 
was determined for normal, 9-12 week old, male CBA/H mice.
In specific experiments, CBA/H mice were subjected to subiethai, 
whole body X-irradiation, which induced haematopoietic damage and 
produced a ’regenerating’ bone marrow. In CBA/H mice 3 and 7 days 
after subieth^ whole body X-irradiation doses of 2 and 4.5 Gy 
respectively (2.15 & 2.16), a 57% reduction in femoral marrow 
cellulcrlty was determined. In both cases, an average femur ceiiularity 
of 6(±ixx106 ceils was observed (±SEM)(n = 30 and n = 7 
respectively).
113
3.4.2. HPP-CFC1L3+ggp_1 frequency in normal and sublethaliy, whole 
bodv X-irradiated CBA/H femoral marrow.
3.4.2.1 HPP-CFC^, CCF1 frequency in normal CBA/H femoral marrow.
HPP-CFC,F+CLai ssaay of normal CBA/H femoral marrow 
(assayed at 2.0-2.5x104 ceiis/mi) gave an average HCP-CFCmccsp-i 
frequency of l00(±1//!05 marrow cells (±SEM)(n=340). In an 
average normal CBA/H femur of approximately 14x/06 marrow ceils, 
an HPP-C^F^CLl34CSF.1 frequency of 100/10® marrow cells, gives a total 
approximate femoral marrow complement of /4x/03 HPP-CFC1Ls+cSF_r 
Approximately 1 in every 1000 marrow ceils will thus be a potential 
HPP-CF-Cfccm [Figure^
3.4.2.2 HPP-CFC|L4+cspi frequency in regenerating femoral marrow.
HPP-CFCjficsf-i assay of femoral marrow from mice 3 days after 
a subiethai, whole body X-irradiation dose of 2 Gy (assayed at 5x104 
regenerating bone marrow ceiis/mi) gave an average HPP- 
CFCN|33CSF_1 frequency of 29(±1)H05 regenerating marrow cells 
(±SEM)(n = 210). In an average femur from a mouse 3 days after a 2 
Gy whole body X-irradiation dose, of approximately 6x106 marrow 
cells, an HPP-CFC n^pi of 29/105 marrow cells gives an 
approximate 2 Gy X-irradiated femoral marrow compliment of 2x103 
HCP-CFC,l33CSpi. Approximately 1 in every 3000 regenerating marrow 
ceils will be a potential HCP-CFC^cs^-
Assayed 3 days after a whole body X-irradiation dose of 2 Gy, the 
total number of HPCC-Cf+c^m is reduced by 85% in
comparison to a normal non-irradiated femur. Hendry and Lajtha
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[1977] reported an 80% reduction in "CFU-S" numbers in murine
femora after a 1.5 Gy X-irradiation dose [Figure 42].
Figure 42: Summary of femur ceilularities and HPP-CFCil.3+csf-i frequencies in 
normal and X-irradiated CBA/H mice.
Normal 'X-irradiated
Average femur cellularity (x106) (±SEM)
Average HPP-CFCil3+csf-i frequency (±SEM)
Approximate number of HPP-CFC|L3+csF-i/temur
14(±1) (n=54)
100(+1)/105 cells (n=340)
14x103
6(±1) (n=30)
29(+1 )/105 cells (n=210)
2x103
Marrow from mice 3 days after a whole body X-irradiation dose of 2 Gy.
Plates
Plate 1 : This photograph illustrates the pattern of colony 
growth obtained from murine bone marrow after 14 days in 
semi-solid agar under different colony-srimulcring factor 
regimes. Colonies observed are derived from 2.5x104 normal 
bone marrow cells per 30mm diameter, 0.3% agar disc and 
have been stoined with INT. Each agar disc is approximately 
30mm In diameter.
Slide A: In the absence of haematopoietic colony- 
stimulating activity. No cellular proliferation is observed.
Slide B: In the presence of 10% (v/v) medium conditioned 
by the L929 fibroblast cell line, a crude source of macrophage 
colony-stimulating factor (M-CSF/CSF-1).
Slide C: In the presence of 10% (v/v) medium conditioned 
by the WEHI 3B myelomonocytic leukaemic cell line, a crude 
source of interleukin 3 (IL3)/multi-CSF.
Slide D: In the presence of a combination of media 
conditioned by the L929 fibroblast cell line and the WEHI 3B 
myelomonocytic leukaemic cell line. The combination of 
colony-stimulating factors "synergize" to stimulate the 
proliferation of a colony-forming cell population characterized 
by c high proliferative potential. This distinct high proliferative 
potential colony-forming cell (HPP-CFC) population is not 
observed when each factor is used singly.
Slide A
• $
*Slide B
»
10mm
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Slide D
Plate 2 : This photograph illustrates the pattern of colony 
growth from 2.5x104 murine bone marrow cells after 14 days, in 
the presence of medium conditioned by the L929 fibroblast cell 
line, as a crude source of M-CSF/CSF-1 fSlide A] (colonies are 
stained with INT and each agar disc is approximately 30mm in 
diameter) and in the presence of a combination of L929 
fibroblast cell line conditioned medium (M-CSF/CSF-1) and:
(1) AF1-19T malignant histiocytosis sarcoma virus- 
transformed cell line conditioned medium, a crude source of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) 
[MdS_B].
(2) Recombinantiy-derived murine granulocyte- 
macrophage colony-stimulating factor (rmuGM-CSF) [Slide C].
(3) WEHI 3B myelomonocytic leukaemic cell line 
conditioned medium, a crude source of interleukin 3 (IL3)/multi- 
CSF [Slide DI.
GM-CSF, as either medium conditioned by the AF1-19T 
cell line or as rmuGM-CSF, and interleukin 3 (IL3)/multi-CSF, 
as medium conditioned by the WEHI 3B cell line, are 
demonstrated to synergise with M-CSF/CSF-1 to stimulate the 
proliferation of a distinct colony-forming cell population with 
high proliferative potential. These high proliferative potential 
colony-forming cell (HPP-CFCGM-csF+csF-i and HPP- 
CFCiL3+csF-i ) - derived colonies, appear to differ 
morphologically and numerically, although the exact 
relationship between HPP-CFC subpopulations is, as yet, 
unclear.
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Plate 3 : This photograph illustrates the pattern of colony 
growth by 5x104 normal bone marrow cells, over a period of 14 
days in the presence of medium conditioned by the L929 cell 
line (as a crude source of M-CSF/CSF-1), the WEHI 3B cell line 
(as a crude source of interleukin 3 (IL3)/multi-CSF) or a 
combination of the two conditioned media.
(Colonies were assayed on days 8, 10, 12 and 14 and 
stained with INT. Each agar disc is approximately 50mm in 
diameter.)
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L929 cell line 
conditioned 
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WEHI 3B + L929 
conditioned media.
WEHI 3B cell line 
conditioned 
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Plate 4: This photograph illustrates the pattern of colony 
growth observed at day 14 after the culture of 5x104 normal 
bone marrow cells with medium conditioned by the L929 
fibroblast cell line (as a crude source of M-CSF/CSF-1 ), the 
WEHI 3B cell line (as a crude source of interleukin 3 (IL3)/ 
multi-CSF) or a combination of the two conditioned media.
The results of both INT and Jenner-Giemsa staining 
techniques are illustrated (each agar disc is approximately 
50mm in diameter).
Jenner-Giemsa
Stained INT Stained
L929 cell line 
conditioned 
medium
WEHI 3B cell line 
conditioned 
medium.
WEHI 3B + L929 
conditioned media
10mm
Plates 5A and 5B : These photographs illustrate, at a 
higher magnification, the contrast in the diameters of an 
HPP-CFC - derived colony, stimulated in the presence of a 
combination of L929 and WEHI 3B conditioned media 
(HPP-CFC|L3+csf_i), which fulfills the 2mm diameter criterion 
(Actual diameters of approximately: Plate 5A - 5mm, Plate 5B - 
4mm) and a non-HPP-CFC - derived colony (Actual diameters 
of approximately: Plate 5A - 0.5mm, Plate 5B - 0.8mm).
(Plate SB has a 1mm grid background against which reference 
can be made. Colonies were stained with INT.)
Plate 5A
•y
I-------- 1
1 mm
Plate 5B
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Plates 6A, 6B and 6C : This series of
photomicrographs illustrate the variety of cell types observed 
when the cellular composition of individual HPP-CFC|L3+csf-i - 
derived colonies was investigated. The photomicrographs are 
of cytocentrifudge preparations of individual 14 day 
HPP-CFC||_3+csf-i - derived colonies cultured in 0.9% 
methylcelluiose and cells are Jenner-Giemsa stained.
PI atG 6A : This photomicrograph illustrates the heavily 
vacuolated nature of the macrophage population which was 
found to be the most abundant cell type within individual 
HPP-CFC|L3+csf-i - derived colonies. This is consistent with the 
presence of M-CSF/CSF-1, as medium conditioned by the 
L929 fibroblast cell line.
Plate 6B: This photomicrograph illustrates the occasional 
finding of a relatively immature myeloid cell population,
showing some degree of differentiation, together with the
mature macrophages within individual HPP-CFCil3+csf-i - 
derived colonies.
Plate 6C : This photomicrograph illustrates the occasional 
finding of a discrete, morphologically distinct cell population, 
characterized by a pale-staining nucleus and abundant 
cytoplasmic granules, together with the mature macrophages 
within individual HPP-CFCil3+csf-i - derived colonies.
10pM
Plate 6A
Plate 6C
Plate 6B
Section 2
An investigation of the 
proliferation and 
proliferation regulation 
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3,5 Determination of the proportion of 
HPP-CFC,+csf 1 *n S-phase in normal and sublethaliy 
X-irradiated, regenerating. CBA/H femoral marrow.
Procedure:
The proportion of HPP-CFCIL3+csm in S-phase was determined by 
use of the S-phase ’suicide’ technique. Cells in S-phase, if incubated 
with the S-phase-specific cytotoxic agent cytosine arabinoside (ARA- 
C)(2.13) are killed. Thus, HAP-CFC,^^ in S-phase during ARA-C 
incubation are killed and their coiony-forming potential is not realised 
in the subsequent HPP-CFCl33+CSp1 assay. The proportion of HPP- 
CFCIL3+csm in S-phase is determined by the difference in the number 
of HPP-CFCILJ3+a3F_1-derived colonies obtained in the absence of ARA- 
C and the number obtained in the presence of ARA-C.
Results:
3.5.1 Determination of the proportion of
HPP-CCCiLa, Qgp! in S-thase in normal femoral marrow.
The proportion of HPPPFCc+^fm S-phase in normal femoral 
marrow was determined as 9(± 1)% (±SEM)(n=255) [Figure 43[.
in vitro GM-CFC assay of normal bone marrow demonstrates that
the proportion of the more mature haematopoietic progenitor cells in 
S-phase is 31(±1)% (±SEM)(n=35) [Figure 43].
3.5.2 Determination of the proportion of 
HPP-CFC,L3 , Cgp-, in S-phase in regenerating femoral marrow.
The proportion of HPP-CFCa3+<pFa in S-phase in regenerating 
femoral marrow from mice 3 days after a whole body M-irradiation
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dose of 2 Gy was determined as 40(±1)% (±SEM)(n = 177) [Figure
43J.
3.6 HPP-CFCIL3+esF ■! t<3 the stem cell-specific
proliferation inhibitor and stimulator.
Procedure:
Haematopoietic stem celt-specific proliferation regulators have 
been identified (1.10). A stem ceil proliferation inhibitor is present in 
normal bone marrow and maintains the reduced proportion of stem 
ceils in S-phase. A stem ceil proliferation stimuiator is present in 
subiethaiiy X-irradiated, regenerating bone marrow and maintains the 
increased proportion of stem cells in S-phase. The stem cell 
proliferation inhibitor has the capacity to reduce the proportion of 
stem cells in S-phase in regenerating bone marrow and similarly, the 
stem cell proliferation stimuiator has the capacity to increase the 
proportion of stem cells in S-phase in normal bone marrow. The 
sensitivity of the HPP-CFCIL3+CSo poputation to these stem cell- 
specific proliferation regulators was investigated.
Results:
3.6.1 HPP-CFC[L3+gyp sensitivity to the stem cell-specific proliferation 
inhibitor.
in regenerating marrow from mice 3 days after a whole body X- 
irradlation dose of 2 Gy, the proportion of HPP-CFCIL3+csm in S- 
phase was determined as 40(±1)% (3.5). if incubated with medium 
conditioned by normal bone marrow (2.14 & 2.16), in which the 
proportion of stem ceils in S-phase is low and which is a crude 
source of stem ceil proliferation inhibitor, the proportion of HPP-
Figure 43: The proportion of HPP-CFC in S-phase 
in normal and X-irradiated, regenerating bone marrow.
The proportion of 
HPP-CFC in S-phase 
in normal bone 
marrow:
9(±1)%
(n=255)(±SEM)
The proportion of
GM-CFC in S-phase in
normal bone marrow:
31 (±1)%
(n=35)(±SEM)
The proportion of
HPP-CFC in S-phase
in X-irradiated, 
regenerating bone
marrow:
40(±1 )%
(n=177)(±SEM)
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CFC^-gsf- in S-phase was reduced from 40(±1)% (3.5) to 25(±1)%> 
(±SEM)(n=127) [Figure 44]. (Medium was conditioned by normal 
bone marrow for 4 hours at 37°C (2.14) and prior to use was diluted 
so as to be derived from 15x106 normal bone marrow ceiis/mi).
3.6.2 HPP-CFCIL36ccr-, sensitiviy/' to the stem cell-specific proiiferation 
stimulator.
in normal bone marrow the proportion of HPP-CFCIL3+csf1 in S- 
phase was determined as 9(±1)% (3.5). if incubated with medium 
conditioned by regenerating bone marrow from mice 7 days after a 
subiethai whole body X-irradiation dose of 4.5 Gy (2.15 & 2.17), in 
which the proportion of stem ceils in S-phase is increased and which 
is a crude source of stimuiator, the proportion of HPP-CFC,66+CgF_,- in 
S-phase was increased from 9(± 1)% (3.5) to 24(± 1)%
(±SEM)(n = 107) [Figure 45[. (Medium was conditioned by 
regenerating bone marrow for 1 hour at 37°C (2.15) and prior to use 
was diluted so as to be derived from 15x10® regenerating marrow 
ceiis/mi.)
No evidence of normal bone marrow conditioned medium-derived 
inhibitor, or regenerating bone marrow-derived sf/zno/afor toxicity 
was detected in the in vitro HPP-CCC^csf-i assay.
3,7 A Aetermination of oh e sensHtivity of oh e
HPP-CFC|L3+csf-1 population to the stem cell 
proliferation inhibitor and stimulator.
Tejero ef a/[1984] demonstrated an 'age' related differential 
sensitivity to the haematopoietic stem ceil proliferation regulators. 
More primitive components of the haematopoietic stem ceil
44
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compartment (day 10-12 CFU-S) proved significantly more sensitive 
to the stem cell proliferation fnhlbftorthan stimulator, while more 
mature components of the haematopoietic stem cell compartment 
(day 7-8 CFU-S and CFC-mix) proved significantly more sensitive to 
the stem cell proliferation stimuiatorihan inhibitor (U7) [Figure 13[.
The sensitivity of the in vitro HPPP-FCIL3+(pM pupulation to the 
stem cell proliferation regulators was thus investigated to allow a 
determination of the position of the population within the 
haematopoietic stem cell compartment.
3.7.1 HPP-CFC[L3, ccr ° sensitivity to the stem cell proliferation 
inhibitor.
Procedure:
Samples of medium conditioned for 4 hours at 37°C by 15-20x106 
normal bone marrow cells/ml were prepared (2.14). Prior to use, 
samples were thawed, centrifuged (x3000 rpm, 15 mins.), MilliPore 
filtered (0.22 pM) and diluted with medium so as to be derived from 1, 
2, 4,6, 8 or 10x106 cells/mL
Regenerating femoral marrow from mice 3 days after a sublethal 
whole body X-irradiatlon dose of 2 Cy, in which the proportion of 
stem ceils in S-phase is increased, was washed and incubated with 
either medium alone, or medium conditioned by 1, 2, 4,6,8 or 10x10® 
normal bone marrow cells/ml (2.16).
Results:
In the presence of medium alone, the proportion of HPP- 
CFC,Lj°(c:p_° in S-phase was determined as 51(±3)% (±SEM) (n=6). 
In the presence of an Increasing concentration of normal bone 
marrow conditioned medium, a progressive reduction in the 
proportion of HPP-CFC°°+°°m In S-phase was observed to a
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minimum, plateau value of approximately 24% [Figure 46]. (Previous 
data (3.6.1) were obtained by incubating regenerating bone marrow
with medium conditioned by 15x10® normal bone marrow cetls/mi and
is included here: 25(±1)% (±SEM) (n = 127) HIPP-CFC^cs^ in S-
phase.)
3.7.2 HPP-CFC|L31CSF, sensitivitv to the stem cell proliferation
stimuiator.
Procedure:
Samples of medium conditioned for 1 hour at 37°C by 15-20x106 
regenerating marrow cells/ml, from mice 7 days after a 4.5 Gy whole 
body X-irradiation dose, were prepared (2.15). Prior to use, samples 
were thawed, centrifuged (x3000 rpm, 15 mins.), MilliPore filtered 
(0.22 juM) and diluted with medium so as to be diluted from 2, 4,6,8 
and 10x10® cells/ml.
Normal bone marrow, in which the proportion of stem cells in S-
phase is relatively low, was washed and incubated with either 
medium alone, or medium conditioned by 2, 4,6, 8 and 10x1<®
regenerating marrow cells/ml (2.17).
Results:
In the presence of medium alone, the proportion of HPP- 
CFClLaacsF-i in S-phase was determined as 9(±2)% (±SEM) (n = 4). in 
the presence of an increasing concentration of regenerating bone 
marrow conditioned medium, a progressive increase in the 
proportion of HPP-CFC,33+csf_1 in S-phase was observed, to a 
maximum, plateau value of approximately 28% [Figure 47\. (Previous 
data (3.6.2) were obtained by incubating normal bone marrow with 
medium conditioned by 15x106 regenerating bone marrow cells/ml
Figure 46: A determination of the sensitivity of the 
in vitro HPP-CFC|L3+csf-i population to 
stem cell proliferation inhibitor.
Concentration of
normal bone marrow
conditioned medium.
(x106 cells/ml)
Proportion of 
HPP-CFC|L3+CSF-1 
in S-phase (%).0) 
(±SEM) (n=6)
— 51 (±3)
1 49(±8) NS(P>O.1)
2 39(±3) S (P<0.05)
4 37(±3) S (P<0.025)
6 30(±4) S (P<0.005)
8 26(±5) S (P<0.01)
10 24(±6) S (P<0.025)
15 25(±1) (n=127)
0) HPP-CFC|i_3+cSF-l derived from regenerating bone marrow. 
(NS-Not significant. S-Significant)
Concentration of normal bone marrow conditioned medium 
(x106 cells/ml)
Figure 47: A determination of the sensitivity of the 
in vitro HPP-CFCh_3+csf-i population to 
stem cell proliferation stimulator.
Concentration of 
regenerating bone marrow 
conditioned medium.
(x106 cells/ml)
Proportion of 
HPP-CFCil3+csf-i 
in S-phase (%).0) 
(±SEM) (n=4)
— 9(±2)
2 17 (±2) S (P<0.005)
4 17(+3) S (P<0.005)
6 24(±3) S (P<0.0005)
8 28(±5) S (P<0.005)
10 26(±2) S (P<0.005)
15 24(±1) (n=107)
(1) HPP-GFC|L3+csfr_i derived from normal bone marrow. (S-Significant)
Concentration of regenerating marrow conditioned medium 
(x106 cells/ml)
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and is included here: 24(±1)% (±SEM) (n = 107) HPP-CFC, in
S-phase.)
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3,8 HPP-CFCIL3+CSFl investigation
inhibitor! stimulator status of medium conditioned by
murine, X-IrradIation-Induced, serially passaged, myeloid
leukaemic marrow.
A number of X-irradiation-induced myeloid leukaemias have been 
produced In CBA/C male mice In this laboratory [Cepburn af a/,1987] 
(2.18). Primary leukaemias were characterized and subsequently 
passaged through syngeneic mice. Passage of the primary 
leukaemias was at both a high and a low cell dose and two distinct 
leukaemic morphologies subsequently developed. Primary leukaemic 
cells, passaged at a relatively high ceil dose (CD), produced a 
leukaemia characterized by a more aggressive nature than the 
primary leukaemia itself, while primary leukaemic cells passaged at a 
relatively low cell dose (LD), produced a leukaemia characterized by 
a near-primary morpholgy [Cepburn ef a/,1987].
Three serially passaged, X-irradiation induced, murine, myeloid 
leukaemias were investigated - classified as SA2, SA7 and SA8 (SA- 
St .Andrews). Specifically, the high cell dose-passaged SA7 myeloid 
leukaemia (SA7CD), the high and low cell dose-passaged SA8 
myeloid leukaemia (SA8 CD and SA8 LD) and low and high passage 
numbers of the SA2 myeloid leukaemia (SA2LP and SA2CP) were 
investigated.
Femoral marrow was taken from overtly leukaemic mice and 
leukaemic marrow conditioned medium produced (2.20). Medium 
conditioned by the leukaemic marrows was subsequently 
investigated using the HPP-CFCIL3+CfF.,l assay to establish the levels 
of the stem cell proliferation regulators in such aberrant 
haematopoiesis. Evidence for a direct-acting leukaemia-associated 
haematopoietic proliferation Inhibitor was also sought (2.16 & 2.17).
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3.8.1 HPP-CFC^, CGr_1 investigation of the inhibitor/stimulator status 
of medium conditioned bv high and iow passage numbers of the SA2
mveloid ieukaemic marrow.
Procedure:
4 batches each of medium conditioned by iow and high passage 
numbers of the SA2 myeloid ieukaemic marrow were produced
(SA2LP & SA2HP)(2«20) and assayed against normal and
regenerating bone marrow (2.16 & 2.17).
Results:
3.8.1.1 The sf/mu/afor status of medium conditioned bv SA2LP and
SA2HP leukaemic marrow.
The proportion of HPP-CFCiL3+GSr.1 in S-phase in washed normal 
bone marrow was determined as 14(±1)% (±SEM) (n=8). In washed 
normal bone marrow, incubated with medium conditioned by iow 
passage number SA2 myeloid ieukaemic marrow (SA2LP), the 
proportion of HPPCFC,f+Csis hi S-phsse was not significantly 
changed (P>0.4) at 15(±1)% (n = 8). In washed normal bone marrow, 
incubated with medium conditioned by high passage number SA2 
myeloid leukaemic marrow (SA2HP), the proportion of HPP- 
CFC^f+csf-i in S-phase was not significantly changed (P>0.4) at 
15(±1)% (n = 8) [Figure 41
No evidence for the presence of stem ceil proliferation stimulator 
was observed at the concentration of conditioned medium assayed, 
in either the SA2LP or SA2HP ieukaemic marrow conditioned media
[Figure 48].
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3.8.1.2 The inhibitor status of medium conditioned bv SA2LP and
SA2HP ieukaemic marrow.
The proportion of HPP-CFCIL3+csF-i ",n S-phase in washed
regenerating bone marrow from mice 3 days after a 2 Gy whole body 
X-irradiation dose was determined as 36(±1)% (±SEM) (n=8). In 
washed regenerating bone marrow incubated with medium 
conditioned by iow passage number SA2 (SA2LP), the proportion of 
HPP-CFC|L3+Csf.i in S-phase was not significantly changed (P > 0.4) at 
36(±5)% (n = 8). In washed regenerating bone marrow incubated with 
medium conditioned by high passage number SA2 (SA2HP), the 
proportion of HPP-CFC[Lll.Csf-l in S-phase was not significantly 
changed (P>0.4) at 36(±1)% (n=8) [Figure 48].
No evidence for the presence of stem cell proliferation inhibitor 
was observed at the concentration of conditioned medium assayed, 
in either the SA2LP or SA2HP ieukaemic marrow conditioned media. 
These results also indicate that, at the concentrations of conditioned 
medium assayed, there was no evidence of a direct-acting leukaemia- 
associated haematopoietic proliferation inhibitor. Rapidly cycling 
HPP-CFCIL3lGSF_lj remain rapidly cycling when incubated with the 
leukaemic marrow conditioned medium. No evidence of SA2LP or 
SA2HP leukaemic marrow conditioned media toxicity was observed.
Figure 48: HPP-CFCil3+csf-i investigation of the
inhibitor/stimulator content of medium conditioned by high and
low passage number SA2 myeloid leukaemic marrow.
Proportion of HPP-CFCils+csf-i 
in S-phase {%) (±SEM) (n=8)
Normal
bone
marrow
(NBM
Regenerating
bone
marrow(1)
(RBM)
Control 14(±1) 36(±1)
+SA2LP conditioned 
medium.(SA2LPcm) 15(±1)<2) 36(±2)(3)’
+SA2HP conditioned 
medium.(SA2HPcm) 15(±1)(2) 36(±1 )(3)
0 ) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose.
(2) No significant increase (P>0.4).
(3) No significant reduction (P>0.4).
+S
A2
H
Pc
m
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3.8.2 HPP-CFCisg 1 ccr i investigation of the inhibitor/stimulator status
of medium conditioned bv high cell dose-passaged SA7 mveloid
leukaemic marrow.
Procedure:
5 batches of medium conditioned by high ceil dose-passaged
SA7 ieukaemic marrow (SA7HD) were produced (2.20) and assayed 
against normal and regenerating bone marrow (2.16 & 2.17).
Resuits:
3.8.2.1 Thh sS/J/ee/afonsSatus po meeium connitioond bv SA7HD
ieukaemic marrow.
in washed normal bone marrow, the proportion of HPP- 
CFC1L3+cslM in S-phase was determined as 12(±1)% (±SEM) (n = 11). 
In washed normal bone marrow, Incubated with medium conditioned 
by SA7HD myeloid ieukaemic marrow, the proportion of HPP- 
CFCn^+csfi in S-phase was not significantly changed (P>0.4) at 
13(±1)% (n=11) [Figure43[,
No evidence for the presence of stem celi proliferation stimulator 
was observed at the concentration of conditioned medium assayed.
3.8.2.2 Tho innibborrtetius oo mee^^m connitlonnd Iw SSATiD
leukaemic marrow.
The proportion of HPP-CFC,c+Cfri In S-phase in washed 
regenerating bone marrow from mice 3 days after a 2 Gy whole body 
X-irradlation dose, was determined as 37(±2)% (±SEM) (n=11). in 
washed, regenerating bone marrow, incubated with SA7HD 
ieukaemic marrow conditioned medium, the proportion of HPP-
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CFC^cs^i in S-phase was not significantly changed (P > 0.1) at 
35(±2)% (n=11) [Figure 4S[.
No evidence for the presence of stem cell proliferation inhibitor 
was observed at the concentration of SA7HD Ieukaemic marrow 
conditioned medium assayed. These results also indicate that, at the
concentrations of conditioned medium assayed, there was no 
evidence of a direct-acting leukaemia-associated proliferation 
Inhibitor. Rapidly cycling WPP-Cfcifv reman rapidly cycling in 
the presence of SA7HD leukaemic marrow conditioned medium. No 
evidence of SA7HD leukaemic marrow conditioned medium toxicity 
was observed.
3.8.3 HPP-CFC1L3 [ ccr i Investigation of the inhibitor! stimuiatorstatus
of medium conditioned bv high cell dose-passaged SA8 mveloid
leukaemic marrow.
Procedure:
4 batches of medium conditioned by high cell dose-passaged 
SA8 (SA8 HD) myeloid leukaemic marrow were produced (2.20) and 
assayed against both normal and regenerating bone marrow (2.16 &
2.17).
Results:
3.8.3.1 The ssfmuiatorssatus of medium conditioned bvSASHD
leukaemic marrow.
The proportion of HPP-CFCILf+cSFs m S-phsse in washed normal 
bone marrow was determined as 13(±1)% (±SEM) (n = 12). In
washed normal bone marrow incubated with medium conditioned by 
SA8HD myeloid leukaemic marrow, the proportion of HPP-
Figure 49: HPP-CFCil3+csf-i investigation of the
inhibitor/stimulator content of medium conditioned by high cell
dose-passaged SA7 myeloid leukaemic marrow.
Proportion of HPP-CFC|L3+csf-i 
in S-phase (%) (±SEM) (n=11)
Normal
bone
marrow
(NBM)
Regenerating
bone
marrowd)
(RBM)
Control 12(±1) 37(±2)
+SA7HD conditioned 
medium.(SA7HDcm) 13(±1)<2) 35(±2)3)
(1) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose.
(2) No significant increase (P>0.4).
(3) No significant reduction (P>0.1).
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CFCjLLccsPi «n S-phase was not significantly changed (P>0.1) at
14(±1)% (n=12) [Figure 5C[.
No evidence for the presence of stem ceii proiiferation stimulator 
was observed at the concentration of SA8 HD ieukaemic marrow
conditioned medium assayed.
3.8.3 .2 The inhibittH status oo medium conditioned bv SA8HD
ieukaemic marrow.
The proportion of HPP-CFC,L3lGSF.l in S-phase in washed 
regenerating bone marrow from mice 3 days after a 2 Gy whole body 
X-irradiation dose, was determined as 36(±2)% (±SEM) (n=12). In
washed regenerating bone marrow incubated with medium 
conditioned by SA8 HD ieukaemic marrow, the proportion of HPP- 
CFC,L3l(33F.l in S-phase was not significantly changed (P>0.1) at 
35(±1)% (n = 12) [Figure Sty.
No evidence for the presence of stem ceii proiiferation inhibitor 
was observed at the concentration of SA8 HD ieukaemic marrow 
conditioned medium assayed, nor was there any evidence for a 
direct-acting leukaemia-associated proiiferation inhibitor. Rapidly 
cycling HPP-CFC1L[, CSM, remained rapidly cycling in the presence of 
SA8 HD ieukaemic marrow conditioned medium. No evidence of 
SA8 HD ieukaemic marrow conditioned medium toxicity was 
observed.
Figure 50: HPP-CFCil3+csf-i investigation of the
inhibitor/stimulator content of medium conditioned by high cell
dose-passaged SA8 myeloid leukaemic marrow.
Proportion of H PP-CFCo+csf-i 
in S-phase (%) (±SEM) (n=12)
Normal
bone
marrow
(NBM)
Regenerating
bone
marrowd)
(RBM)
Control 13(±1) 36(±2)
+SA8HD conditioned 
medium.(SA8HDcm) 14(±1)(2) 35(±1)P)
(1 ) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose. 
(2) No significant increase (P>0.1).
(2) No significant reduction (P>0.1).
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3.8.4 HPP-CFF,^, ccr 4 investigation of the inhibitor!  stimulator status
of medium conditioned bv low cell dose passaged SA8 mveloid
leukaemic marrow.
Procedure:
8 batches of medium conditioned by low ceii dose-passaged SA8 
(SA8 LD) myeioid leukaemic marrow were produced (2.20) and 
assayed against both normal and regenerating bone marrow (2.16 & 
2.17).
Results:
3.8.4.1 The stimulator satis co medium connitionnd CvSASLD
leukaemic marrow.
The proportion of HPP-CFCIl3+(^R1 in S-phase in washed normal 
bone marrow was determined as 13(±1)% (±SEM) (n=29). in 
washed normal bone marrow incubated with medium conditioned by 
SA8 LD myeloid leukaemic marrow, the proportion of HPP-CFCIL3+csf 
in S-phase was not significantly changed (P > 0.1) at 12(± 1)% (n=29) 
[Figure 51],
No evidence for the presence of stem ceii proiiferation stimulator 
was observed at the concentration of SA8 LD ieukaemic marrow
conditioned medium assayed.
3.8.4.2 TTh /nnz/jy/tostitats oo meeium connitionne^^bv SS8LD
ieukaemic marrow.
The proportion of HPP-CFC1Ll+l$ll in S-phase in regenerating 
bone marrow from mice 3 days after a 2 Gy whole body X-^adiation
dose, was determined as 35(±1)% (±SEM) (n=29). In washed
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regenerating bone marrow incubated with medium conditioned by 
SA8 LD leukaemic marrow, the proportion of HPP-CFC1L3+GSfM in S- 
phase was not significantly changed (P > 01) at 34( ± 1)% (n=29) 
[Figure 51],
No evidence for the presence of stem ceii proiiferation inhibitor 
was observed at the concentration of SA8 LD ieukaemic marrow 
conditioned medium assayed, nor was there any evidence for a 
direct-acting ieukaemia-associated proiiferation inhibitor. Rapidiy 
cycling HPP-CFC11J3+csf_1 remained rapidiy cycling when incubated 
with SA8LD ieukaemic marrow conditioned medium. No evidence of 
SA8 LD ieukaemic marrow conditioned medium toxicity was 
observed.
3.8.5 An investigation of the 'concentration' and duration of
conditioning of ieukaemic marrow conditioned medium.
The absence of evidence for stem ceii proiiferation stimulator or 
inhibitor, or of a direct-acting ieukaemia-associated proiiferation 
inhibitor in the SA2LP, SA2HP, SA7HD, SA8HD and SA8LD ieukaemic 
marrow conditioned media, was further investigated by increasing 
the concentration of ieukaemic marrow conditioned medium assayed 
and by increasing the period of time over which the medium was 
conditioned by the ieukaemic marrow.
Figure 51 : HPP-CFCils+csf-i investigation of the
inhibitor/stimulator content of medium conditioned by low cell
dose-passaged SA8 myeloid leukaemic marrow.
Proportion of HPP-CFCil3+csf-i 
in S-phase (%) (±SEM) (n=29)
Normal
bone
marrow
(NBM)
Regenerating
bone
marrowd)
(RBM)
Control 13(±1) 35(±1)
+SA8LD conditioned 
medium.(SA8LDcm) 12(±1)2) 35(±1)3)
0) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose.
(2) No significant increase (P>0.1 ). .
(3) No significant reduction (P>0.1), •
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3.8.5.1 An investigation of the ’concentration’ of leukaemic marrow
conditioned medium.
Procedure:
Experiments were performed In which medium conditioned by 
25x106 SA8 HD leukaemic marrow cells/mi was assayed against both 
normal and regenerating bone marrow (2.16 & 2.17).
Result:
No evidence of stem ceil proiiferation stimulator or inhibitor, or of 
a direct-acting ieukaemia-associated proiiferation inhibitor was
observed [Data not shown],
3.8.5.2 An investigation of the duration of conditioning of ieukaemic
marrow conditioned medium.
Procedure:
Experiments were also performed in which medium conditioned 
for 5 hours by SA8 HD Ieukaemic marrow was assayed against both 
normal and regenerating bone marrow (2.16 & 2.17).
Result:
No evidence of stem ceii proiiferation stimulator or inhibitor, or of
a direct-acting Ieukaemia-associated proiiferation Inhibitor was 
observed [Data not shown],
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3-9 Time study of the progression of the SA8LP myeloid
leukaemia.
The apparent absence of stem cell proliferation inhibitor and 
stimulator in medium conditioned by overtly ieukaemic marrow from 
SA2LP, SA2HP, SA7HD, SA8HD and SA8LD myeloid leukaemias was
further investigated by specific reference to the SA8 low ceii dose- 
passaged (SA8LD) myeioid leukaemia.
Over a reproducible period of approximately 21 days, 9-10 week 
old, male, CBA/H mice injected intravenously with 105 SA8LD myeioid 
leukaemic ceils, developed myeioid leukaemia (2.19). To determine 
whether the marked haematopoietic dysfunction associated with the 
development of SA8LD myeioid leukaemia was a direct consequence 
of abnormal stem ceii proiiferation regulation during disease 
progression, a time study of the SA8LD myeioid ieukaemic 
progression was performed. Variations in the levels of
haematopoietic stem ceii proiiferation inhibitor and stimuiator with 
disease progression were investigated and evidence sought for a 
direct-acting ieukaemia-associated proiiferation inhibitor.
Procedure:
4 groups of 6-7,9-10 week old, male, CBA/H mice per group were 
injected intravenously with 105 SA8LD myeioid ieukaemic ceils, 
individual groups of mice were assayed at day 0 (day of injection), 
day 15, day 18 and day 21 (by which time mice were overtly 
ieukaemic). Assay involved a determination of the total body weight 
of each mouse, a determination of the weight of the spleen of each 
mouse and a determination of the femoral marrow ceiiuiarity of each 
mouse. Medium was subsequently conditioned by the combined 
femoral bone marrow of each group (2.20) and inhibitor and 
stimuiator assay performed on the conditioned medium (2.16 & 2.17).
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Results:
3.9.1 The variation in total body weight, femoral cellularitv and spleen
weight with SA8LD myeloid leukaemic progression.
3.9.1.1 The variation of total body weight with SA8LD ieukaemic
progression.
The total body weight of 9-10 week old male CBA/H mice on the 
day of injection (day 0) was determined as 28(±2)g (± SD) (n = 6). By 
day 15, the total body weight was determined as 30(±2)g (n = 6) and 
by day 18, the total body weight was determined as 30(±2)g (n=7). 
By day 21 and overt leukaemia, total body weight was determined as 
32(±2)g (n = 7).
No significant variation in total body weight was observed with 
SA8LD ieukaemic progression [Figures 52 & 52a].
3.9.1.2 The variation in femoral ceiiuiaritv with SA8LD ieukaemic
progression.
Femoral ceiiuiarity of 9-10 week old CBA/H mice on the day of 
injection (day 0) was determined as 14(±2)x106 ceils (±SD) (n = 6).
By day 15 femoral ceiiuiarity was determined as 15(±1)x106 cells 
(n=6) and by day 18, femoral ceiiuiarity was 13(±1)x106 ceils (n=7). 
By day 21 and overt leukaemia, femoral ceiiuiarity was determined as 
15(± 1)x106 ceils (n=7) [Figures 52&52b].
No significant variation in femoral ceiiuiarity was observed with 
SA8LD myeioid ieukaemic progression, although the cellular 
composition of the femoral marrow was significantly changed. in 
normal (day 0) femoral marrow, a predominance of relatively mature
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haematopoietic progenitors was observed (metamyelocytes, 
erythroblasts, lymphocytes and band ceils [Hepburn ef a/,1987]). in 
overtiy ieukaemic SA8LD ieukaemic femoral marrow (day 21), there 
was a predominance of immature blast ceils (increased numbers of
myelocytes, promyelocytes and generalized blast cells [Hepburn et
a/,1987]).
3.9.1.3 The variation in spieen weight with SA8LD ieukaemic
progression.
Spieen weight of 9-10 week old, male, CBA/H mice on the day of
injection (day 0) was determined as 67(±7)mg (±SD) (n = 6). By day 
15 spieen weight was 67(±7)mg (n=6) and by day 18 spieen weight 
was 76(±8)mg (n=7). By day 21 and overt leukaemia, spieen weight 
was 138(±55)mg (n = 7) [Figures 52 & 52c].
A significant increase in spleen weight was observed with disease 
progression. The increase in spleen weight was associated with a 
marked spienomegaiiy, which is the result of a marked Infiltration by 
ieukaemic ceils. The spieen, originally red-brown, becomes pale with 
infiltrated ieukaemic ceils with disease progression. In normal spieen, 
the lymphocyte is the predominant ceii type, in overtiy ieukaemic 
mice the spieen becomes heavily intiltrated with non-lymphocytic, 
leukaemic blast ceils (myelocytes, promyelocytes and generalized 
blast ceils [Hepburn ef a/,1987]).
Figure 52: A time study of total body weight, femoral cellularity and spleen weight 
with SA8 low cell dose-passaged, myeloid leukaemic progression.
Progession of
SA8LD myeloid 
leukaemia.
Total body 
weight (g)
(+SD)
Femur 
cellularity 
(x106 cells) 
(±SD)
Spleen 
weight (mg) 
(±SD)
Control, Day 0 (n=6) 28(±2) 14(±2) 67(±7)
Day 15 (n=6) 30(+2) 15(±1) 67(±7)
Day 18 (n=7) 30(±2) 13(±1) 76(±8)
Day 21, (n=7)
(overt leukaemia)
32(±2) 15(±1) 138(±55)
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Figure 52a: Variation in body weight 
with SA8LD leukaemic progression.
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Figure 52b: Variation in femoral ceiiuiarity
with SA8LD ieukaemic progression.
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Figure 52c: Variation in spleen weight 
with SA8LD leukaemic progression.
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3.9,2 Assay of the stem eel I proliferation inhibitor and stimulator
content of medium conditioned bv femoral marrow after 0,15,18 and
21 days progression of SA8 LP mveioid leukaemia.
3.9.2.1 Abass of of e stem meU prolioeratton stimulatoroovObre of
medium conditioned bv femoral marrow after 0,15.18 and 21 days
progression of SA8LD mveioid leukaemia.
The proportion of HPP-CFC,L3+(c^i=.i in S-phase in washed normal 
bone marrow was determined as 11 (±1)% (±SEM) (n = 8). in washed 
normal bone marrow incubated with medium conditioned by 'day 0' 
SA8 LD femoral marrow the proportion of HPP-CFC^ggp 1 in S-phase 
was not significantly changed (P>0.1) at 12(±1)% (n=2). In washed 
normal bone marrow incubated with medium conditioned by 'day 15’ 
SA8LD femoral marrow the proportion of HPP-CFCll1+CSo. 1 in S-phase 
was not significantly changed (P>0.1) at 12(±1)% (n=2). in washed 
normal bone marrow incubated with medium conditioned by ’day 18’ 
SA8LD femoral marrow the proportion of HPP-CFC1L3+Cyf_| in S-phase 
was not significantly changed (P>0.1) at 11 (±=2)% (n=2). in washed 
normal bone marrow incubated with medium conditioned by ’day 21 ’, 
overtly leukaemic SA8 LD femoral marrow, the proportion of HPP- 
CFCl3icsf-i in S-phase was not significantly changed (P>0.1) at 
11(±1)% (n = 2) [Figures 53&53a].
No evidence for the presence of stem ceii proiiferation stimuiator 
was observed during the progression of the SA8 LD myeloid 
leukaemia.
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3.9.2.2 Assay of the stem cell proliferation inhibitor content of
medium conditioned bv femoral marrow after 0,15.18 and 21 days
progression of SA8 LD mveloid leukaemia.
The proportion of HPP-CFC!(Jl+3Sll in S-phase in washed
regenerating marrow from mice 3 days after a 2 Gy whole body X- 
irradiation dose was determined as 35(±1)% (±SEM) (n = 8). In 
washed regenerating bone marrow incubated with medium 
conditioned by 'day 0' SA8 LD femoral marrow the proportion of HPP- 
CFCIL3+GSF_i in S-phase was significantly reduced (P< 0.025) at 
18(±3)% (n = 2). in washed regenerating bone marrow incubated with 
medium conditioned by ’day 15' SA8 LD femoral marrow the 
proportion of HPP-CFCIL3+GSFm in S-phase was significantly reduced 
(P<0.05) at 24(±4)% (n=2). In washed regenerating bone marrow 
incubated with medium conditioned by 'day 18' SA8 LD femoral 
marrow the proportion of HPP-CFC,ll+<3f.i in S-phase was 
significantly reduced (P<0.05) at 25(±4)% (n = 2). In washed 
regenerating bone marrow incubated with medium conditioned by 
’day 21' SA8 LD femoral marrow the proportion of HPP-CFCiL3+C3F.1 in 
S-phase was not significantly changed (P > 0.1) at 34(±2)% (n=2) 
[Figures 53 & 53b].
Evidence was observed for the presence of the stem cell 
proliferation inhibitor in ’day 0' SA8LD marrow conditioned medium. 
This was not an unexpected finding since ‘day 0’ SA8 LD femoral 
marrow was essentially 'normal bone marrow' and 'normal bone 
marrow conditioned medium' has been demonstrated to be a crude 
source of the stem ceii proiiferation inhibitor {3.6). With SA8LD 
myeioid ieukaemic progression, the levels of proliferation inhibitor 
were observed to reduce. By 'day 21’, overtiy ieukaemic SA8 LD
Figure 53: A time study of the variation of inhibitor and 
stimuiator in medium conditioned by marrow 0,15, 18 and 21 
days after injection of SA8LD myeloid leukaemic cells.
Proportion of HPP-CFCil3+csf-i 
in S-phase (%)(±SEM)(n=2)
Normal
bone
marrow
(NBM)
Regenerating
bone
marrow(t)
(RBM)
Control (n=8) 11(±1) 35(±1 )
+’Day O' 3A8LDcm 12(±1)(2> 18(±2)(3)
+'Day )5' SASLDcm 12(±1)<2) 24(±3)W
+'Day 18' SASLDcm 11(±2)<2) 25(+3)W
4'Day 2)' SASLDcm 11(±1)(2) 34(±1(<s)
("1 Regenerating bone marrow from mice3 days after a 2 Gy whole body X-irradiation dose.
(2) No significant increase (P>0.1).
(3) Significant reduction (P<0.025).
(4) Significant reduction (P<0.05).
(5) No significant reduction (P>0.1).
Figure 53a: The variation in stimulator 
with SA8LD leukaemic progression.
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femoral marrow conditioned medium demonstrated no stem ceii
proliferation inhibitor.
A progressive reduction in the detectable levels of inhibitor with 
disease progression, may explain the absence of inhibitor m the
overtly leukaemic SA2 LP, SA2HP, SA7HD, SA8 HD and SA8 LD marrow 
conditioned medium (3.8). No evidence of a direct-acting Ieukaemia- 
associated proliferation inhibitor was observed during SA8 LD 
myeioid leukaemic progression and no evidence of SA8 LD marrow 
conditioned medium toxicity was observed.
3.10 An investigation of the effects of medium cor^<^ii^ii^i^<^<j
by SA8HD leukaemic marrow on stimulator and inhibitor
action.
The absence of demonstrable stem cell proliferation regulators in 
medium conditioned by overtly ieukaemic SA2LP, SA2HP, SA7HD, 
SA8 HD and SA8 LD, may be due to an inactivation of the stem cell 
proliferation stimulator and /n/r/Mor. The stem cell proliferation 
regulators may be produced, but their action may be blocked by the 
developing leukaemia. The action of medium conditioned by SA8 HD 
ieukaemic marrow, at the level of both stimulator and inhibitor action 
was investigated.
Procedure:
Medium, conditioned by regenerating bone marrow from mice 7
days after a subiethal whole body X-irradiation dose of 4.5 Gy, as a
crude source of stimuiator {2A5) and medium conditioned by normal 
bone marrow, a crude source of inhibitor (2.14), were assayed for
stimulator and /nd/d/for activity (2.16 & 2.17) in the absence and
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presence of medium conditioned for 3 hours by SA8 HD leukaemic
marrow and diluted so as to be derived from 15x1(6 cells/mi (2.22). 
Results:
3.10.1 The effects of medium conditioned bv SA8 HD ieukaemic
marrow on sf/mu/ator action.
The proportion of HPP-CFC!L3+csm in S-phase in washed normal 
marrow was determined as 10(±1)% (±SEM) (n = 6). In washed 
normal bone marrow incubated with medium conditioned by 
regenerating bone marrow from mice 7 days after a 4.5 Gy whole 
body X-irradiation dose, as a crude source of stimulator (2.15), the 
proportion of HPP-CFC^+gg^ in S-phase was significantly increased 
(P< 0.0005) at 25(±2)% (n = 6). in washed normal bone marrow 
incubated with medium conditioned by regenerating bone marrow in 
the presence of medium conditioned by SA8 HD leukaemic marrow 
cells, the proportion of HPP-CFC^cs^ in S-phase was significantly 
increased (P < 0.0005) at 23(±3)% (n=4) [Figure 54 & 54a].
The presence of medium conditioned by SA8 HD leukaemic 
marrow conditioned medium did not appear to impair the ability of 
stimulator to increase the proportion of HPP-CFC^csf in S-phase.
3.10.2 The effects of medium conditioned bv SA8 HD ieukaemic
marrow on inhibitor action.
The proportion of HPP-CFC^csm in S-phase in washed 
regenerating bone marrow from mice 3 days after a 2 Gy whole body 
X-irradiatlon dose, was determined as 31(±1)% (±SEM) (n = 2). in 
washed regenerating marrow, incubated with medium conditioned by 
normal bone marrow, as a crude source of inhibitor (2.14), the
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proportion of HPP-CFCIU4.GSfM in S-phase was significantly reduced 
(P<0.05) at 24(±3)% (n=2). in washed regenerating bone marrow
incubated with medium conditioned by normal bone marrow in the 
presence of SA8 HD leukaemic marrow, the proportion of HPP- 
CF^Cl34CSpi in S-phase was significantly reduced (P<0.05) at 
26( ± 1)% (n=2) [Figure S4 & 54b].
The presence of the SA8 HD leukaemic marrow conditioned 
medium, did not appear to impair the ability of the inhibitor to reduce 
the proportion of HPP-CFCIL3+Cgp4 in S-phase.
3.11 An investigation of the effects of. medium conditioned
by SA8HD leukaemic marrow on stimulator and inhibitor
production.
The absence of detectable stem cell proliferation inhibitor and 
stimuiator in medium conditioned by SA2LP, SA2HP, SA7HD, SA8HD 
and SA8 LD leukaemic marrow, was further investigated to determine 
whether the leukaemic marrow conditioned medium was capable of 
inhibiting the production of the stem ceil proliferation regulators. A 
mechanism similar to that previously discussed (1.14), where 
inhibitor is capable of preventing stimulator production and similarly 
stimulator is capable of preventing inhibitor production, may exist.
3.11.1 The effects of medium cancdttoned by SA8HD leukaemic
marrow on sf/mu/ator production bv regenerating bone marrow.
Procedure:
Regenerating femoral marrow was produced from mice 7 days 
after a 4.5 Gy whole body X-irradiation dose. Ceils were washed once 
and resuspended in either fresh medium or medium conditioned for 3
Figure 54: An investigation of the effects of medium conditioned 
by SA8HD leukaemic marrow on stimulator and /nfr/TMor action.
Proportion of HPP-CFCiL3+csF-i 
in S-phase (%) (±SEM)
Normal
bone
marrow
(NBM)(n=6)
Regenerating
bone
marrow(i)
(RBM)(n=2)
Control 10(±1) 31(±1)
+RBMcm(2) (Stimulator) 25(±2)5) —
+RBMcm+SA8HDcm(3) 23(±1)<5) —
+NBMomW (Inhibitor) — 24(±2)6)
+NBMcm+SA8HDcm — 26(±1)6)
0) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose.
(2) Regenerating tx>ne marrow conditioned medium from mice 7 days after a 4.5 Gy whole 
body X-irradiation dose.
(3) Medium conditioned by SA8HD leukaemic marrow.
W Medium conditioned by normal bone marrow.
(5) Significant increase (P<0.0005).
(G) Significant reduction (P<0.05).
Figure 54a: The effect of SA8HD leukaemic
marrow conditioned medium on
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Figure 54b: The effect of SA8HD leukaemic 
marrow conditioned medium on
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hours by 15x106 SA8 HD leukaemic marrow cells/ml. The regenerating 
marrow was subsequently incubated for 4 hours in the presence of 
fresh or SA8 HD leukaemic marrow conditioned medium, to allow 
stimulator synthesis. 3 batches of regenerating bone marrow
conditioned medium and regenerating bone marrow conditioned 
medium conditioned in the presence of SA8 HD ieukaemic marrow 
conditioned medium, were produced and assayed for stimulator 
content (2.17).
Results:
In washed normal bone marrow the proportion of HPP- 
CFC!L66csf-i in S-phase was determined as 15(±1)% (±SEM) (n = 11). 
In washed normal bone marrow, incubated in the presence of 
regenerating bone marrow conditioned medium, the proportion of 
HPP-CFCIL3+6pp6 in S-phase was significantly increased (P< 0.0005) 
at 24(±1)% (n = 11). In washed normal bone marrow incubated with 
regenerating bone marrow conditioned medium, conditioned in the 
presence of SA8 HD leukaemic marrow conditioned medium, the 
proportion of HPP-CFC^in S-phase was not significantly 
changed (P>0.1) at 14(±2)% (n = 11) [Figure 55&55a].
The presence of SA8 HD leukaemic marrow conditioned medium 
appears to impair the production of the stem cell proliferation 
stimuiator by regenerating bone marrow.
3.11.2 The effects of medium conditioned by SASHP. I eukaemlc
marrow on the production of inhibitor by normal bone marrow.
Procedure:
Normal bone marrow cells were washed and resuspended in 
either fresh medium or in medium conditioned for 3 hours by 15x106
SA8 HD ieukaemic marrow cells/ml. The normal bone marrow was
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subsequently incubated for 6 hours In the presence of fresh medium, 
or medium conditioned by SA8 HD leukaemic marrow, to allow
//7h/Mor synthesis. 3 batches of normal bone marrow conditioned
medium and normal bone marrow conditioned medium conditioned 
in the presence of SA8 HD leukaemic marrow conditioned medium,
were produced and assayed for inhibitor (2A6).
Results:
In washed regenerating bone marrow, from mice 3 days after a 2 
Gy whole body X-irradiation dose, the proportion of HPP-CFCIL3+gSM 
in S-phase was determined as 37(±1)% (±SEM) (n=12). In washed 
regenerating bone marrow Incubated In the presence of normal bone 
marrow conditioned medium, the proportion of HPP-CFCIL3lCSM in S- 
phase was significantly reduced (P< 0.0005) at 26(±1)% (n = 12). In 
washed regenerating bone marrow incubated with normal bone 
marrow conditioned medium, conditioned in the presence of SA8 HD 
ieukaemic marrow conditioned medium, the proportion of HPP- 
CFC1L33cSf-i in S-phase was not significantly changed (P>0.1) at 
38(±1)% (n = 12) [Figure 55 & 55b}.
The presence of SA8 HD leukaemic marrow conditioned medium 
appears to impair the production of the stem cell proliferation 
inhibitor by normal bone marrow.
This finding may explain the absence of detectable levels of stem 
ceil proliferation regulators in the SA2LP, SA2HP, SA7HD, SA8 HD and 
SA8 LD leukaemic marrow conditioned medium. An inhibition of stem 
cell proliferation regulator production may explain the apparent 
inability of the normal haematopoietic tissue to respond to the 
deterioration in the quality of the peripheral blood which Is 
associated with leukaemic progression, and may also explain the 
leukamia-associated suppression of normal haematopoiesis, allowing 
the leukaemic cells to develop a proliferative advantage.
Figure 55: An investigation of the effects of medium conditioned 
by SA8HD leukaemic marrow on stimulator and inhibitor
production.
Proportion of HPP-CFC|L3+csf-i 
in S-phase (%) (±SEM)
Normal
bone
marrow
(NBM)(n=11)
Regenerating
bone
marrow(i)
(RBM)(n=12)
Control 15(±1 ) 37{±1 )
+RBMcm(2) (Stimulator) 24(±1)(7) —
+[RBMcm+SA8HDcm<3) ]W 14(±1)(8) —
+NBMcm3) (Inhibitor) — 26(±1)9)
+[NBMcm+SA8HDcm]6) — 38(±1(<1°)
0) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose.
(2) Regenerating bone marrow conditioned medium from mice 7 days after a 4.5 Gy whole 
body X-irradiation dose.
(3) Medium conditioned by SA8HD leukaemic marrow.
(4) Regenerating bone marrow conditioned medium, conditioned in the presence of 
SA8HD leukaemic marrow conditioned medium
(5) Medium conditioned by normal bone marrow.
(®) Normal bone marrow conditioned medium conditioned in the presence of SA8HD 
leukaemic marrow conditioned medium.
(7) Significant increase (P<0.0005).
(G No significant increase (P>0.1).
(9) Significant reduction (P<0.0005).
(10) No significant reduction (P>0.1).
Figure 55a: The effect of SA8HD leukaemic 
marrow conditioned medium on
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Figure 55b: The effect of SA8HD leukaemic 
marrow conditioned medium on
Section 4
An investigation of 
the possible mechanism 
of action of the low molecular 
weight, haemoregulatory 
peptide Acetyl-N-Ser-Asp-Lys-Pro 
(AcSDKP).
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3,12 An Snvessiqatgon of the pos^s^it^lee mechanism of action
of the low molecular weight, haemoregulatory peptide
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) using the minimal
active amino acid sequence Ser-Asp-Lys (SDK),
The low molecular weight haemoregulatory tetrapeptide Acetyl-N-
Ser-Asp-Lys-Pro (AcSDKP, Mr=487amu)(1.20) is reported to reduce 
the haemotoxicity of S-phase-specIfic cytotoxic agents by preventing 
the 'recruitment' of haematopoietic stem cells into S-phase. The 
mechanism of action of the tetrapeptide AcSDKP was Investigated 
using the in vitro HPP-CFCrL^gpr assay and the minimal active 
amino acid sequence Ser-Asp-Lys (SDK, Mr=348amu). (AcSDKP was 
not initially available to this laboratory).
Procedure:
Preliminary experiments were performed to determine the
Inherent Inhibitory, or stimulatory characteristics of the
haemoregulatory peptide.
3.12.1 .. An ii nnvcS^gatgon ot the direcC effecCs ot trr.ii^€^r^ti<i^€? £sg^ni^s;s
the in vitro GM-CFC population.
The proportion of GM-CFC in S-phase in normal washed bone
marrow was determined as 34(±2)% (±SEM) (n = 16) (2.25). In 
normal washed bone marrow incubated for 3 hours In the presence 
of SDK, the proportion of GM-CFC In S-phase was not significantly 
changed (P>0.1) at 31(±8)% (n = 16). (SDK was added at t=0,1 and 
2 hours to a final concentration of 1 ng/ml, 2.87x1 O_9M) [Figure 56].
At 1 ng/ml, 2.87x1. O'9M, the tripeptide SDK does not demonstrate 
inherent inhibitory or stimulatory activity against the haematopoietic
Figure 56: An investigation of the direct inhibitory or stimulatory 
effects of tripeptide Ser-Asp-Lys (SDK) on the proportion of 
GM-CFC in S-phase.
Proportion of GM-CFC in 
S-pnase.(%)(±SEM)(n=16)
Normal bone marrow (NBM) 34(±2)
NBM + SDK 
(1 ng/ml, 2.87x10-9M)
31 (+2)0) .
C) No significant change (P>0.1).
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progenitor GM-CFC population. No evidence of SDK toxicity was 
observed.
3.12.2 An investigation of the direct effects of tripeptlde SDK against
the in vitro HPP-CFCtL3, population.
3.12.2.1 An investigation oif the direct stimulatory effects of triipeptide
SDK against the in vitro HPP-CFC|Ll , ccr_t population.
The proportion of HPP-CFC^+Qgpt in S-phase in normal bone 
marrow was determined as 12(±1)% (±SEM) (n = 19). In normal 
bone marrow incubated for 3 hours in the presence of SDK (2.25), the 
proportion of HPP-CFC^+lsll in S-phase was not significantly 
changed (P>0.1) at 12(±1)% (n=19). (SDK was added att=0,1 and 
2 hours to a final concentration of 1 ng/mi, 2.87x1 O'LM) [Figure 57\.
At 1 ng/ml, 2.87x1 fO-M', the tripeptlde SDK does not demonstrate 
inherent stimulatory activity against the HPP-CFCILl+GSsl population. 
No evidence of SDK toxicity was observed.
3.12.2.2 An Investigation of the direct inhlbitorv effects of tripeptlde
SDK against the in vitro 
HPP-CFCl^cp population.
The proportion of HPP-CFClc+cscl in S-phase in washed 
regenerating marrow from mice 3 days after a 2 Gy whole body X- 
irradiation dose, was determined as 33(±1)% (±SEM) (n = 6). In 
washed regenerating marrow incubated for 3 hours in the presence 
of SDK, the proportion of HPP-CFC,c+Csli in S-phase was not 
significantly changed (P>0.1) at 32(±2)% (n = 6). (SDK was added at
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t=0,1 and 2 hours to a final concentration of 1 ng/ml, 2.87x1 O‘9M) 
[Figure 57].
At 1 ng/ml, 2.87x1 O'9M, the tripeptide SDK does not demonstrate 
inherent inhibitory activity for the haematopoietic precursor HPP-
CFC^+csp- population. No evidence of SDK toxicity was observed.
3.13 An investigation of the effects of tripeptide SDK on
stem cell proliferation inhibitor and stimulator action.
3.13.1 Investigating the effects of SDK on sf/mu/afror action.
The proportion of HPP-CFC^+Qgp^ in S-phase in washed normal 
bone marrow was determined as 14(±1)% (±SEM) (n = 11). In 
washed normal bone marrow incubated with medium conditioned by 
regenerating bone marrow from mice 7 days after a 4.5 Gy whole 
body X-lrradiation dose, the proportion of HPP-CFC,L3+CSf-_1 in S- 
phase was significantly increased (P < 0.0005) at 28( ± 1)% (n = 11). In 
washed normal bone marrow, incubated with medium conditioned by 
regenerating bone marrow and in the presence of SDK (2.26), the 
proportion of HPP-CFC^+gp^ In S-phase was not significantly 
changed (P>0.1) at 13(±1)% (n = 11). (SDK was added att = 0 and at 
each subsequent hour of incubation, to a final concentration of 1 
ng/ml, 2.87x1 O"9M) [Figure 58 & 58a]
The presence of SDK at 1 ng/ml, 2.87x10"9M, appears to impair 
the capacity of stimuiator, derived from regenerating bone marrow 
conditioned medium, to increase the proportion of HPP-CFC^ggp.9 
in S-phase. No evidence of SDK toxicity was observed.
Figure 57: An investigation of the direct inhibitory or stimulatory
effects of tripeptide Ser-Asp-Lys (SDK) on the proportion of
HPP-CFCii_3+csf-i in S-phase.
Proportion of HPP-CFCil3+csf-i 
in S-phase (%)(±SEM)
Normal
bone
marrow
(NBM)
(n=19)
Regenerating
bone
marrowO)
(RBM)
(n=6)
Control 12(±1) 33(+1) .
+ SDK
(1 ng/ml, 2.87x10-9M)
12(±1)(2) 32(±2)(2)
(1) Regenerating bone marrow from mice 3 days after a 2 Gy whole body X-irradiation 
dose.
(2) No significant change (P>0.1).
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3.13.2 Investigating the effects of SDK on /n/y/dfor action.
The proportion of HPP-CFCILLt<cs-t in S-phase in washed
regenerating bone marrow from mice 3 days after a 2 Gy whole body 
X-irradiation dose was determined as 37(±3)% (± SEM) (n = 7). In 
washed regenerating marrow Incubated with medium conditioned by 
normal bone marrow, as a crude source of inhibitor, the proportion of 
WP-FCC^cf in S-phase was significantly reduced (P< 0.005) at 
23(±2)% (n = 7). In washed regenerating bone marrow incubated with 
medium conditioned by normal bone marrow and in the presence of 
SDK (2.26), the proportion of HPP-CCCm+cssc in S-phase was not 
significantly changed (P>0.1) at 36(±3)% (n = 7). (SDK was added at 
t=0 and at each subsequent hour of incubation, to a final 
concentration of 1 ng/ml, 2.87x1 O'LM) [Figure 58 & 58b]
The presence of SDK at 1 ng/ml, 2.87x1 O'-M, appears to impair 
the capacity of inhibitor, derived from normal bone marrow 
conditioned medium, to reduce the proportion of HPP-CFC|Ll+Clsl in 
S-phase. No evidence of SDK toxicity was observed.
3.14 An investiicati^on of the effect of SDK on stem cell
proliferation inhibitor and stimulator production.
3.14.1 The effect of SDK on stimulator production bv regenerating
bone marrow.
Procedure:
Regenerating femoral marrow was produced from mice 7 days 
after a whole body X-irradiation dose of 4.5 Gy. Washed regenerating 
marrow was resuspended in serum-free medium and split into 2 
samples. To one a volume of SDK was added sufficient to produce a
Figure 58: An investigation of the effects of tripeptide 
Ser-Asp-Lys (SDK)on stimulator and inhibitor action,
Proportion of HPP-CFCil3±csf-i 
in S-phase (%) (±SEM)
Normal
bone
marrow
(NBM)
(n=11)
Regenerating
bone
marrow(i)
(RBM)
(n=7)
Control 14(±1) 37{±3)
+RBMcm2) (Stimulator) 28(±1)<5) -——
+RBMcm+DKK3) 13(±1)6) —
+NBMcm4) (Inhibitor) — 23(±1)W
±NBMcm±DDK@) — 36(±1 )(8)
(1 ) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose.
(2) Regenerating bone marrow conditioned medium from mice 7 days after a 4.5 Gy whole
body X-irradiation dose.
(2) SDK p resent at 1 ncyml, 2 .87x10'9M
(4) Medium conditioned by normal bone marrow.
(®) Significant increase (P<9.9995).
(®) No significant increase (P>9.1).
(7) Significant reduction (P<9.995).
(8) No significant reduction (P>9.1).
Figure 58a: The effects of tripeptide
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Figure 58b: The effects of tripeptide
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final concentration of 1 ng/mi, 2.87x1 O'-LM, to the other an equivalent 
volume of serum-free medium was added. The regenerating marrow 
was subsequently incubated for 5 hours to allow sf/mtZ/?forsynthesis 
(2.27). (SDK was added at t=0 and at each hour of subsequent 
incubation to a final concentration of 1 ng/ml, 2.87x10'LM). 2 batches 
of regenerating bone marrow conditioned medium and regenerating 
bone marrow conditioned medium conditioned in the presence of 
SDK, were produced and assayed to determine their stimulator 
content (2.17).
Results:
In washed normal bone marrow the proportion of HPP- 
CFF^L3Lctt-r in S-phase was determined as 16(±1)% (±SEM) (n = 5).
In washed normal bone marrow incubated with medium conditioned 
by regenerating bone marrow, a crude source of stimulator, the 
proportion of HPP-CFCIl3+Cls_l in S-phase was significantly increased 
(P< 0.005) at 28(±2)% (n=5). In washed normal bone marrow, 
Incubated with medium conditioned by regenerating bone marrow 
conditioned in the presence of SDK, the proportion of HPP- 
CFC1L3LCtt.r in S-phase was significantly increased (P<0.05) at 
22( ± 4)% (n = 5) [Figure 59 & 59a].
While the presence of SDK at 1 ng/ml, 2.87x1 O'LM, does appear to 
impair the capacity of regenerating bone marrow to synthesize 
stimulator, these results should be considered in view of the findings 
of (3.13.1) where SDK was reported to impair the action of stimulator. 
The apparent impairment of stimulator synthesis by SDK may actually 
be due to the presence of residual SDK in the regenerating bone 
marrow conditioned medium during the stimulator assay. If stimulator 
synthesis was unaffected by the presence of SDK, during subsequent 
stimulator assay any residual SDK may act to impair stimulator 
action, giving the impression of an absence of stimulator. Before any
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conclusion as to the effects of DKP on s.fiznu/af<or production by 
regenerating bone marrow can be drawn, removal of residual DKP
from the regenerating bone marrow conditioned medium prior to 
stimulator assay would be necessary. The low molecular weight of
DKP should enable it to be readily removed from the regenerating
bone marrow conditioned medium by dialysis or Amlcon
ultrafiltration.
3.14.2 The effect of SDK on ZnftZb/forpeoduction bv normal bone
marrow.
Procedure:
Normal bone marrow was washed, resuspended in serum-free
medium and split into 2 samples. To one, a volume of DKP sufficient 
to produce a final concentration of 1 ng/ml, 2.87x19® was added, to 
the other, an equal volume of serum-free medium was added. The 
normal bone marrow was subsequently incubated for 7 hours to 
allow inhibitor synthesis, with the addition of DKP at each hour of 
incubation, to a final concentration of 1 ng/ml, 2.87x1 0®, or an 
equivalent volume of serum free medium (2.27). 1 batch of normal 
bone marrow conditioned medium, and normal bone marrow 
conditioned medium conditioned in the presence of DPP, was 
produced.
Results:
In normal regenerating bone marrow, from mice 3 days after a 2 
Gy whole body X-irradiation dose, the proportion of HPP-CFC|L3 CSF1 
in D-phase was determined as 49(±1) (±SEM) (n = 2). In washed
regenerating bone marrow Incubated with normal bone marrow 
conditioned medium, as a crude source of inhibitor, the proportion of 
HPP-CFCIL3lcsf-i in D-phase was significantly reduced (P < 0.95) at
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26(±6)% (n=2). In washed regenerating bone marrow incubated with 
medium conditioned by normal bone marrow in the presence of SDK, 
the proportion of HPP-CFCIL3+csm in S-phase was significantly 
reduced (P < 0.05) at 26(±4)% (n=2) [Figure 59 & 59b].
The presence of SDK at 1 ng/ml, 2.87x109M, does not appear to 
impair the synthesis of inhibitor by normal bone marrow. Concern 
over the presence of residual SDK in the normal bone marrow 
conditioned medium and SDK effects in the subsequent inhibitor 
assay, could be answered by dialysis or Amlcon ultrafiltration of the 
normal bone marrow conditioned medium to remove the low 
molecular weight SDK prior to inhibitor assay (3.13.2).
3.15 A comparative analysis of the tripeptide Ser-Asp-Lys
(SDK) with tetrapeptide Acetyl-Ser-Asp-Lys-Pro
(AcSDKP), and tripeptides Asp-Lvs-Pro (DKP) and
Aia-Asp-Lvs (ADK).
In the first instance our laboratory was only given access to the 
minimal active amino acid sequence of the AcSDKP moiety, the 
tripeptide Ser-Asp-Lys (SDK). Latterly, access was given to the 
tetrapeptide AcSDKP and a number of tripeptide analogues (ADK and 
DKP). A limited number of experiments were performed to compare 
the relative activities of SDK and AcSDKP, ADK and DKP.
3.15.1 investigation of the d ire<a effects of AcSDDP
against the haematopoietic progenitor in vitro GM-CFC popuiation.
The proportion of GM-CFC in S-phase in normal washed bone 
marrow was determined as 28(±1)% (±SEM) (n=2). In normal bone 
marrow incubated for 3 hours in the presence of AcSDKP, the
Figure 59: An investigation of the effects of tripeptide
Ser-Asp-Lys (SDK) on stimulator and /nft/h/tor production.
Proportion of HPP-CFCl3+csf-i 
in S-phase (%) (±SEM)
Normal
bone
marrow
(NBM)
(N=5)
Regenerating
bone
marrow(1)
(RBM)
(n=2)
Control 16(+1) 40(+1)
4RBMcm2) (Stimulator) 28(±^1)6) —
+[RBMcm+SDKl<3) 22(±4)7) —
+NBMcm4) (Inhibitor) — 26(+1)(8)
+[NBMcm+SDK((5> — 26(±4)(8)
(1 ) Regenerating marrow from mice 3 days after a 2 Gy whole body X-irradiation dose.
(2) Regenerating bone marrow conditioned medium from mice 7 days after a 4.5 Gy whole 
body X-irradiation dose.
(3) Regenerating bone marrow conditioned medium, conditioned in the presence of SDK 
at 1 ng/ml, 2.87x10‘Lm
(4) Medium conditioned by normal bone marrow.
(5) Normal bone marrow conditioned medium conditioned in the presence of SDK at
1 ng/ml, 2.87x10'-M.
(®) Significant increase (P<0.005).
m Significant Increase (P<0.05).
(®) Significant reduction (P<0.05).
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proportion of GM-CFC in S-phase was not significantly changed 
(P>0.4) at 28(±4)% (n=2). (AcSDKP was added at t=0,1 and 2 
hours to a final concentration of 1 ng/mi, 2.05x10'9M) {Figure 60\.
At 1 ng/mi, 2.05x1 O‘9M, AcSDKP does not demonstrate either 
inherent inhibitory or stimuiatory activity against the haematopoietic 
progenitor GM-CFC population. No evidence of AcSDKP toxicity was 
observed.
3.15.2 Investigation of the direct stimulatory effects of tetrapepti<de
AcSDKP and tripeptide ADK against the haematopoietic precursor
HPP-CFC|L99cSp1, population.
The proportion of HPP-CFClL3+Cs^1 in S-phase in washed normal
bone marrow was determined as 12(±1)% (±SEM) (n = 15). in 
normal bone marrow incubated for 3 hours in the presence of 
AcSDKP, or ADK, the proportion of HPP-CFCIL99CSF9 in S-phase was 
not significantly changed at 13(±1)% (P>0.1) (n = 15) and 11 (±1)% 
(P>0.1) (n=13), repectively. (AcSDKP and ADK were added at t=0,1 
and 2 hours to a final concentration of 1 ng/mi or 2.05x1 O‘LM and 
3.01x10"9M respectively.) {Figure 61].
At 1 ng/ml neither the tetrapeptide AcSDKP, or the tripeptide ADK 
demonstrated inherent stimuiatory activity for the haematopoietic 
precursor HPP-CFC|L3+csM population. No evidence of AcSDKP or 
ADK toxicity was observed.
3,16 Investigation of the effects of AcSDKP, ADK and DKP
on sf/maf action.
The proportion of HPP-CFC1L9+Cgip1 in S-phase in washed normal 
bone marrow was determined as 8(±1)% (±SEM) (n = 7). In washed
Figure 60: An investigation of the direct inhibitory or stimulatory
effects of tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) on 
the proportion of GM-CFC in S-phase.
Proportion of GM-CFC 
in S-phase (%){±SEM)(n=2)
Normal bone marrow (NBM) 28(±1)
NBM + AcSDKP 28(±4)0)
(1 ng/ml, 2.05x10‘9M)
0) No significant change (P>0.4)
NBM NBM+AcSDKP
Figure 61 : An investigation of the direct stimulatory effects of
tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) and
tripeptide Ala-Asp-Lys (ADK) on the proportion of HPP-
CFCIL3+CSF-1 in S-phase.
Proportion of HPP-CFCh_3+csf-i 
in S-phase (%)(±SEM)
Normal bone marrow (NBM) 
(n=15)
12(±1)
NBM + AcSDKP 
(1 ng/ml, 2.05x10‘9M)
(n=15)
13(±1)1)
NBM + ADK 
(1 ng/ml, 3.01x10’9M)
(n=13)
11(±1)0)
(") No significant change (P>0.1).
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normal bone marrow incubated with medium conditioned by 
regenerating bone marrow from mice 7 days after a 4.5 Gy whole 
body X-irradiation dose, as a crude source of stimulator, the 
proportion of HPP-CFCIL3+CSM in S-phase was significantly increased 
(P< 0.0005) at 28(±2)% (n=7). In washed normal bone marrow 
incubated with medium conditioned by regenerating bone marrow 
and In the presence of AcSDKP, the proportion of HPP-CFCIL3 ’n
S-phase was not signlficanty changed (P>0.1) at 10(±2)% (n = 7). In 
washed normal bone marrow incubated with medium conditioned by 
regenerating bone marrow and in the presence of DKP, the 
proportion of HPP-CFCIL3+c^R1 in S-phase was not significantly 
changed (P>0.05) at 16(±1)% (n=3).in washed normal bone marrow 
incubated with medium conditioned by regenerating bone marrow 
and in the presence of ADK, the proportion of HPP-CFCjig+cgp! in S- 
phase was significantly increased (P< 0.025) at 22(±8)% (n=4). 
(AcSDKP,DKP and ADK were added att=0 and at each hour of 
subsequent assay, to a final concentration of 1 ng/ml, 2.05x10"3m, 
2.79x10'3m and 3.01x10‘9M respectively.) [Figure 52].
The presence of both AcSDKP and DKP at 1 ng/ml appeared to 
impair the capacity of stimulator, derived from regenerating bone 
marrow conditioned medium, to increase the proportion of HPP- 
CFC^icsp-i in S-phase. The presence of ADK at 1 ng/ml, however, 
gives a less clear result and may imply that the tripeptlde ADK is a 
less efficient stimuiator-blocklng moiety than SDK, AcSDKP or DKP. 
No evidence of AcSDKP, DKP or ADK toxicity was observed.
Figure 62: An investigation of the effects of tetrapeptide 
AcSDKP and tripeptides DKP and ADK on stimulator action
Proportion of HPP-CFCh_3+csf-i 
in S-phase (%)(±SEM)
Normal bone marrow (NBM).
Control (n=7) 8(±1)
+ RBMom t(Stimulator)
(n=7)
28(±2)2)
Stimulator + AcSDKP (n=7)
(1 ng/ml, 2.05x10'9M)
10(±2)3)
Stimulator + DKP (n=3)
(1 ng/ml, 2.79x1 O-°fM)
16(±1)W
Stimulator + ADK (n=4)
(1 ng/ml, 3.01 x1 0'9M)
22(±8)5)
n) Medium conditioned by marrow 7 days after a 4.5 Gy whole body X-irradiation dose.
(2) Significant increase (P<0.0005).
(3) No significant change (P>0.1).
(4) No significant change (p>0.05).
(5) Significant increase (P<0.025)
Chapter 4:
Discussion.
Section 1
The characterization of the
in vitro HPP-CFCils+csf-i
assay.
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4,1.1 Characterization of haematopoietic colony-stimulating factor
synergism.
In the presence of interleukin 3 (IL3)/muiti-CSF, macrophage 
coiony-stlmuiating factor (M-CSF/CSF-1), or granuiocyte- 
macrophage coiony-stimuiating factor (GM-CSF), coiony-forming 
ceiis of limited proiiferative potential were sfimuiated. In the presence 
of combined haematopoietic coiony-stimuiating factors, the 
proliferation of a morphologically distinct colony-forming ceil 
popuiation, characterized by a high proiiferative potential, was 
stimulated, The stimulation of the high proiiferative potential colony­
forming ceil (HPP-CFC) popuiation, is a demonstration of 
haematopoietic coiony-stimuiating factor synergism. A synergistic 
interaction may be broadly described as one in which the end 
product of combining two (or more) components, proves significantly 
different to the sum of each of the component parts acting singly, 
Combinations of interleukin 3 (lL3)/multi-CSF and M-CSF/CSF-1, GM- 
CSF and M-CSF/CSF-1, and interleukin 3 (IL3)/multi-CSF were 
demonstrated to synergize to stimulate the proliferation of distinct 
HPP-CFC populations, The relationship between these distinct HPP- 
CFC subpopuiations is, as yet, unclear, The capacity of well defined, 
recombinantiy-derived haematopoietic colony-stimulating factors to 
synergisticaiiy interact with each other and to replace the synergistic 
activities in the appropriate ceil line conditioned media, is strong 
evidence to suggest that the interleukin 3 (IL3)/muiti-CSF, M- 
CSF/CSF-1 and GM-CSF are the synergizing activities in the WEHl 3B, 
L929 and AF1-19T ceil line conditioned media, although these results 
do not exclude the possible contribution of factors contained in the 
ill-defined horse serum (20% v/v) also present during in vitro HPP- 
CFC assay, In the absence of horse serum no colony formation was
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observed, even in the presence of colony-stimulating factors; while
horse serum aione failed to demonstrate coiony-stimuiating activity. 
Putative factors present in the horse serum may not be ;coiony- 
stimuiating activities, rather they may be colony-potentiating/ 
initiating factors, enhancing coiony-stimuiating factor synergism by a 
possible stimulation of coiony-stimuiating factor receptor expression 
by factor-sensitive colony-forming ceiis.
4.1.2 Possible mechanism of synergism between haematopoietic
coionv-stimuiatinq factors.
The capacity of ’sub-optimal’ concentrations of haematopoietic
coiony-stimuiating factors to synergize and stimulate the proliferation 
of high proiiferative potential colony-forming ceil populations, may 
suggest a possible mechanism for the synergistic interaction. The in 
vitro GM-CFC assay, is effectively a measure of the colony-forming 
cell proliferation induced by a coiony-stimuiating activity. The finding 
that ’sub-optimal’ concentrations of haematopoietic coiony- 
stimuiating factors, as determined by the GM-CFC assay, were 
effective in synergistic interactions, implies that the factors may be 
acting not as proliferation ’stimuli', rather, they may be acting as 
proliferation ’inttiatosg. A model can be proposed in which M- 
CSF/CSF-1 effectively acts to promote the proliferation of interleukin 
3 (iL3)/multi-CSF-, or GM-CSF- ’initiated’ coiony-forming ceiis, which 
are subsequently capable of the high proiiferative potential. The 
putative coiony-forming ceil ’initiation’ by interleukin 3 (iL3)/multi- 
CSF, or GM-CSF may involve the stimulation of the expression of ceil 
surface receptors for the more lineage-specific haematopoietic 
coiony-stimuiating factors, for example M-CSF/CSF-1. HPP-CFC 
populations sensitive to interleukin 3 (IL3)/multi-CSF, or GM-CSF
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initiation, may subsequently develop increased M-CSF/CSF-1 
receptors and, in the presence of M-CSF/CSF-1 undergo the marked 
proliferation characteristic of the HPP-CFC population.
During the assay of murine marrow in the presence of interleukin 
3 (IL3)/multi-CSF alone, colonies in excess of 1mm, but less than 
2mm, were occasionally observed after 14 days of culture. These 
relatively high proliferative potential colony-forming cells may be 
interleukin 3 (IL3)/multi-CSF initiated coiony-forming cells which, in 
the absence of M-CSF/CSF-1, do not subsequently receive as strong 
a proliferation stimulus from the interleukin 3 (lL3)/muiti-CSF and do 
not realise their full proiiferative potential. The presence of the 
interleukin 3 (IL3)/muiti-CSF may induce increased M-CSF/CSF-1 
receptor expression, however, in the absence of M-CSF/CSF-1, 
subsequent proliferation is limited to that stimulated by the 
interleukin 3 (IL3)/multi-CSF aione.
4.1.3 The absence to ’small in the in vitro HPP-CFC assay.
When appropriate haematopoietic coiony-stimulating factors
were combined in vitro, in addition to stimulating the proliferation of 
the high proiiferative potential coiony-forming ceil population, a 
consistent finding was the absence of a population of relatively small 
colonies, which were evident in the presence of M-CSF/CSF-1 aione. 
McNiece ef a/[1988b] suggest that the presence of the second 
synergizing factor as either interleukin 3 (iL3)/muiti-CSF, or GM-CSF, 
may act on the small coiony-forming ceil popuiation to stimulate 
granulocytic rather than macrophagic differentiation. Granulocytic 
colonies are less ’stable' than macrophagic colonies in 14 day semi- 
soiid agar culture and degenerate to be absent at subsequent assay. 
in the presence of M-CSF/CSF-1 aione, 'stable’ macrophagic colonies
152
would develop to be observed as the small colony population at 
assay, Alternatively, the developing HPP-CFC popuiation may 
elaborate factors which act to suppress the development of the small
colony background,
4,1,4 The optimal time of assay of the in vitro HPP-CFC[?ccr 1 
population,
The optimal time of assay of the ^P-CFCgg+ggpe popuiation was 
investigated, At assay, sufficient cellular proliferation was required to 
allow a distinction to be made between the HPP-CFC^ecsp/derived 
colonies and the non-HPP-CFCIL3 LQ^-^drived colonies, Whiie 
differences in colony morphologies were evident at as early as day 7­
8 of culture when comparing WEHl 3B, L929 and combined cell line 
conditioned media as stimuli, a 12-15 day assay period was 
considered to best emphasize the HPP-CFClL3+CSp1/non-HPP- 
CFC^LcsFi"3erive3 colony distinction, Assay at day 14 of culture was 
determined as the standard time of HPP-CFClllcspl assay,
A number of other groups report a similar 12-15 day assay period 
when Investigating a number of high proiiferative potential coiony- 
forming cell populations stimulated by a variety of combinations of 
haematopoietic coiony-stimuiating factors [Bradley & Hodgson,1979; 
Kriegier ef a/,1982; 1990; Bradley ef a/,1985; McNiece ef a/,1986; 
1987a; 1987b; 1988a; 1988b; 1989a; 1989b; Quesenberry ef a/,1987; 
Williams ef a/,1987; Faik& Vogei,1988; Barteimez ef a/,1989; Niskanen 
ef a/,1990; Bot ef a/,1990], Pragneli ef a/[1988], Eckmann ef a/ [1988] 
and Lorimore et ai [1990], report the assay of the HPP-CFC 
popuiation stimulated by the combination of GM-CSF and M- 
CSF/CSF-1 (HPP-CFCqmcsplcsf-1 "CFU-A") on day 11 of culture,
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4.1.5 A criterion bv which to define the HPP-CFC|L3, c SF1 population.
The development of a criterion by which to define the HPP- 
CFCiL3 +(qf1-derived coionies at assay, was of considerable 
importance. The unique aspect of the HPP-CFC-derived coionies is 
their relatively large size in comparison to non-HPP-CFC-derived 
colonies in in vitro semi-solid agar culture. A size criterion was thus 
used to distinguish between HPP-CFC and non-HPP-CFC-derived 
coionies. HPP-CFClL34.CSM-derived colony diameter was effected by 
the number of marrow cells plated. During the titration of the cell 
dose required to achieve ’optimal’ numbers of HPP-CFC|L3+C3F.1, it 
was observed that while low ceil numbers gave few HPP-CFC1L3lCsf-i‘ 
derived colonies, those which did form were occasionally observed 
to exceed 5mm in diameter. With increasing ceil numbers, the 
diameters of the HPP-CFCuLL-cgp-rd'eNved coionies was observed to 
reduce. This observation may be a consequence of limiting in vitro 
culture conditions, alternatively the HPP-CFC population may 
elaborate factors which, in the absence of physical overlapping of 
coionies, serve to restrict cellular proliferation, in a similar manner to 
that suggested for the inhibition of small colony formation.
A cell dose of 2.5x104/5.0x104 normal marrow cells per 
30mm/50mm petri dish was found to give ’countable’ HPP 
-CFC^ lcsf-1 numbers (10-15/20-30). At this cell dose a direct 
comparison was made between the sizes of the coionies observed 
after 14 days in the presence of WEHI 3B, L929 or a combination of 
the cell line conditioned media, in the presence of the factors acting 
singly, coionies rarely exceeded a 1.0-1.5mm diameter, and never 
exceeded a 2.0mm diameter. A 2mm diameter criterion was thus set 
to preferentially select the HPP-CFCjLgL.QgF.fderived colonies, which 
generally exceeded a 2.0-3.0mm diameter. Pragnell et al [1988],
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Eckmann ef a/[1988], Falk and Vogel [1988] and Lorlmore ef a/[1990] 
apply a 2mm diameter criterion in the characterization of the HPP- 
cfcgm-csf+csf-i “CFU-A'—derlved colonies.
in contrast to the 2mm diameter criterion, set as the definition of 
an HPP-CFCIL3+csf-i - and HPP-CFCg^Qg^ "CFU-A" - derived 
colony [Pragneli ef a/,1988; Eckmann ef a/,1988; Falk & Vogel,1988; 
Lorlmore ef a/,1990], a number of laboratories apply a 0.5mm 
diameter as the criterion for the definition of an HPP-CFC derived 
colony. Coionies of less than 0.5mm diameter are considered derived 
from colony-forming ceils of a low proliferative potential (LPP-CFC) 
[Bradley & Hodgson,1979; Kriegier ef a/,1982; Bradley ef a/,1985, 
McNIece ef a/,1986; 1987; 1988a; 1988b; 1989; Williams ef a/,1987; 
Bertonceiio ef a/,1989; Barteimez ef a/,1989; NIskanen ef a/, 1990; 
Morris ef a/,1990]. However, the application of a 0.5mm diameter 
criterion as a definition of an HPP-CFC-derived colony would not 
have been appropriate in this instance. Such a criterion would not 
have been effective in distinguishing between HPP-CFC1L3+CS_1ZGM. 
csf+csf-i and non-HPPCSCCi^ccsf-i/gmcsf+csf-i derived coionies. Non 
HPP-CFCIL3+c^£^F-1/GM'CSF+cs^F., dorivod coionies, stimulated in the 
presence of interleukin 3 (lL3)/muiti-CSF, M-CSF/CSF-1 or GM-CSF 
alone, were often observed to exceed a 0.5mm diameter and 
occasionally reached a 1.0-1.5mm diameter.
Significantly, confidence in the 2mm diameter criterion in 
distinguishing between HPP-CFC|(|+CfM and non-HPR-CFC,^+<3^ 
derived colonies was justified when the effects of incubating normal 
murine femoral marrow with the S-phase-specific cytotoxic agent 
cytosine arabinoside (ARA-C) were investigated. Colony-forming 
ceils in S-phase during incubation with ARA-C are killed and their 
colony-forming potential is not realised in subsequent colony­
forming cell assays. The proportion of colony-forming cells in 8-
155
phase is determined by the difference in the coiony numbers 
obtained in the absence and presence of ARA-C treatment, The 
number of colonies in excess of 2mm diameter in normal murine 
marrow was only slightly reduced in the presence of ARA-C, implying 
that the proportion of the colony-forming cells giving rise to these 
2mm diameter colonies in S-phase is relatively low, The number of 
’sub-2mm’ diameter coionies was markedly reduced by the presence 
of ARA-C, implying the proportion of colony-forming cells giving rise 
to these ’sub-2mm’ diameter colonies in S-phase is relatively high, 
The difference in the proliferative potential and proportion of colony­
forming ceils in S-phase implies that the ’sub-2mm’ and ’in excess of 
2mm’ diameter colonies are derived from distinct populations of 
colony-forming ceils, and that the 2mm criterion is able to distinguish 
between HPP-CFC and non-HPR-CFC-derived colonies,
4,1,6 The cellular composition oo the HPP-CFClL0+CSF1-derived 
coionies,
The use of 0,9% methyiceiluiose as a semi-solid support medium, 
allowed the cellular composition and celiuiarity of individual HPP- 
CFClL3+CsF_., -derived colonies to be investigated, The majority of HPP- 
CFC|L3-csF1-derived colonies were composed of large, mature 
macrophages, characterized by a heavily vacuolated cytoplasm, This 
would be consistent with the presence of M-CSF/CSF-1,
Occasionally, in association with the large mature macrophages, a 
population of relatively immature, haematopoietic progenitors and a 
population of mature cells characterized by a pale-staining nucleus 
and a cytoplasm containing abundant, uniform granules, were 
observed, In some cases, all three ceil types were observed within an 
individual HPP-CFClF+^F.1•rteiVved coiony, individual HPP-
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CFClL3+GSM-derived colonies are the product of the proliferation of an 
individual HPP«CFCi44+CFF4 and the presence of at least two 
morphologically distinct mature cell populations and a relatively 
immature ceil population, implies that the HPPsCFF|L3+CsF.i 
population is at least bipotential.
Pragneli efa/[1988], Eckmann efa/[1988] and Lorlmore eta! 
[1990], report the finding of at least four morphologically distinct 
blood cell lineages in day 11 HPP-CFCGIVFC3F+CSp1 "CFU-A"-derlved 
coionies. Macrophages, granulocytes, early erythroid ceils, 
megakarocytes and cells with a ’biast-iike morphology’ are reported. 
These ’mixed’ colonies, which demonstrate the muitipotency of the 
HPP-CFCGM_CSL+3SF_1 "CFU-^" population, were only demonstrable 
under defined culture conditions: a 37°C, fully humidified, 10% COg, 
5% Og, 85% Ng atmosphere. Pragnell efa/11988], Eckmann eta! 
[1988] and Lorlmore ef a/ [1990], report that the use of a 37°C, fully 
humidified, 5% CO4 in air atmosphere proved less effective at 
demonstrating the formation of ’mixed’ colonies. A 37°C, fully 
humidified, 5% COl in air atmosphere was used throughout this 
project in the culture of 14 day HPPsFFF|L3+CSF_1 and if these culture 
conditions are limiting, this does not rule out the possible multlpotent 
nature of the HIPP-CFC^^- population.
An average 14 day HPP-FFCaL+(LpL^<derived colony, in excess of 
2mm in diameter, was determined to have a celiularity of 
6.0(±0.4xx104 ceils. By comparison, colonies obtained after 14 days 
culture in the presence of either L929 ceil line or WEHi 3B cell line 
conditioned medium, were composed of an average of 0.8x104 and 
1.4x104 cells respectively.
Pragneli ef a/[1988], Eckmann ef a/[1988], Falk and Vogel [1988] 
and McNiece ef a/[1988b], report similar cellularities for individual 
HPP-CFCgm_C3F..C3pl OCFU-Ao-^derived coionies, while Bradley and
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Hodgson [1979], Kriegier ef a/ [1982] and McNiece ef a/ [1988b]
report similar cellularities for individual M-CgF/CGF-t-derived 
coionies.
4.1.7 The fto the HPP-CFC|L3+CGF1 population.
At assay the average HPP-CFC,^+Csp.i frequency in normal 9-12 
week old CBA/H mice was determined as 100(±1)1105 normal marrow 
ceils. In a normal CBA/H femur of 14(±1)xFp6 marrow ceils, a total 
femoral compliment of 14x103 HPP-CCCuacaa would be predicted. 
Approximately 1 in every 1000 femoral marrow ceils will be a potential 
WP-CTC,,^.
in comparison, Pragneli ef a/ [1988] report the average HPP- 
CFCGaassFa-ssF-i "CFU-A" frequency in NIHOia, BD26F1 and BALB/c 
mice to be 197(±22), 145(±16) and 180(±14) per105 normal marrow 
ceils respectively. By combining a range of typical values quoted by a 
number of laboratories for a wide range of mouse strains [Boggs ef 
a/,1982], an average in vivo CFU-Sday frequency of approximately
10-40 per 10i marrow ceils is reported. A seeding factor of 
approximately 8% [Playfair & Coie,1965] gives the absolute number 
of CFC-S per 105 normal marrow cells as 125-500 and a total femoral 
compliment of approximately 1(-a CFC-S. The frequency of the in vitro 
HPP-CFC[L3 icsf^ population in femoral marrow compares favourably 
with the frequency of the in vitro HPP-CCCGM.ssFa-csF-i "CFU-A" and in 
vivo CFU-Sday8.1Q populations.
In femoral marrow from 9-12 week old CBA/H mice, 3 days after a 
sublethai whole body X-irradiation dose of 2 Gy, the average HPP- 
CFC,^+qsm frequency was determined as 29(±1)1105 regenerating 
marrow ceils and femoral celiuiarity was significantly reduced to 
6(± ixx106 ceils, giving a total femoral HPP-CFC^acspa compliment
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of approximately 2x103. Approximately 1 in every 3000 regenerating 
marrow cells will be a potential HPP-CFC|L3+csf1.
An 85% reduction in the femoral complement of HPP-CFC|L34.csf1 
was observed 3 days after a whole body X-irradiation dose of 2Gy. 
interestingly, Hendry and Lajtha [1977] report an 80% reduction in the 
femoral marrow complement of CFU-S after a 1.5 Gy whole body X- 
irradiation dose.
4.1.8 In vitro HIPi^-<^IF<C seH-renewai and relationship with the In vivo
CFU-S population.
While providing a continuous and varying cellular output to meet 
the haematoiogicai requirements of the body, haematopoietic stem 
ceils must, of necessity, be capable of maintaining their own 
numbers. This implies the existance of a stem ceil self-renewal 
capacity. Siminovitch ef a/[1963] demonstrated that individual CFU- 
S-derived colonies contained a number of CFU-S giving evidence of 
CFU-S self-renewal. By replating individual HPP-CFCgm_csl+csf-i "CFU- 
A'-derived coionies, Pragneli ef a/ [1988] and Eckmann ef a/[1988], 
report evidence of HPP-CFCgm_csf+csfl "CFU-A" self-renewal. 
However, attempts to demonstrate a self-renewal capacity for the 
HPP-CFC|L3 lCSF_l population in this laboratory proved inconclusive. 
Replating individual day 7 HPP-CFCjLLccs-r-teNved coionies, cultured 
in 0.9% methyiceiluiose, gave rise to only sub-2mm, non-HPP- 
(LFC^LcL^ccS^L-e^rii/ed colonies. While this does not apparently 
represent evidence of HPP-CFC^ccss-i self-renewal, it does not rule 
out the possibility that the HPP-CFC1LlcCSs.i population is giving rise 
to other HPP-CFC subpopuiations for which the combination of 
interleukin 3 (ILSymulti-CSF and M-CSF/CSF-1 is not an optimal 
stimulus. This would correlate with the findings of McNiece et at
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[1987b], who report the replating of individual HPP-CFCsf 1+CSF^- 
derived colonies ("SF-1" - 'Synergistic Factor-1’) gives rise to a more 
mature HPP-CFC subpopulation (HPP-CFC-2), which is optimally 
stimulated by the presence of interleukin 3 (iL3)/multi-CSF and M- 
CSF/CSF-1 (HPP-CFC^+csm)- 11 W be that the sub-2mm colonies 
observed on the repiating of individual HPP4CFC1L3+GSf-1 may be a 
more mature HPP-CFC subpopuiation (HPP^CFC-3), for which the 
combination of other haematopoietic colony-stimulating factors is 
required to allow optimal proliferation. Alternatively, in day 7 HPP- 
CFCIL3iccsF-denved coionies, any in vitro HPP-CFC1L3+csf-l generated 
by the self-renewal mechanism, may have undergone maturation and 
differentiation with a resultant reduction in the high proliferative 
potential of the colony-forming ceil population, producing colonies of 
less than 2mm in diameter. Further experiments would be required to 
determine the optimal time at which to best illustrate HPP-CFC|L3+GSf 1 
self-renewal within individual HPP-CFC,L3+(cp-iLderived colonies.
in conclusion, the in vivo CFU-S and in vitro HPP-CFC 
populations demonstrate a high proliferative potential and 
multipotentiai character. in this respect they fulfill a number of the 
criteria expected of a component of the heterogenous 
haematopoietic stem ceil compartment. McNiece ef a/ [1987b] and 
Pragneli ef a/[1988], further demonstrated the relationship between 
the in vivo CFU-S and the in vitro HPP-CFC-1 (HPP-CFCfll +Ccf. J and 
HPP-CFCgm_csf+csf_i '’CFU-A” populations, respectively. The injection 
of a suspension of pooled ceils of day 4 HPP-CFC-1-derived colonies 
into lethaiiy X-irradiated recipient mice (approximately 200 
cells/mouse), lead to the development of day 13 CFU-S (0-6 
colonies/spieen), while the injection of a suspension of day 5 HPP- 
cfcgmcsf+csf-i "CFU-A"-derived coionies into lethaiiy X-irradiated 
mice, lead to the development of day 12 CFU-S (approximately 6, day
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12 CFU-S/ day 5 HPP-CFCgmgpggsffg "CFU-A"-derived colony). 
Further evidence of the ciose correlation between the in vivo CFU-S 
and in virro WP-CCCFC.^and "CFU-A“
populations is observed when the idnetics of the in vivo and in vitro 
populations are compared.
Section 2
An investigation of the 
proliferation and 
proliferation regulation 
of the in vitro 
HPP'CFC|L3+CS.F'i 
population.
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4.2.1 , The, proportion of the in vitro Hf^i^"-^IFF^,+CSM
population in S-phase.
The proportion of the HPP-CFCIL3+CsFo pulsation in S-phase in 
normal and subiethaiiy X-irradiated femoral marrow was determined 
using the S-phase specific cytotoxic agent cytosine arabinoside 
(ARA-C) (1.17). The proportion of the HPi-CFC^ccs-i population in 
S-phase in normal femoral marrow was determined as 9(±1)%, while 
the proportion of the GM-CFC population in S-phase was determined 
as 31 (±1)%.
Pragneli ef a/[1988], Eckmann ef a/[1988] and Lorlmore eta! 
[1990], report the proportion of the HPP-CFCgm.csf+csf-i "CFU<A" 
population in S-phase as approximately 8% and the proportion of the 
GM<CFC population in S-phase as approximately 30% in normal 
femoral marrow.
The proportion of the HPP-CFC|L3+Gll_s population in S-phase In 
S-phase in regenerating marrow from mice 3 days after a 2 Gy whole 
body X-irradiation dose, was determined as 40(±1)%. The proportion 
of the GM<CFC population in S-phase in the regenerating marrow was 
not significantly changed at approximately 30%.
Pragneli efe/[1988], Eckmann efu/[1988] and Lorlmore etal 
[1990], used a regimen of subcutaneously-injected phenylhydrazine 
hydrochloride to induce haemoiytic anaemia and produce a 
haematopoieticaiiy-stressed marrow. The proportion of the HPP- 
FFCcm.csf+csm "CFU-A" population In S<phase In the
haematopoieticaiiy-stressed marrow was determined as
approximately 28%.
it is significant that the in vitro HPP-CFF:1^+i^l^s- 1 and in vitro HPP- 
FLLLgm<csF+csf-i "CFU-A" populations show similar kinetic changes in 
normal and huematopoietlcally-stressed marrow, changes not
162
observed with the in vitro GM-CFC population. Of greater significance 
is the fact that the kinetic changes observed for the in vitro HPP- 
CFC1L3+CSf.i and HPP-C^^g^,^sf+CSm "CFU-A1* populations mirror 
those observed for the in vivo CFU-S population. The proportion of 
the in vivo CFU-S population in S-phase in normal femoral marrow is 
reported as approximately 10% [Becker ef a/,1965], increasing to 40­
50% in S-phase in regenerating marrow from mice subjected to 
sublethai whole body X-irradiation [Guzman & Lajtha,1970] and 30­
50% in S-phase in marrow from mice subjected to phenylhydrazine 
hydrochloride treatment [Rencrlcca ef a/,1970] [Figure 63].
The favourable comparison of the kinetic changes observed in 
the normal and haematopoieticaiiy-stressed marrow, for both the in 
vitro HPP-CFC and in vivo CFU-S populations, together with evidence 
of a similar high proliferative potential and muitipotency, is further 
evidence of the relatively primitive nature of the in vitro HPP-CFC 
subpopuiations within the haematopoietic system.
4.2.2 ^r i^-ensitivitvt(3 the stem ceii pFQilferation
regulators.
The proportion of the HPP-CFC|L3+csM population in S-phase in 
regenerating bone marrow from mice 3 days after a 2 Gy whole body 
X-irradiation dose was determined as 40(±1)%. When incubated with 
medium conditioned by normal bone marrow, in which the proportion 
of stem celis in S-phase is relatively low, the proportion of the HPP- 
CFCO lcsf-v population in S-phase was significantly reduced from 
40(±1)% to 25(±1)% [Figure 64}.
Similarly, the proportion of the HPP-CFC,ll+CSf_ l population in S- 
phase in normal marrow was determined as 9(±1)%. When incubated 
with medium conditioned by marrow From mice 7 days after a 4.5 Gy
Figure 63: A comparison of the proportion of the in vitro HPP-CFC|L3+csf-i. 
in vitro HPP-CFCqm-csf+csf-1 "CFU-A" and in vivo CFU-S populations in S-phase in normal 
and haematopoietically-stressed marrow.
Colony-forming cell population.
Proportion of colony-forming cells in S-phase (+SEM)
Normal Bone Marrow Regenerating Bone Marrow
In vitro HPP-CFC|i_3+cSF-i 9(±1)% (n=255) 40(+1)% (n=177) Hl
in vitro HPP-CFCGm-csf+csf-i "CFU-A’ Pl ~8% -28% Pl
In vivo CFU-S -10% w 30-50% n &3-5l
- Approximately.
M Marrow from mice subjected to sublethal whole body X-irradiation. 
[2] Pragnell et a/[1988] and Eckmann et a/[1988].
Pl Marrow from mice pretreated with phenylhydrazine hydrochloride. 
I43 Becker et al [1965].
Pl Guzman and Lajtha [1970] and Rencricca et a/[1970].
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whole body X-irradiation dose, in which the proportion of the 
haematopoietic stem ceii popuiation in S-phase is reiativeiy high, the 
proportion of the HPP-FFF1l-+CfFo pupalation in S-phase was 
significantly Increased from 9(± 1)% to 24(+1)% [Figure 64].
The in vitro HPP-CFCIL3+CpFo puputation demonstrates a 
sensitivity to both the normal bone marrow-derived stem cell 
proliferation inhibitor and the regenerating bone marrow-derived 
proliferation stimulator. Significantiy, the changes in the proportion of 
the HPP-FFFlp3+CSF.1 population in S-phase under the influence of 
appropriate stimuli, mirror those observed for the in vivo FFU-S 
popuiation, and in common with the in vivo FFU-S population, no 
evidence of either stem ceii proliferation inhibitor or stimulator 
toxicity was observed against the HPP-CFCIL3+csf_ 1 popuiation.
Pragneli etal[1988], Eckmann efa/[1988] and Lorimore etal 
[1990], report a similar HPP-FFFccfc+cfl "CFU-A"-sensItIvity to the 
stem ceii proliferation regulators, in haematopoieticaiiy-stressed 
marrow from mice subjected to phenylhydrazine hydrochloride- 
treatment, the proportion of the HPP-FFF(ckccF+<ccF "FFU-A" 
popuiation in S-phase was determined as approximately 28%. When 
incubated with a source of the stem ceii proliferation inhibitor, the 
proportion of the HPP-FFFGc_CSFcgspl "FFU-A" popuiation in S-phase 
was reduced from approximately 28% to approximately 11%.
Similarly, the proportion of the HPP-F^F^F^sjcc^il+cc^f-l "FFU-A" 
popuiation in S-phase in normal bone marrow was determined as 
approximately 8%. When incubated with a source of stem cell 
proliferation stimulator, the proportion of the HPP-FFCgm.cfF+cffc 
"FFU-A11 popuiation in S-phase was increased from approximately 8% 
to approximately 49% [Figure 64[.
The demonstration of both in vitro HPP-FFC|c+CcF- c and in vitro 
HPF>-3FFiC(^^_csf+cslc "FFU-Au-sensitivity to the in vivo FFU-S-
Figure 64: A comparison of the proportion of the in vitro HPP-CFC|L3+csf-i , 
in vitro HPP-CFCqm-CSF+CSF-1 "CFU-A” and in vivo CFU-S populations in S-phase in the 
absence and presence of the stem cell proliferation regulators..
Colony-forming cell population.
Proportion of colony-forming cells in S-phase (±SEM)
Regenerating 
Bone Marrow DI
RBM +
inhibitor l2J
Normal
Bone Marrow
NBM+
StimulatorM
In vitro HPP-CFC1L3+CSF-1 40(+1)%
(n=177)
25(±1)%
(n=127)
9(±1)%
(n=255)
24(±1)%
(n=107)
In vitro HPP-CFCgm-CSF+CSF-1 
"CFU-A" HI
-28% -11% ~8% -49%
In vivo CFU-S Pl 30-50% -10% -10% 30-40%
~ Approximately.
DI Haematopoieticaiiy-stressed marrow.
t2l Medium conditioned by normal bone marrow.
I3i Medium conditioned by haematopoieticaiiy-stressed marrow.
(41 Pragnell etal [1988] and Eckmann et a/[1988] and Lorimore etal [1990].
Becker eta/[1965], Guzman and Lajtha [1970] and Rencricca etal[1970].
164
characterized proliferation regulators, in addition to the evidence of a 
high proliferative potential, multipotency and kinetic changes similar 
to those observed for the in vivo CFU-S population, is further 
evidence for the in vitro HPP-CFC^, cSM nnd HPP^-(^I^CGM.CSF+ca^^1 
‘"CFU-A" populations being relatively primitive haematopoietic 
precursors, possibly components of the stem cell compartment 
within the haematopoietic system.
4.2.3 The relative sensitivity of the in vitro HHP-CFC,c,CSF 1 population 
to the stem cell proliferation regulators.
Tejero et al [1984], Wright et ai [1985] and Lorlmore et ai [1990], 
demonstrate an 'age-related' variation in the sensitivity of the various 
components of the haematopoietic stem cell population to the stem 
cell proliferation inhibitorand stimuiator(1A7). Day 10-12 CFU-S, 
believed to be a more primitive component of the haematopoietic 
stem cell compartment, demonstrate a significantly increased 
sensitivity to the stem ceii proliferation inhibitor, in comparison, day 
7-8 CFU-S, believed to be a more mature component of the 
haematopoietic stem cell compartment, demonstrate a significantly 
increased sensitivity to the stem cell proliferation stimulator [Figure 
13\.
The sensitivity of the in vitro HPP-CFCILs+csf„1 population to the 
stem cell proliferation regulators was investigated in an attempt to 
determine the relative position of the population within the stem cell 
compartment. Assay of the stem ceii proliferation regulators against 
the in vitro HPP-CCC^poi pupata^^, demonstrated that both 
normal and regenerating bone marrow-derived inhibitor and 
stimulator, are titratable activities. increasing the 'concentration’ of 
the medium conditioned by the normal, or regenerating marrow,
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resulted in an appropriate reduction, or increase, to a
minimum/maximum plateau value, of the proportion of the in vitro 
HPP-FFFIL3l.l£s_1 population in S-phase. Similar observations are 
reported by Wright efar/[1982] and Lord and Wright [1982], when 
assaying similarly-derived proliferation inhibitor and stimuiator 
against the in vivo FFU-S population.
A number of groups report the use of lyophilized Amicon 
ultrafiltered fractions of normal and regenerating marrow extracts, as 
sources of NBME-IV(stem cell proliferation inhibitor) and RBME-iii 
(stem cell proliferation stimuiator), and the use of increasing weights 
of lyophilized material similarly demonstrates that both factors are 
titratable activities against the in vivo FFU-S population [Lord et 
a/,1981; Wright & Lord,1979; Wright ef a/,1980a; Fork ef a/,1981; 
Tejero ef a/,1984; Wright ef a/,1985; Wright and Lorimore,1987; 
Lorlmore ef a/,1990].
in addition to the demonstration that both inhibitor and stimuiator 
are titratable activities, it is significant that the in vitro HPP- 
FFF„cccsf-i population demonstrates an approximately equal 
sensitivity to the stem cell proliferation regulators. in comparison to 
the day 10-12 FFU-S popuiation, which proves more sensitive to the 
stem cell proliferation inhibitor, and the day 7-8 CFU-S population, 
which proves more sensitive to stimulator, a cell population which 
demonstrates an equal sensitivity to each factor should theoretically 
prove to be more mature than the day 10-12 CFU-S population, and 
more primitive than the day 7-8 CFU-S population. in this manner, an 
approximate position for the in vitro HPP-CFCILcccsF.i population 
within the already established in vivo CFU-S hierarchy within the 
haematopoietic stem cell population, can be proposed [Figure 55].
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Figure 65: A diagramatic 
representation of the 
variation in inhibitor and 
stimulator sensitivity 
with haematopoietic stem 
maturation.
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Lorimore et a/[1990], report a direct comparison between 
inhibitor and stimulator sensitivities of day 12 CFU-S, day 7 CFU-S 
and in vitro HPP-CFCgg.gFG+csf-i "CFU-A" population. Using 
lyophilized Amicon uitratiltered NBME-lVand RBME-iii, as sources ot 
stem ceii proliferation inhibitor anb stimuiator, a significant difference 
in the HPP-CFCGg.gsfgcsf-i "CFU-A" sensitivity to the stem cell 
proliferation regulators was reported. The HPP-CFCGgglfggsfg "FFU- 
A" population demonstrated a markedly increased sensitivity to 
inhibitor and a reduced sensitivity to the stem cell proliferation 
stimuiator. This pattern of stem ceil proliferation regulator sensitivity 
proved similar to that of the day 12 CFU-S population, believed to be 
a more primitive component of the haematopoietic stem cell 
compartment, rather than the day 7 CFU-S population and implies 
that the in vitro HPP-CFCgggsfgcsfg "CFU-A" population is a relatively 
primitive haematopoietic precursor within the haematopoietic stem 
cell hierarchy.
The age-related variation in the relative sensitivity of the 
haematopoietic stem ceii popuiation to inhibitor and stimuiator, may 
subsequently allow the positions of the various in vitro HPP-CFC 
populations within the haematopoietic stem cell hierarchy, to be 
established. Since the HPP-CFC-2 (HPP-CFC1L3+csm) population 
appears to demonstrate an approximately equal sensitivity to 
inhibitor and stimuiator, the more primitive HPP-FFF1 (HPP- 
CF-Lf gcsf^) population might be expected to demonstrate an 
increased /nr&tfor sensitivity, whiie the more mature HPP-CFF-3 
population might be expected to demonstrate an increased 
stimuiator sensitivity.
Section 3
An investigation of 
proliferation 
stimulator and 
inhibitor 
in myeloid 
leukaemia.
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4.3.1 An of cell prollferation
regulators in murine mveioid , leukaemia.
The in vitro HPP-CFCf+cui assay technique was subsequently 
used to investigate the regulation of the haematopoietic stem ceil 
popuiation in the haematopoietic, neoplastic proliferative disorder, 
myeioid ieukaemia. 'Leukaemia1, a term applied to a group of 
maiignant haematopoietic proliferative disorders, is characterized by 
an inappropriate production of white biood cells (1.28). in the case of 
'myeioid ieukaemig? there is an inappropriate production of abnormal 
myeloid precursors. One particuiarly significant aspect of most 
ieukaemias, is an apparent leukaemia-associated suppression of 
normal haematopoiesis. As a result, with disease progression, the 
'quality' of the peripheral blood deteriorates and anaemia, 
haemorrhage and infection are common secondary symptoms. The 
apparent suppression of normai haematopoiesis by the leukaemia 
allows the leukaemic population to deveiop a proiiferative advantage 
over the normai haematopoietic tissue. The possible mechanism(s) 
by which the leukaemias may suppress normal haematopoiesis were 
investigated using a number of X-irradiation-induced, murine myeloid 
ieukaemias [Hepburn ef a/,1987] and the in vitro HPP-CFC,c+Ccc 
assay.
initial investigations were performed to determine the levels of 
the stem ceil proliferation inhibitor and stimuiator in media 
conditioned by overtly leukaemic marrow samples (2.20). Media 
conditioned by overtly leukaemic marrow was assayed against 
normal marrow, to investigate the presence of the stem ceil 
proliferation stimuiator, and regenerating marrow to investigate the 
presence of the stem cell proliferation inhibitor OR the presence of a 
direct-acting ieukaemia-associated proliferation inhibitor. No
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evidence of the presence of the haematopoietic stem ceil 
proliferation stimulatorwas detected in media conditioned by the 
murine myeloid leukaemias. The proportion of the HPP-CFCIL3+csri 
population in S-phase in normal marrow was not increased by 
incubation with the leukaemic marrow conditioned media. Similarly, 
no evidence of the presence of the haematopoietic stem ceii 
proliferation inhibitor, or of any direct-acting leukaemia-associated 
proliferation inhibitor, was detected in the media conditioned by the 
murine myeloid ieukaemias. The proportion of the HPP-CFC^+CSF1 
popuiation in S-phase in regenerating marrow was not reduced by 
incubation with leukaemic marrow conditioned media. The absence 
of stem ceii proliferation stimuiator and inhibitor, or of any direct- 
acting ieukaemia-associated proliferation inhibitor, was not 
apparently a consequence of either the concentration of the 
leukaemic marrow conditioned medium, or the length of time used in 
the conditioning of the medium.
A time study of leukaemic progression was performed to 
investigate the variation in the levels of the haematopoietic stem ceii 
proliferation regulators with disease progression.
No evidence of the stem ceii proliferation stimuiator was 
observed during the progression of the murine myeloid leukaemia, 
however, significant changes in the levels of detectable stem ceii 
proliferation inhibitorwere observed with disease progression.
A possible explanation of such a finding may be to relate the 
levels of the stem cell proliferation inhibitorio the way in which the 
cellular composition of the femoral marrow changes with disease 
progression. In normai murine femoral marrow, there is a 
predominance of relatively mature haematopoietic progenitors: 
metamyelocytes, erythrobiasts, lymphocytes and band cells 
[Hepburn ef a/,1987]. In overtly leukaemic SA8LD marrow, there is a
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predominance of relatively immature haematopoietic progenitors: 
myelocytes, promyelocytes and generalized blast ceils [Hepburn et
a/,1987]. The change in cellular composition of the marrow may also 
include the cell population responsible for tpe production of the stem 
cell proliferation inhibitor. The inhibitor-producing cell population 
may become ’diluted' as the marrow becomes more leukaemic, with 
the possible result that the observed 'concentration' of detectable 
inhibitorwould reduce. However, while this dilution effect may play a 
role, subsequent evidence implies that the reduction in the levels of 
the stem cell proliferation inhibitor, may be a direct consequence of 
the leukaemic cell population.
The mechanism(s) by which the levels of detectable proliferation 
inhibitorwere reduced with leukaemic progression was investigated 
to determine whether the reduction was inherently linked to the 
developing leukaemia. Was the leukaemic popuiation reducing the 
levels of detectable inhibitor by either acting to prevent it's action, or 
acting to prevent it's production ? The effects of medium conditioned 
by overtly leukaemic marrow on the action of both the
haematopoietic stem cell proliferation inhibitor and stimuiator was 
investigated by performing assays of normai and regenerating bone 
marrow-derived inhibitor and stimuiator in the absence or presence 
of medium conditioned by overtly leukaemic marrow.
The presence of the medium conditioned by the overtly 
leukaemic marrow, did not significantly impair the capacity of the 
normal bone marrow-derived inhibitorto reduce the proportion of the 
HPP-CFC|1^+CSF_i population in S-phase, or regenerating bone 
marrow-derived stimuiatorto increase the proportion of the HPP- 
CFC|L3+csF.i population in S-phase. These results suggest that the 
reduction in the level of the proliferation /n/i/btfor observed with 
disease progression is not apparently due to a ieukaemia-associated
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inactivation of the haematopoietic stem ceii proliferation regulator. 
Stimulator action is similarly unaffected by the presence of medium 
conditioned by overtly leukaemic marrow.
The effects of medium conditioned by overtly leukaemic marrow 
on the production of the haematopoietic stem ceil proliferation 
regulators was investigated. Normal bone marrow conditioned 
medium was conditioned in the absence, or presence of medium 
conditioned by overtly leukaemic marrow and similarly, medium was 
conditioned by regenerating marrow from mice 7 days after a 4.5 Gy 
whole body X-irradiation dose in the absence or presence of medium 
conditioned by overtly leukaemic marrow.
Proliferation inhibitor, produced from normal bone marrow 
reduced the proportion of the HPP-CFC,cfsm ’n S-phase. Medium 
conditioned by normal bone marrow in the presence of medium 
conditioned by overtly leukaemic marrow, did not reduce the 
proportion of the HPP-CFC,cclcf-l population in S-phase. Similarly, 
proliferation stimuiator, produced from regenerating marrow 
increased the proportion of the HPP-FFC|L3cCst_1 population in S- 
phase. Medium conditioned by regenerating bone marrow in the 
presence of medium conditioned by overtly leukaemic marrow, did 
not increase the proportion of the HPP-CFC|p3ccsf_i population in S- 
phase. The presence of medium conditioned by overtly leukaemic 
marrow appears to significantiy impair the capacity of normal bone 
marrow to produce the stem cell proliferation inhibitor and 
regenerating bone marrow to produce the stem cell proliferation 
stimuiator.
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4,3.2 Possible of murine mveloid Ieukaemic
progression.
These results suggest that the leukaemic popuiation may be able 
to manipulate the levels of endogenous stem cell proliferation 
inhibitor and stimuiator by apparently impairing their production. 
Normally, stem cell proliferation inhibitor and stimuiator subtly 
interact to coordinate the proportion of the haematopoietic stem ceil 
population in S-phase and so tailor haematopoietic output to the 
haematopoietic demands of the body, if the production of the stem 
cell proliferation regulators was impaired, this subtle regulatory 
interaction could not occur and the coordination of haematopoietic 
output to haematopoietic demand would fail. With the additional 
haematopoietic stress induced during leukaemic progression and the 
inappropriate production of abnormal white biood ceils by a 
population of ceils able to proliferate presumably independently of 
inhibitor and sf/mu/gfor regulation, the 'quality' of the peripheral 
blood will deteriorate leading to anaemia, haemorrhagic episodes 
and infection due to the reduced levels of functional erythrocytes, 
platelets and granulocytes and macrophages.
The action of the leukaemic popuiation in apparently blocking the 
production of the stem cell proliferation regulators may be a 
modification of an already existing mechanism. For example, distinct 
inhibitor- and stimulator-producing cell populations exist (1.11) and 
are both present regardless of the proiiferative state of the 
haematopoietic tissue. Only one proliferation regulator is however 
predominant at any one time, which implies a distinct coordinating 
mechanism must exist. Lord and Wright [1982], demonstrated that 
isolated inhibitor-producing cells cease /W/Mtor production in the 
presence of exogenous stimuiator. Similarly, Lord and Wright [1982]
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and Riches and Cork [1987] demonstrated that sf/miz/afor-producing 
cells cease stimulator production in the presence of exogenous 
inhibitor (lzl4), One couid envisage a slight modification ot this 
regulatory mechanism could be exploited to the advantage of the 
leukaemic population. A putative leukaemic factor could be produced 
which mimics the proliferation stimuiator and inhibitor, but which is 
itself inactive. In this way both inhibitor and stimuiator production 
would cease, to give the observed absence of regulators in overtly 
leukaemic marrow. With the characterization of the stem cell 
proliferation regulators and identification of appropriate receptors, It 
may prove possible to perform competitiverbinding studies between 
appropriate factors, factor-producing ceils and the putative 
leukaemic factor, to further investigate the possible mechanism by 
which this apparent, Ieukaemia-associated suppression of the 
proliferation regulators occurs.
Similarly, a modification of the 'stem cell feedback factor' (SCFF) 
could be developed to leukaemic advantage. SCFF Is reported to be 
produced by the haematopoietic stem ceii popuiation and acts to 
maintain stem ceil numbers [Lord,1986] (1.1S). if stem ceii numbers 
are 'sufficient', levels of SCFF inhibit the production of stimuiator by 
stimuiator-produclng cells, if stem cell numbers are reduced, the 
levels of SCFF reduce and the inhibition of stimulator production is 
lifted. Increased stimuiator production acts to increase the proportion 
of haematopoietic stem cells in S-phase and stem cell numbers are 
restored through a self-renewal mechanism. Increased stem ceii 
numbers, increase SCFF production, which inturn increases the 
inhibition of sMator production, enabling the subsequent 
production of the proliferation inhibitor. The production of a 
ieukaemia-associated SCFF-mimic could thus be envisaged to 
modulate the production of the stem cell proliferation regulators.
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While the leukaemic population may inhibit the production of the 
stem cell proliferation regulators, by possibly modifying and 
subsequently exploiting these existing regulatory mechanisms to it's 
advantage, this does not rule out the possibility that the leukaemic 
population may use an, as yet unclear, novel mechanism. Future 
studies might involve attempts to characterize the putative 
leukaemia-associated, proliferation regulator production-inhibiting 
factor, perhaps through Amicon ultrafiltration. If such a factor could 
be isolated, it may be possible to exploit it to clinical advantage. By 
preventing the production of the stem cell proliferation stimulator, 
and so preventing the recruitment of haematopoietic stem cells into 
S-phase, it may be possibie to reduce certain aspects of 
chemotherapeutic haemotoxicity.
In conclusion, if the leukaemia-associated suppression of normal 
haematopoiesis and the subsequent development of a leukaemic 
proliferative advantage over the normal haematopoietic tissue, is in 
part due to a suppression of stimiAator production, would the 
controlled reintroduction of stimulator, as an exogenous factor, assist- 
in the management of leukaemia ? Provided the leukaemic 
population is not itself sensitive to the stem cell proliferation 
stimulator, a controlled reintroduction of the factor may allow 
sufficient ’activation’ of the marrow to allow a partial restoration of the 
’quality’ of the peripheral blood, which would inturn, reduce the 
secondary, often debilitating symptoms of anaemia, haemorrhage 
and infection. The ’activation’ of the normal, suppressed 
haematopoietic tissue may also act to overcome the leukaemic 
proliferative advantage, which may inturn act to Impair the 
progression of the disease and give a better disease prognosis. Such 
disease management may lead to essentially healthier (less anaemic, 
less haemorrhagic and less susceptible to infection) leukaemic
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patients, more able to withstand the subsequent rigors of chemo- and
radiotherapeutic regimes.
Section 4
An investigation of 
the possible mechanism 
of action of the low molecular 
weight, haemoregulatory 
peptide Acetyl-N-Ser-Asp-Lys-Pro 
(AcSDKP).
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4.4.1 . Stability and activity of AcSDKP.
Information about the stabiiity and activity of AcSDKP was initially 
very limited. Caution was advised against the use of serum in 
medium used to dilute and incubate AcSDKP, due to the presence of 
degradatlve enzymes, and while heat inactivated serum (serum 
incubated at 56°C for 30 mins.) proved less degradatlve, AcSDKP 
activity was stili reduced. The use of serum albumin was also 
precluded by adverse binding of the AcSDKP to the molecule 
[Lenfant, personal communication]. After consideration, dilution and 
subsequent incubations involving the peptides were performed under 
serum-free conditions. Manipulation of diluted peptides was kept to a 
minimum and dilutions performed in polypropylene vials (Nunclon) to 
reduce loss of peptides by adhesion to plastic. Stock solutions of 100 
ng/ml of each peptide were produced, aliquoted and frozen (-20°C) 
and individual 100 ng/mi aliquots were not refrozen once thawed. The 
stability and activity of AcSDKP, SDK, ADK and DKP under incubation 
conditions and in the presence of marrow ceils was uncertain, and 
addition of peptides at t=Oand at each subsequent hour of 
incubation was hoped to maintain at least a minimum concentration 
of peptide present should degradation occur. A standard 
concentration of 1 ng/ml (approximately 10®M) was adopted for each 
of the peptides, following reference to reports of Monpezat and 
Frindel [1989] and Lauret ef a/[1989]. Subsequent reports of Guigon 
ef a/[1990] demonstrated maximal AcSDKP activity at a 10"9-10' 10M 
(approximately 1 ng/ml) concentration against a human progenitor 
cell population.
[Recent research performed by Lenfant ef a/,[unpublished], has 
characterized the enzyme present In serum which is responsible for
AcSDKP degradation as "angiotensin converting enzyme!1 (ACE). ACE
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has been previously characterized in the renin-angiotensin system, 
responsible for the regulation of blood pressure. Angiotensinogen, 
an inactive precursor found in the plasma and tissue fluid, is 
converted to angiotensin /, an inactive 10 amino acid peptide, by 
renin. inactive angiotensin I'is converted to an active, 8 amino acid 
peptide, angiotensin it, by the carboxydipeptidase activity of 
angiotensin converting enzyme (ACE), which is widely distributed in 
tissue. ACE aiso apparently acts to degrade the active AcSDKP 
peptide by enzymatic cleavage, and the behaviour and regulation of 
ACE in normal and aberrant haematopoiesis is currently under 
investigation by Lenfant ef a/in collaboration with this laboratory. The 
half-life of AcSDKP in serum has subsequently been reported as 
approximately 80 mins. After 4 hours no AcSDKP activity is 
detectable. in heat inactivated serum, the AcSDKP half-life is reported 
as approximately 20 hours [Lenfant & Wdzleczak-Bakala, personal 
communication].]
4.4.2 The direct and indirect haemoregulatory activity of SDK.
The direct, inherent stimulatory or inhibitory activity of SDK was 
investigated against both the in vitro HPP-CFCHL3+csf_1 and the in vitro 
GM-CFC populations. No evidence of inherent stimulatory or 
inhibitory activity against either the in vitro HPP-CFC^tQSf.i or in vitro 
GM-CFC populations was observed. Significantly, no evidence of 
SDK toxicity against either the in vitro HPP-CFC,^+CsF_t or in vitro GM- 
CFC population was observed at 1 ng/ml, 2.87x1 OtM.
The activity of SDK against stimuiator and /n/r/b/for action was 
investigated. The proportion of the HPP-CFC,^+csFt in S-phase in 
normal bone marrow was increased in the presence of medium
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conditioned by regenerating marrow, as a crude source of stimulator. 
However, in the presence of stimulator and SDK at 1 ng/mi, 
2.87x10'9M, no significant increase in the proportion of the HPP- 
CFCnl3+csF-i in S-phase was observed. Similarly, the proportion of the 
HPP-CFC|L3+GSm population in S-phase in regenerating marrow was 
reduced in the presence of medium conditioned by normal marrow, 
as a crude source of inhibitor. However, in the presence of inhibitor 
and SDK at 1 ng/ml, 2.87x1 O~9M, no reduction in the proportion of the 
HPP-CFC1L3+csF9 was observed.
These results imply that SDK at 1 ng/ml, 2.87x1 <O9M is apparently 
effective at blocking the action of the stem ceil proliferation 
regulators, in the presence of SDK, stimuiator aats to increase the 
proportion of the HPP-CFC^^gp in S-phase and /n/tf/Mtorfails to 
reduce the proportion of the HPP-CFC,^^,^ in S-phase.
The activity of SDK against stimulator and inhibitor production 
was investigated. The proportion of the HPP-CFC , ^ ccpi population 
in S-phase was increased in the presence of medium conditioned by 
regenerating marrow. incubated with medium conditioned by 
regenerating bone marrow in the presence of 1 ng/ml, 2.87x1 O'9M 
SDK, the proportion of the HPP-CFC|93+9cs_1 population in S-phase 
was similarly increased. The proportion of the HPP-CFC^ 
population in S-phase was reduced in the presence of medium 
conditioned by normal bone marrow. incubated with medium 
conditioned by normal bone marrow in the presence of 1 ng/mi, 
2.87x10'9M SDK, the proportion of the HPP-CFC,^ .gp population in 
S-phase was similarly reduced. These results imply that SDK at 1 
ng/ml, 2.87x1 0'9M does not act to block the production of the stem 
cell proliferation regulators. in the presence of SDK, regenerating 
bone marrow continues to produce stimulator and normal bone 
marrow continues to produce inhibitor.
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4.4.3 The direct and Indirect haemoregulatory activity of AcSDKP.
A limited number of experiments were performed with the parent 
molecule AcSDKP. No evidence of an Inherent stimulatory activity for 
the in vitro HPP-CFCIL3+csf_|, or of an inherent stimulatory, or 
Inhibitory activity for the in vitro GM-CFC population was observed 
For AcSDKP at 1 ng/ml, 2.05x109M over a 3 hour period. In addition, 
no evidence of AcSDKP toxicity against either the in vitro HPP- 
CFCIL3+gsm, or in vitro GM-CFC was observed.
The effect oF AcSDKP on the action of t^e stem cell proliferation 
stimuiatorwas also investigated. The proportion of the HPP- 
CFC^cs-i in S-phase was increased on incubation with medium 
conditioned by regenerating marrow as a crude source of stimulator. 
In the presence of stimuiator and AcSDKP at 1 ng/ml, 2.05x1 O~9M, the 
proportion of the HPP-CFC|mpi in S-phase was not increased, 
implying that, in common with the Findings of SDK, AcSDKP appears 
to block the action of the stem cell proliferation stimulator.
4.4.4 The direct and indirect haemoreaulatorv activity of DKP and
ADK.
A limited number of further experiments were performed using 
the tripeptide analogues DKP and ADK. The proportion of the HPP- 
cfcil3+csf-i population in S-phase was not increased by the presence 
of 1 ng/ml, 3.01x10'9M ADK for 3 hours and no evidence of ADK 
toxicity against the HPP-CFCtL3+GSpi population at 1 ng/ml, 3.01x10'9M 
was observed.
The effects of both ADK and DKP on the action of the stem cell 
proliferation stimuiatorwere investigated. The proportion of the HPP- 
CFCl3lcspi in S-phase was increased in the presence of medium
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conditioned by regenerating marrow as a crude source of stimulator. 
in the presence of stimuiator and 1 ng/ml, 2.79x10'tM DKP, the 
proportion of the HPP-CFC, ^(gp, population in S-phase was not 
increased. No evidence of DKP toxicity against the HPF>-CFCt!tt+<D<^F.1 
population of 1 ng/ml, 2.79x10'tM was observed. in the presence of 
stimuiator and 1 ng/ml, 3.01x1 09M ADK, however, the proportion of 
the HPP-CFCIL3+qstt population was increased. These results imply 
that while DKP proved effective at blocking the action of the 
haematopoietic stem cell proliferation stimuiator, ADK appeared to 
be a less effective sf/mf//afor-’blocking’ agent. in conclusion, these 
results suggest that the low molecular weight, haemoregulatory 
tetrapeptide AcSDKP, may act by blocking the action of the 
haematopoietic stem cell proliferation stimulator. A number oF 
observations involving AcSDKP may now be explained in light oF this 
suggestion.
4.4.5 Possible mechanism of action of the haemoreg^Uatorv
tetrapeptide AcSDKP.
Lauret ef a/ [1989b], report the production of a polyclonal 
antiserum against an extended AcSDKP peptide, which cross-reacts
with the AcSDKP tetrapeptide. Use of this antiserum in vivo in mice is 
reported to markedly increase the proportion oF the haematopoietic 
stem cell population in S-phase [Monpezat & Frindel,1989]. iF as 
postulated, AcSDKP acts to block stimuiator action, the removal oF 
endogenous AcSDKP by the neutralizing antiserum, would remove 
the block to sf/mrz/afor action, and allow a subsequent increase in the 
proportion of haematopoietic stem cells in S-phase, as was 
observed.
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The exogenous administration of AcSDKP in vivo to mice, as 
crude diaiysate of foetal liver or bone marrow, semi-purified factor or 
synthetic peptide, is reported to prevent the recruitment of 
haematopoietic stem cells into S-phase and so acts to protect the 
haematopoietic system from the potentially haemotoxic effects of the 
S-phase-specic cytotoxic agent cytosine arabinoside (ARA-C)
[Guigon & Frindei,1978; Guigon ef a/,1980; 1981; 1982; 1989; 
Wdzieczak-Bakala ef a/,1983]. if as postulated AcSDKP acts to block 
the action of the haematopoietic stem cell proliferation stimulator, 
then the exogenous addition of AcSDKP will act to further increase 
the block in stimulator action. With the cellular damage induced as a 
result of an S-phase cytotoxic drug challenge, levels of endogenous 
sf/nttz/dferwill rise to increase the proportion of stem ceils in S-phase 
and begin tissue regeneration. However, with the continued presence 
of the S-phase cytotoxic agent, an increase in the proportion of stem 
cells in S-phase would lead to severe tissue damage. The presence 
of increased levels of AcSDKP would be envisaged to block the 
action of stimuiator, prevent G9-G1 transition of the haematopoietic 
stem cells, so ’protecting’ them from the persistant effects of the S- 
phase-specic cytotoxic agent.
Wdzieczak-Bakala ef a/[1990], report cyclical changes in the 
proliferative state of the haematopoietic stem cell population in in 
vitro long-term bone marrow cultures with refeeding, and offered an 
explanation in terms of levels of AcSDKP in the culture medium. 
Removal of exhausted medium at the refeeding of a long-term bone 
marrow culture and its replacement with fresh medium, would reduce 
the endogenous levels of AcSDKP and allow an increased proportion 
of haematopoietic stem cells to enter S-phase. With time, levels of 
endogenous AcSDKP would be restored, inhibition of stem cell Gi-G1 
transition would be restabllshed and a reduction in the proportion of
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the haematopoietic stem cell population in S-phase would occur. This 
can be compared with the observations of Dexter et al [1977], Toksoz 
[1980] and Cashman ef a/[1985], who also report cyclical changes in 
long-term bone marrow cultures at refeeding. They interpret these 
observations as the result of changing ievels of the stem cell 
proliferation inhibitor and stimulator. Cellular depletion of the 
haematopoietic culture, leads to the production of sf/anZafior and an 
appropriate increase in the proportion of the haematopoietic stem 
cell population in S-phase. An increase in the cellular output and 
cellular repopulation of the haematopoietic layer, subsequently leads 
to the production of inhibitor and a reduction in the proportion of the 
haematopoietic stem cells in S-phase. The two distinct models of 
proliferation regulation may be reconsiled with the finding that 
AcSDKP does not act directly, rather It interacts with the stem cell 
proliferation stimuiator. At refeeding exhausted medium is removed 
and replaced with fresh medium. AcSDKP levels in the medium after 
refeeding are reduced. The cellular depletion of the layer leads to the 
production of stimuiator. The low levels of AcSDKP allow stimulator 
produced to be active and to increase the proportion of theA
haematopoietic stem cell population and so increase the cellular 
output and repopulation of the layer. With time the levels of AcSDKP 
increase with an associated Increase in the blocking of stimulator 
action. A biock in stimuiator action may subsequently allow inhibitor 
production with the result that the proportion of the haematopoietic 
stem population in S-phase is reduced.
It is significant that the use of a neutralizing polyclonal antiserum 
against AcSDKP and the exogenous addition of AcSDKP elicit 
haematopoietic responses in vivo. This is strong evidence for the 
physiological role of the tetrapeptide AcSDKP. However, the precise 
mechanism by which the action of the haematopoietic stem cell
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proliferation stimulator is compromised, Is at present unclear,
although a number of possible mechanisms can be suggested. 
Stimulator-sensitive cells, which are likely to include the
haematopoietic stem cell population and possibly the inhibitor- 
producing cell population, are likely to express membrane-bound 
sf/rnu/afar receptors. An oversimplified illustration of the stimuiator! 
stimuiator r<^c^ejp'tor interaction may be that of a ’lock and key [Figure 
dda]. Subtle molecular interactions will occur between the active sites 
of both the stimulator and the stimuiator receptor and with the 
formation of a. stimulator! stimui/forrecepo complex Intracellular 
mechanisms are likely to elicit secondary messenger activity with 
subsequent signal transduction to the nucleus and the stimulation of 
the haematopoietic stem ceil population into S-phase. One possible 
mechanism of AcSDKP action may be to directly Interact with either 
the sfimniator molecule or the receptor, in the interaction of AcSDKP 
and SDK in the inhibition of rosette formation between human Jurkat 
T-cells and sheep erythrocytes the addition of exogenous AcSDKP, 
or SDK, is proposed to compete with the presence of an endogenous 
-SDK- sequence in a region of the T-celi CD2 receptor which 
subsequently determines the interaction with the sheep erythrocyte. 
The presence of exogenous AcSDKP, or SDK, is thought to Impair 
rosette formation by competing with the intramolecular interaction of 
the putative native -SDK- sequence and disrupting the tertiary 
structure of the T-cell receptor moiety so that no interaction with the 
sheep erythrocyte can occur [Lenfant, personal communication]. A 
similar mechanism may exist in the stimulator! stimniator receptor 
system, with native -SDKP-, or -SDK-, sequences being potentially 
significant in the interaction between agonist and receptor. The 
presence of free AcSDKP may compete with these putative native - 
SDKP-, or -SDK-, sequences at the level of qither the stimulator or the
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stimulator receptor, to impair the access of the one molecule to the 
other. Whether the AcSDKP interacts with either stimuiator [Figure 
66b] or the sf/mzzZafor receptor [Figure 66c] is, at present unclear, 
although Wdzieczak-Bakala ef a/ [personal communication] report 
the iow affinity binding of radiolabelled AcSDKP to a small population 
of, as yet unclassified, haematopoietic precursors in murine bone 
marrow. This may be interpreted as an interaction of AcSDKP at the 
level of the membrane bound receptor [Figure 66c}. This
low affinity binding of the AcSDKP to the putative sfZmi/Zafor receptor 
could imply that the interaction is possibly reversible. The use of 
unlabeiled AcSDKP is reported to displace the radiolabelled AcSDKP, 
suggesting that the binding of the AcSDKP to certain cells is 
relatively specific.
To investigate evidence for an AcSDKP interaction with stimuiator 
[Figure 66b}, a purified source of stimulator (RBME-lift could be 
incubated with radiolabelled AcSDKP. Dialysis of the combination of 
the stimulator and AcSDKP should remove unbound AcSDKP and the 
binding of AcSDKP to stimulator could be investigated by measuring 
the retained radioactivity. The specificity of any interaction could be 
investigated by the simultaneous addition of unlabeiled AcSDKP and 
the displacement of labelled AcSDKP observed.
Alternatively, the AcSDKP molecule may not interact within the 
active sites of the stimulator and receptor, but may bind to the 
appropriate molecule and indirectly alter the 3-dimensional 
conformation of the active site. Binding of AcSDKP may alter critical 
intermolecular bonds within the molecule, spfficient to disrupt the 
tertiary structure of the molecule and impair the interaction of agonist 
with receptor [Figures 66d& 66e}.
The above hypotheses are significant since they do not require
the presence of discrete AcSDKP receptors. An alternative
Stimulator 
and receptor 
interact to
elicit
secondary 
messenger 
activity and
intracellular
signal
transduction 
to the nucleus
AcSDKP
Figure 66: The possible mechanism by which the 
tetrapeptide AcSDKP may act to impair the action
of the stem cell proliferation stimulator.
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interpretation of the reports of Wdzieczak-Bakala et al [personal 
communication] of low affinity binding of radiolabelled AcSDKP to an 
unclassified population of haematopoietic precursors, may be 
evidence of AcSDKP receptors. If discrete AcSDKP receptors exist, 
the binding of AcSDKP to the receptor may elicit a number of 
intracellular responses amongst which may be the inhibition of 
expression of stimulator receptors on the extracellular surface of the 
cell membrane. Other possible mechanisms may be envisaged.
The attraction of a haemomodulatory role for the low molecular 
weight tetrapeptide AcSDKP is its great potential flexibility. An 
increase in the levels of endogenous AcSDKP could be produced by 
increasing the activity of endoproteinase Asp-N, and so the cleavage 
of AcSDKP from the putative precursor Thymosin B4 and/or a 
reduction in the AcSDKP-degrading activity of angiotensin converting 
enzyme. Similarly, a reduction in the levels of AcSDKP could be 
produced by reduced endoproteinase Asp-N activity and/or 
increased angiotensin converting enzyme activity. In this manner, a 
less coarse regulatory mechanism can be envisaged than were 
changes in the proportion of the stem ceil population in S-phase 
solely reliant on changes in the production of inhibitor and stimulator. 
How the levels of AcSDKP are coordinated, possibly through the 
variation in the relative activities of endoproteinase Asp-N and 
angiotensin converting enzyme, to tailor the appropriate activity of 
the haematopoietic stem cell proliferation stimulator to the 
haematopoietic demands of the body is, as yet unclear.
In addition to thymosin 84, the -SDKP- amino acid sequence is 
also reported in tumour necrosis factor-alpha (TNF-alpha) [Lenfant et 
a/,1989a; Pradelles et a/,1990]. TNF-alpha is reported to demonstrate 
haemoregulatory activity [Old,1985; Broxmeyer et a/,1986; Munker et 
ai,t^QT, Peetrie ef a/,1988; Slordal ef a/,1989] and in this respect the -
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SDKP- sequence may be significant. Similarly, the minimal active 
amino acid sequence of the AcSDKP tetrapeptide, the SDK tripeptlde 
sequence Is found in murine leukaemia inhibitory factor (muLIF) 
[Gearing ef a/,1987]. LIF Is aiso reported to demonstrate 
haemoregulatory activity [Gearing ef a/,1987; Leary ef a/,1990; Metcalf 
ef a/,1990; Verfaille & McGlave,1991] and in this respect, the presence 
of the -SDK- sequence may be significant. With the characterization 
of other haematopoieticaily active molecules, the significance of the - 
SDKP-,or -SDK-, amino acid sequences may become clearer,
4.4.6 Another I ow moleeular weight haemoregulatory
oEEDCK/HP5b/SP1.
In addition to AcSDKP, another low molecular weight 
aaematopoietlcaily active peptide is reported. A pentapeptide of 
amino acid sequence pyro^Glu-Gh-A^j^|3cyy£^^Lys (pEEDCK) has been 
isolated from mature granulocytes and produced synthetically as 
"haemoregulatory pentapeptidd (HP5b), or "synthetic pentapeptide- 
T (SP1) [Laerum ef a/,1987; Foa ef a/,1987; Lu ef a/,1989; Paukovits ef 
a/,1990a; Paukovits ef a/,1990b]. The pentapeptide is reported to be 
non-species-specific, of low toxicity and is active in vivo and in vitro 
against both normal and murine myeloid progenitor cells and human 
and murine leukaemic cell lines. The molecule is reported to inhibit 
colony-formation by haematopoietic colony-forming cells and to 
suppress "myelopoietic stem cells" in a non-toxic, reversible manner. 
Paukovits ef a/[1990] have suggested HP5b/SP1 may prove to be a 
potential myelosuppressive agent effective during S-phase-specific 
cytotoxic chemotherapy, keeping the haematopoietic stem cell 
population out of a drug sensitive S-phase. Laerum ef ai [1990] have 
identified the EEDCK amino acid sequence of HP5b/SP1 in a
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subclass of G-protein, suggesting a possible interference by 
HP5b/SP1 with G-protein-mediated intracellular signal transduction. 
This Is additional evidence that low molecular weight peptides may 
be able to interfere with mechanisms involved in proliferation 
regulation and that smaii, iow molecular weight peptides can 
effectively mimic the binding sites of larger molecules. 
pEEDCK/HP5b/SP1 has also been demonstrated to possess a similar 
C-terminal chemical structure to the tripeptlde Giy-Cys-Giu (GCE, 
"glutathiond1), isolated from calf spleen and reported to regulate 
granulopoiesis [Fetsch & Maurer,1990]. Both pEEDCK and GCE 
possess similarly configured -COOH, -SH and -COOH and -NH2 
groups which may be significant in understanding their similar 
biological activity. Glutathione is reported to exist in a reduced, 
monomeric form and an oxidised, dimeric form. The former is 
reported to be a granulopoietic proliferation inhibitor, the latter is 
reported to be a granulocytic proliferation stimulator [Fetsch & 
Maurer,1990]. Neither pEEDCK/HP6b/SP1, or GCE/giutathione, show 
any structural similarity to AcSDKP.
Further evidence of the significance of iow molecular weight, 
potent regulatory peptides in biological systems can also be drawn 
from studies of the nervous system [Cottrell & Bewick,1989; Price et 
a/,1990]. A number of potent low molecular weight neuroactive 
peptides have been isolated in the invertebrate nervous system. One 
group of neuroactive peptides are characterized by a common 
terminal -Phe-Met-Arg-Phe-NH2 (-FMRFamide, Mr approximately 600 
amu) motif. The FMRFamide tetrapeptide is the minimal active amino 
acid sequence of the peptide family, and amino acid extensions of 
the tetrapeptide to a penta-, hexa-, or heptapeptide appears to play a 
role in modulating the activity of the FMRFamide moiety.
Section 5
Potential clinical 
applications.
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4.5.1 An in vitro assay of a primitive haematopoietic
precursor.
It has been demonstrated that the high proliferative potential 
colony-forming cell population stimulated by the synergistic 
interaction between interleukin 3 (IL3)/multi-CSF and macrophage 
colony-stimulating factor (M-CSF/CSF-1) (KPP-CFCl3.,csm) shares 
many behavioural and regulatory similarities with the in vitro KPP- 
cfcgm-csf+csf--i "CFU-A" population and more significantly with the in 
vivo '"CFU-S" population. This is considerable evidence to imply that 
the in vitro KPP-CFCIL3+csf1 population Is a relatively primitive 
haematopoietic precursor and is possibly a component of the stem 
cell compartment within the haematopoietic system.
The in vivo CFU-S assay has allowed considerable investigation 
of the behaviour and regulation of the haematopoietic stem cell 
population, however, a major drawback of this assay is it's use of 
large numbers of mice. Since each mouse has only one spleen, the 
numbers of mice required to achieve statistically significant results 
can be large. The development of an in vitro assay of a cell 
population which shares many behavioural and regulatory similarities 
with the in vivo CFU-S population would be significant, and while the 
replacement of the in vivo CFU-S assay with the in vitro KPP- 
CFC^+cf Of KPP-C^C:,iMYcs+CSf_i "CFU-A" assay, is not being 
advocated, these relatively simple, reproducible in vitro assays of a 
primitive haematopoietic precursor, should provide powerful tools 
with which to investigate haematopoietic stem ceil regulation and 
behaviour in normal and aberrant haematopoiesis.
The sensitivity of the in vitro KPP-CFC1L3+csm population to the 
haematopoietic stem cell proliferation regulators may, as previously 
demonstrated in the case of the X-irradiation-induced, murine,
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myeloid leukaemias, allow the levels of the endogenous stem cell 
proliferation stimulator and inhibitor in aberrant haematopoiesis to be 
investigated. Of particular significance is the possible use of the 
murine in vitro HPP-CFC|lh.c;.f-i or HPP-CFCGM.CSF+CSw "CFU-A" 
populations to investigate the levels of the stem cell proliferation 
regulators in aberrant human haematopoiesis, since inhibitor and 
stimuiator apparently demonstrate a non-species specificity (1.18). if 
human haematopoietic dysfunction could be related to abnormal 
levels of the haematopoietic stem cell proliferation regulators, it may 
prove possible to develop novel treatment regimes, perhaps 
involving the administration of exogenous inhibitor and stimuiator.
At present, no assay of the human haematopoietic stem cell 
population exists. However, McNiece ef a/[1989b] report the 
demonstration of a colony-forming cell population with a high 
proliferative potential from human haematopoietic tissue. if, as in the 
murine HPP-CFC,L3+csf1 and HPP-CFCsM.csf+ssfi "CFU-A" assays, the 
human HPP-CFC population could be demonstrated to be a primitive 
haematopoietic precursor, this may significantly assist the direct 
investigation of human haematopoietic stem cell behaviour and 
regulation.
it is significant that the in vitro HPP-CFCILg+CSf.i and HPP- 
CFCsm-csf+csfi "CFU-A" population prove sensitive to the 
haematopoietic stem cell proliferation inhibitor and stimuiator, and 
the in vitro HPP-CFCqm.csf+csf"CFU-A" played a significant role in 
the identification and characterization of the stem cell proliferation 
inhibitor as "macrophage inflammatory protein-1 aiphst' (MiP-1 alpha) 
[Graham ef a/,1990]. Similar procedures are likely to identify and 
characterize the haematopoietic stem cell proliferation stimuiator.
The clinical implications of a number of positive and negative
haemoregulatory activities have been reviewed [Moore,1991].
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Specifically, the clinical significance of the identified and 
characterized haematopoietic stem cell proliferation inhibitor and 
stimuiator will be great. The controlled administration of apparently 
non-toxic proliferation regulators, may allow the manipulation of the
haematopoietic system to clinical advantage.
4.5.2 Potential cili^i<^^i applications of the stem cell proliferation
inhibitor.
The use of exogenous stem ceil proliferation inhibitor may be 
particularly useful in reducing the proportion of the haematopoietic 
stem cell population in S-phase during chemo- or radiotherapeutic 
regimes. A reduction in the proportion of the haematopoietic stem 
cell population in S-phase prior to the administration of S-phase- 
specific chemotherapeutic agents, or radiotherapy, could markedly 
reduce the damage sustained by the haematopoietic system, damage 
which is usually a significant limiting factor of the dose and frequency 
of therapy. A potential reduction in the haemotoxicity of specific 
chemo- or radiotherapeutic regimes, may allow increased, or more 
frequent, and potentially more effective levels of treatment to be 
used. With a potentially greater tumour kill and reduced 
haemotoxicity, more effective chemo- and radiotherapeutic regimes 
may be developed.
Lord and Wright [1980], demonstrated the administration of 
exogenous stem cell proliferation inhibitor, prior to the administration 
of potential haemotoxic doses of tritiated thymidine, hydroxyurea or 
cytosine arabinoside, was able to 'protect’ the murine haematopoietic 
system, sufficient to allow survival. Lord ef a/[1987], report similar 
findings in the administration of the stem cell proliferation inhibitors 
in vitro long-term bone marrow cultures, prior to the addition of
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cytosine arabinoside. Cultures exposed to cytosine arabinoside
alone were markedly suppressed, while those subjected to cytosine
arabinoside after pretreatment with the haematopoietic stem celi
proliferation inhibitor, were observed to perform at least as well as
control cultures not exposed to either inhibitor or cytosine 
arabinoside.
4.5.3 Potential cllnical appllcations of the stem cell prollferation
stimuiator.
The clinical potential of the stem cell proliferation stimuiator may
also be significant. The only sucessful treatment of a number of 
haematological disorders with the failure of chemo- and 
radiotherapeutic regimes, is haematopoietic transplantation. Prior to 
haematopoietic transplantation patients are subjected to a dose of 
whole body irradiation and/or chemotoxic drugs sufficient to ablate 
their haematopoietic tissues and subsequently receive 
haematopoietic tissue intravenously. However, while the 
haematopoietic tissue becomes established and haematopoietic 
reconstitution occurs, the patient develops a marked pancytopenia. 
During this period of pancytopenia, patients are subjected to marked 
anaemia and haemorrhagic episodes and a particularly high 
vulnerability to infection. With successful transplantation, after this 
period of marked pancytopenia, haematopoietic regeneration will 
occur and restore the quality of the peripheral blood. Management of 
this period of pancytopenia, specifically the neutropenia, by the 
administration of individual haematopoietic colony-stimulating 
factors, has met with considerable success and the potential use of 
the haematopoietic stem cell proliferation stimuiator, may allow a 
further reduction in the period of pancytopenia. The addition of
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exogenous stem cell proliferation stimulatorto donor tissue in vitro,
prior to its intravenous transplantation, may serve to ’prime’, or
’activate’ the haematopoietic stem cell population.
The controlled administration of the haematopoietic stem cell 
proliferation stimulator, may also serve to assist haematopoietic 
reconstitution after sublethal haemosuppressive therapies. Chemo- 
and radiotherapeutic regimes, by their nature, will unavoidably 
damage normal as well as target tissue. The haematopoietic system 
is particularly sensitive to such agents and the damage to the 
haematopoietic system is often a significant limiting factor to the 
dose and frequency of therapy. Provided the tumour system is not 
itself sensitive to the haematopoietic stem cell proliferation 
stimulator, it’s use may allow a more rapid haematopoietic recovery 
after and between treatments and may subsequently allow more 
frequent and potentiaiiy • more effective levels of therapy to be 
employed.
The potential efficacy of the appropriate use of controlled levels 
of both the stem cell proliferation inhibitor and stimuiator to 
manipulate the normal haematopoietic tissue to clinical advantage 
during both chemo- and radiotherapy, may be of great significance. 
The use of the haematopoietic stem cell proliferation stimuiator may 
also be significant in assisting the management of certain diseases 
which present with haematological suppression. Leukaemia- 
associated suppression of normal haematopoiesis has been 
discussed, and is largely responsible for the deterioration in the 
’quality’ of the peripheral blood. Leukaemic patients often present 
with anaemia, haemorrhage and increased susceptibiiity to infection 
which can be severeiy debilitating. The controiled use of the 
haematopoietic stem cell proliferation stimuiator, may serve to 
eleviate these symptoms and improve the quaiity of life’ for the
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patient. The use of stimulatorwould however, be precluded if the 
leukaemic cell population proved sensitive to it's action. in managing 
the disease in this manner, 'healthier' patients, more abie to tolerate 
more intense and/or frequent treatment regimes may allow a more 
optimistic disease prognosis.
4.5.4 Potential cilmcal appllcations of the low molecular weight
haemorequiatorv tetrapeptide AcSDKP.
Many of the beneficial aspects of the use of the stem cell 
proliferation inhibitor and stimuiator involving the manipulation of the 
haematopoietic system to clinical advantage, are equally applicable 
in discussing the clinicai potential of the haemoregulatory 
tetrapeptide AcSDKP. AcSDKP appears to modulate haematopoietic 
stem cell proliferation at the ievel of haematopoietic stem cell 
proliferation stimulator action. The addition of exogenous AcSDKP 
has been demonstrated to block the recruitment of haematopoietic 
stem cells into S-phase in vivo in mice [Frindel & Guigon,1977;
Guigon & Frindel,1978; Guigon ef a/,1980; 1981; 1982; 1989; 
Wdzieczak-Bakala ef a/,1983], while removal of endogenous AcSDKP 
by a polyclonal antiserum has been demonstrated to increase the 
proportion of haematopoietic stem cells in S-phase [Frindel & 
Monpezat,1989].
The use of exogenous AcSDKP to prevent the recruitment of 
haematopoietic stem cells into S-phase has been demonstrated to 
protect the murine haematopoietic system from potentially 
haemotoxic doses of the S-phase-specific cytosine arabinoside 
[Frindei & Guigon,1977; Guigon & Frindei,1978; Guigon ef a/,1980; 
1981; 1982; 1989; Wdzieczak-Bakala ef al,1983]. The manipulation of 
the proportion of the haematopoietic stem cell population in S-phase,
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through the use of the non-species-specific, non-toxic, low molecular
weight tetrapeptide AcSDKP to clinical advantage could thus be
envisaged.
Increasing the concentration of AcSDKP, by the addition of 
exogenous factor, would increase the impairment of stimulator 
action, and prevent the recruitment of haematopoietic stem cells into 
S-phase and would be particularly effective in protecting the 
haematopoietic stem cell population from the effects of both 
chemotherapeutic agents and radiation.
A reduction in the levels of AcSDKP, by the administration of anti- 
AcSDKP poiyclonai antiserum, wouid reduce the blocking effect on 
the action of stimulator and the proportion of haematopoietic stem 
ceils in S-phase would increase. Such increased haematopoietic 
stem cell proliferation would assist in haematopoietic recovery after 
an episode of chemo- or radiotherapy, or else may be effective in the 
priming of haematopoietic tissue in vitro prior to transplantation, and 
so to reduce the period of pancytopenia. Similarly, the clinical 
manipulation of AcSDKP levels In diseases which present with 
haematological dysfunction may assist in disease management.
Liozon ef a/[1991] report evidence which may implicate a 
pathological role for AcSDKP in a number of human 
myeloproliferative disorders, increased levels of AcSDKP are 
reported, which may act to suppress normal haematopoiesis to the 
advantage of the pressumably AcSDKP-, or sf/mu/afor-insensitive 
aberrant myeloproliferative disease. The physlopathology of AcSDKP 
may prove significant and the roies of the AcSDKP-liberating enzyme 
endoproteinaseAspN and AcSDKP-degrading enzyme angiotensin 
converting enzyme, may also play an important role in certain 
disease mechanisms. It may prove possible to manipulate the relative 
activities of these two enzymes to indirectly manipulate the
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endogenous levels of AcSDKP to clinical advantage, or to correct 
possible pathologically high or iow enzyme activities.
4.5.5 In conclusion.
The manipulation of the haematopoietic stem celi population to
clinical advantage would be a powerful technique. By manipulation of 
either the levels of the haematopoietic stem cell proliferation 
stimulator or inhibitor, and/or levels of the low, molecular weight, 
haemoregulatory tetrapetide AcSDKP, appropriate changes in the 
proportion of the haematopoietic stem cell population in S-phase 
could be induced. However, while, at present, no alternative role has 
been attributed to AcSDKP, the identification and characterization of 
the stem ceil proliferation inhibitor as macrophage inflammatory 
protein-1 alpha (MiP-1 alpha) [Graham ef a/,1990], might suggest that 
the administration of exogenous inhibitor, with a view to reducing the 
proportion of the haematopoietic stem celi population in S-phase, 
may also elicit an inflammatory response and macrophage activation. 
MIP-1 alpha Is also reported to be active against clonogenic 
epidermal cells. A monocyte/ lymphocyte-derived Langerhans ceil 
population within the murine skin ’epidermal proliferative unit’ (EPU), 
is reported to produce MIP-1 alpha and to inhibit EPU proliferation 
[Dr.M.PIumb, instutute for Cancer Studies, University of Leeds, 
personal communication]. These alternative roles for MIP-1 alpha 
may somewhat restrict it’s potentiai clinical use in vivo.
Evidence of MIP-1 alpha activity in a number of different tissues 
implies that the molecule is an important, conserved proliferation 
regulator, and Its effects may subsequently be identified in other 
tissue systems. To act separately in these different tissues and elicit 
an appropriate proliferative response, MIP-1 alpha must be produced
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and active locally. Evidence of the local haematopoietic action of 
MIP-1 alpha has been identified by part body X-irradiation studies 
[Croizat ef a/,1970; Gidail & Lajtha,1972] (1.9). The localization of MiP- 
1 alpha to either bone marrow, skin EPU or foci of Inflammation, may 
be maintained by a biood-bone marrow/ EPU barrier, similar to that 
demonstrated for M-CSF/CSF-1 [Shadduck ef a/,1989]. However, 
while the presence of such a localizing barrier is precluded by 
evidence that the intravenous administration of the stem cell 
proliferation inhibitorio mice demonstrated a haematopoietic 
response [Lord & Wright,1980], such a compartmentalized system 
would allow levels of MiP-1 alpha to vary Independently between the 
various MiP-1 alpha sensitive tissues. By comparison, the low 
molecular weight haemoregulatory tetrapeptlde AcSDKP, has been 
demonstrated to be present in both serum and within the 
haematopoietic system, using an AcSDKP enzyme Immunoassay 
technique [Pradelles ef a/,1990] and It's relatively low molecular 
weight would allow it to cross any putative blood-bone marrow 
barrier to effect a haematopoietic response. The local concentration 
and subseqent activity of AcSDKP could be regulated by the 
presence of the AcSDKP-degradIng enzyme activity, ACE, within the 
haematopoietic microenvironment. The intravenous administration of 
AcSDKP to effect a haematopoietic response may thus prove less 
problematic than the use of the multiple activity MiP-1 alpha. Whether 
alternative roles for AcSDKP will subsequently be identified and 
whether similar multiple functions will be attributable to the 
haematopoietic stem cell proliferation stimulator, once identified and 
characterized, will be of considerable Interest.
Section 6
Summary.
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1) Characterization of the in vitro HPP-CFC^+CSM population.
a) In conclusion, the combination of interleulin 3 (!L3)/multi-CSF
and macrophage colony-stimulating factor (M-CSF/CSF-1), as either 
media conditioned by the WEHi 3B myelomonocytic leukaemic cell 
line and L929 fibroblast ceil line, or recombinantly-derived factors, 
stimulates the proliferation of a distinct coiqny-forming cell 
population from murine haematopoietic tissue in vitro. The colony­
forming cell population, not observed when either factor Is used 
singly, is characterized by a high proliferative potential. The high 
proliferative potential colony-forming cell (HPP-CFC1L3+csf_ J 
population has the capacity to produce macroscopic colonies in 
excess of 2 mm diameter and of approximately 6x 10" cells after 14 
days In seml-solid agar culture. The HPP-CFC|Li+CsF1-derived 
colonies are occassionaiiy composed of cells of more than one 
haematopoietic lineage, which implies a degree of HPP-CFC1U3+Cspi 
multipotency.
b) An HPP-CFCJL3+csf- frequency of approximately 100/105
normal CBA/H femoral marrow cells is determined, which, in an 
average femoral marrow cellularity of 14x10® cells, gives an 
approximate total CBA/H femoral marrow compliment of 14x103 HPP- 
CFCllJ3—gsf-v ,n marrow from CBA/H mice 3 days after a 2 Gy sublethal 
whole body X-lrradlatlon dose an HPP-CFClL3+CSFb frequency of 
approximately 29/105 regenerating marrow cells is determined, which. 
In an average femoral marrow cellularity of approximately 6x106 cells, 
gives an approximate total femoral marrow compliment of 2x103 HPP- 
b-FCjuj+FSFr
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c) The proportipn oo nhe HPP-CFCfj+fspi population tio S-phase as 
normal femoral marrow was determined as approximately 9% and
Increases to approximately 40% in marrow from mice 3 days after a 2
Gy whole body X-irradiation dose.
d) The in vitro HPP-CFC1Lc+copl population proves sensitive to the 
previously characterized haematopoietic stem cell-specific 
proliferation regulators. Stimulator, derived from regenerating bone 
marrow from mice 7 days after a 4.5 Gy whqie body X-^adiation 
dose, significantly increased the proportion of the HPP-CFCILccccpl 
population In S-phase from approximately 9% to approximately 24%, 
while inhibitor, derived from normal bone marrow, significantly 
reduced the proportion of the HPP-CFC,l3+qcp l population in S-phase 
from approximately 40% to approximately 25%. No evidence of stem 
cell proliferation stimulator or /p/r//Mertoxic<ty against the HPP- 
CFC|L3 ccso-< popuiation was observed.
c) Titration of the stem cell proliferation regulators demonstrated 
that the HPP-CFC,cl+cpFc population proved equally sensitive to both 
stimulator and inhibitor.
f) A high proliferative potential, evidence of multlpotency and a
sensitivity to the stem cell proliferation regulators, is strong evidence 
to suggest that the in vitro HPP-FFFCCc+ccpl population is a relatively 
primitive haematopoietic precursor, possibly a component of the 
heterogenous stem cell compartment.
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2) In vitro HPP-CFC,,+^r-i investigation of haematopoietic stem cell 
regulation in murine, mveioid leukaemia.
a) The use of the in vitro HPP-CFC,3+CSp3 assay to Investigate the 
levels of the haematopoietic stem cell proliferation regulators In a 
number of X-lrradiation-induced murine myeloid leukaemias, 
demonstrated the absence of detectable levels of the haematopoietic 
stem cell proliferation inhibitor and stimulator, and no evidence of a 
direct-acting leukaemia-associated proliferation inhibitor was 
observed, in medium conditioned by overtly leukaemic marrow.
b) Medium conditioned by overtly leukaemic marrow did not 
Impair the capacity of stimuiator, derived from regenerating bone 
marrow, to increase the proportion of the HPP-CFC|L3GSf3 population 
in S-phase or, the capacity of inhibitor, derived from normal bone 
marrow, to reduce the proportion of the HPP-CFC,^ggp, population 
in S-phase.
c) Medium conditioned by overtly leukaemic marrow did appear 
to impair the capacity of regenerating bone marrow to produce 
stimuiator or, of normal bone marrow to produce inhibitor.
d) The mechanism by which the leukaemic population impairs the 
production of the haematopoietic stem cell proliferation regulators Is 
at present unclear. Characterization of this mechanism may allow the 
development of more effective disease treatment and management
regimes.
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3) In vitro HPP-CFC,^, ccr i investigation of the possible mechanism 
of action of the low molecular weight, haemoregulatory tetrapeptide
AcSDKP.
a) Use of the in vitro HPP-CFCIL3+Cpi.i population to investigate 
the possible mechanism(s) of action of the haemoregulatory 
tetrapeptlde acetyi-N-Ser-Asp-Lys-Pro (AcSDKP, Ml=487 amu) and 
the minimal active tripeptide sequence Ser-Asp-Lys (SDK, IV r=348 
amu), demonstrate that neither peptide is inherently a stimulatory 
activity. The proportion of the HPP-CFC,LL+CgFL population in S-phase 
is not significantly increased by the presence of AcSDKP, or SDK, at 
1 ng/mi (2.05x10'9M and 2.87x10dM respectively) for 3 hours.
b) The presence of AcSDKP, or SDK at 1 ng/mi (2.05x1 O_9M and 
2.87x1 O*lm respectively), did however, Impair the capacity of the stem 
ceil proliferation stimulator to significantly increase the proportion of 
the HPP-CFCLgLcsM population in S-phase.
c) The tripeptide Asp-Lys-Pro (DKP, Mr=358 amu, at 1 ng/mi, 
2.79x10'LM) proved less effective In impairing the action of the stem 
cell proliferation sf/muiatorthan either AcSDKP, or SDK while the 
tripeptide Ala-Asp-Lys (ADK, Mr=332 amu, at 1 ng/ml, 3.01x1 0'LM) did 
not significantly impair stimulafgr action.
d) Once the mechanism of action of AcSDKP and SDK has been 
characterized, a further investigation of other peptide analogues can 
be made in association with molecular modelling techniques, to 
produce potentially more potent peptides, or peptides more resistant
to enzymatic degradation.
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